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The search for non-steroidal anti-inflammatory drugs (NSAIDs) with less gastrointestinal 
toxicity, led to the introduction of the selective cyclooxygenase-2 (COX-2) inhibitors.  
However, with this introduction into the market, there have been concerns regarding their 
safety, particularly cardiovascular safety.  
   
The purpose of this study was to assess the cardiovascular risk (events included: 
myocardial infarction, stroke, and myocardial infarction-related deaths) associated with 
long-term (after 180 days of exposure) and short-term (≤ 180 days exposure) use of 
nonselective NSAIDs and COX-2 inhibitors.     
 
A retrospective analysis of the Veterans Integrated Service Network 17 Veteran’s Affairs 
(VA) database was conducted.  Medicare data and Texas Department of Health mortality 
data were incorporated to capture events occurring outside the VA healthcare network.  
 
vii
Patients 35 years of age and older receiving celecoxib, rofecoxib, ibuprofen, etodolac, 
and naproxen from January 1, 1999 through December 31, 2001, were included.  
Multivariate Cox proportional hazard models were used to analyze the relationship 
between cardiovascular risk and NSAID/COX-2 inhibitor use while adjusting for various 
risk factors.     
 
We identified 12,194 exposure periods and 146 cardiovascular events over the entire 
study period.  Compared to long-term ibuprofen use, long-term use of celecoxib 
(Celebrex®) was associated with a 3.64 fold (95% CI 1.36 – 9.70; p = 0.01) increase in 
cardiovascular risk.  Long-term use of rofecoxib (Vioxx ®) was associated with a 6.64 
fold (95% CI 2.17 – 20.28; p ≤ 0.01) increased risk when compared to long-term use of 
ibuprofen.  Short-term use of celecoxib and rofecoxib was not associated with any 
significant change in cardiovascular risk when compared to ibuprofen use (celecoxib – 
adjusted risk ratio (aRR) 0.67; 95% CI 0.31 – 1.47; p = 0.32 / rofecoxib – aRR 1.40; 95% 
CI 0.59 – 3.33; p = 0.44).  Long-term and short-term exposure to naproxen and etodolac 
was not associated with a cardionegative or cardioprotective effect when compared to 
ibuprofen use.  Additionally, overall exposure (long-term and short-term exposure) to 
study medications was evaluated; results indicated no significant findings with any COX-






The findings of this observational study along with recent clinical trial results suggest 
that long-term exposure to COX-2 inhibitors is associated with an increased 
cardiovascular risk.  In addition, the study results do not support the hypothesis that 
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The gastrointestinal (GI) toxicity associated with nonsteroidal anti-inflammatory 
drugs (NSAIDs) led to the search for and development of the selective cyclooxygenase-2 
(COX-2) inhibitors.  The introduction of COX-2 inhibitors into the market has raised 
concerns regarding their safety, particularly cardiovascular safety.  Several recent studies 
and reports have been published addressing these concerns.  This chapter will focus on 
the reports and studies relating to the cardiovascular safety of NSAIDs and COX-2 
inhibitors.  Information regarding NSAIDs/COX-2 inhibitors’ gastrointestinal safety is 
also included to provide the reader with an overall understanding of the associated risks 
and benefits.   
 
To obtain an understanding of the complex nature surrounding cardiovascular 
disease, this chapter will begin with an in-depth look into the epidemiology, etiology, 
precipitating factors, treatment, and risk factors for cardiovascular disease.  Information 
provided in this section will help explain and support the rationale for and design of the 
study.  The purpose of this study was to assess the cardiovascular risk (events included: 
myocardial infarction, stroke, and myocardial infarction-related deaths) associated with 
long-term (after 180 days of exposure) and short-term (≤ 180 days exposure) use of 






Note:  This section will utilize the American Heart Association, National Center for 
Health Statistics (CDC/NCHS), and the National Heart, Lung, and Blood Institute 
(NHLBI) criteria to define cardiovascular disease terminology.1  A comprehensive list of 
definitions is provided below along with the corresponding International Classification of 
Diseases (ICD) 10 codes.  The corresponding ICD 10 codes are placed in parentheses.1   
 
• “Major cardiovascular diseases”  (I00-I78) 
• “Congenital cardiovascular defects”  (Q20-Q28) 
• “Diseases of the heart” – representing roughly three-fourths of “total 
cardiovascular disease” mortality, indicated with a (*) below   
• “Total cardiovascular disease” – comprising all “diseases of the circulatory 
system”  (I00-I99) 
o Acute rheumatic fever/chronic rheumatic heart diseases  (I00-I09)* 
o Hypertensive diseases (I10-I15) 
o Hypertensive heart disease (I11)* and hypertensive heart and renal disease 
(I13)* 
o Ischemic (coronary) heart disease (I20-I25)* 
 Angina pectoris (I20) 
 Acute myocardial infarction (I21-I22) 
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 Other acute ischemic coronary heart disease (I24) 
 All other forms of chronic ischemic heart disease (I25.1-I25.9)  
o Pulmonary heart disease and diseases of pulmonary circulation (I26-I28)* 
o Congestive heart failure (I50.0)* 
o Other forms of heart disease (I29-I49, I50.1-I52)* 
o Cerebrovascular disease (stroke) (I60-I69) 
o Atherosclerosis (I70) 
o Other diseases of  arteries, arterioles and capillaries (I71-I79) 
o Diseases of veins, lymphatics and lymph nodes, not classified elsewhere 
(I80-I89) 
o Other and unspecified disorders of the circulatory system (I95-I99) 
 
Total Cardiovascular Disease 
 
Prevalence/Incidence/Mortality – In the United States, one in five Americans is living 
with some form of cardiovascular disease.  There are over 50,000,000 people living with 
high blood pressure (HBP), 12,900,000 with coronary heart disease, 4,900,000 with 
congestive heart failure (CHF), and 4,700,000 with stroke (National Health and Nutrition 
Examination Survey III, CDC/NCHS).1    
 
Despite improvements in clinical care and public awareness, coronary heart 
disease (CHD) remains the leading cause of death for men and women in the United 
 
4
States.  In the United States, heart disease and stroke account for approximately 40% of 
all deaths.1,2  Coronary heart disease and stroke account for 72 percent of cardiovascular-
related deaths (Appendix A).1  Mortality resulting from congestive heart failure (CHF), 
high blood pressure (HBP), diseases of the arteries, rheumatic heart disease, and 
congenital cardiovascular defects has had a smaller but significant impact on 
cardiovascular mortality, comprising roughly 15 percent of cardiovascular mortality.  
Through the years, improvements in cardiovascular care and treatment have been made, 
resulting in a reduction in morbidity and mortality.  From 1950 to 1996, deaths from 
“diseases of the heart” have declined 56 percent, from 307.4/100,000 to 134.6/100,000.2  
Furthermore, during this same period, stroke rates dropped 70 percent, from 88.8/100,000 
to 26.5/100,000.2   
 
Age and Cardiovascular Disease – It has been noted that there is an increased prevalence 
of cardiovascular diseases among older Americans (Appendix B).3  Likewise, the 
incidence of cardiovascular events among older Americans is also higher.  Based on 
information obtained from the National Heart, Lung, and Blood Institute’s (NHLBI) 
Framingham Heart Study, the annual rates of a first major cardiovascular event rise from 
7 per 1,000 in men age 35-44 to 68 per 1,000 in men age 85-94.1  Comparable rates for 
women occur 10 years later in life, narrowing with advancement in age.   
 
Roughly 84 percent of cardiovascular disease-related deaths occur in persons 85 
and older.  Among the 6,294,000 patients discharged from a short-stay hospital with a 
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primary diagnosis of cardiovascular disease in the year 2000, 64.5 percent were 65 and 
older.3       
 
Gender and Ethnicity in Cardiovascular Disease – Important differences based on 
race/ethnicity and gender exist.  Since 1984, the number of cardiovascular-related deaths 
for females has exceeded those of males.  In 2000, 440,175 (46.5%) males and 505,661 
(53.5%) females died of cardiovascular-related deaths.4,5  Similar gender differences were 
noted when broken down into racial categories (Appendix C).6-8  Even though women 
have a higher total number of cardiovascular-related deaths, men have a higher overall 
death rate from cardiovascular disease (CVD).  Additionally, black females and males 
have higher rates of CVD when compared to white males and females.  Hispanic males 
and females had a lower percent of cardiovascular-related deaths in 2000.  Gender and 
racial differences for overall death rates from CVD are as follows: 
 
• Males – 404.0 per 100,000 
o White males – 397.6 per 100,000 
o Black males – 509.6 per 100,000 
• Females – 294.3 per 100,000 
o White females – 285.8 per 100,000 




Among African-American adults, 40.5 percent of men and 39.6 percent of women 
have some form of cardiovascular disease.  Comparatively, cardiovascular disease 
prevalence is estimated to be lower among whites and Hispanics. (Appendix D).6-8      
 
Ischemic/Coronary Heart Disease 
 
Prevalence/Incidence/Mortality – An estimated 650,000 Americans had a new coronary 
attack in the year 2003 and 450,000 will have a recurrent attack.  Coronary heart disease 
comprises greater than 50 percent of all cardiovascular events in men and women 
(Appendix A).  The lifetime risk of developing CHD after the age of 40 is 49 percent for 
men and 32 percent for women.  Once the age of 70 is reached, the lifetime risk drops to 
35 percent for men and 24 percent for women.1  For total CHD, the incidence of CHD in 
women lags 10 years behind males and 20 years for events such as acute myocardioal 
infarction (AMI) and sudden death.  Of those who experience a coronary attack in a given 
year, 47 percent will die and around 80 percent of CHD mortality in people under the age 
of 65 will occur during their first heart attack.1             
 
Age/Gender/Race – As observed in total cardiovascular disease, the Framingham Study 
found an increasing rate of coronary heart disease and myocardial infarctions with age, in 
both genders.  The crude 24-year incidence rate of coronary heart disease increased from 
152 per 1,000 in men aged 30-34 to 383 per 1,000 in men aged 55-59 and from 59 per 
1,000 to 294 per 1,000 in women, respectively.  Regarding MI, the rate increased from 92 
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per 1,000 in men aged 30-34 to 252 per 1,000 in men aged 55-59 and from 13 per 1,000 
to 117 per 1,000 in women, respectively.  Results are displayed in Appendices E and F.9  
Information provided from the Cardiovascular Health Study (CHS) found a similar trend 
in adults aged 65 and older, with annual rates of new and recurrent myocardial infarctions 
increasing with age.1  However, among African American men and women, the annual 
incidence rate of events declined after the age of 84 (see Appendix G). 
 
In 2000, 50.6 percent of CHD-related deaths were males and 49.4 percent were 
females.  In 2000, the overall coronary heart disease related death rate was 186.9 per 
100,000.  The gender and racial differences are as follows (gender specific data were 
available only for whites and African Americans; additionally, 1999 data were used to 
calculate death rates for Hispanics, American Indians/Alaska Natives and Asian/Pacific 
Islanders):1   
 
• White males – 252.4 per 100,000 
• Black males – 262.4 per 100,000 
• White females – 145.3 per 100,000 
• Black females – 187.5 per 100,000 
• Hispanics – 138.4 per 100,000 
• American Indians/Alaska Natives – 123.9 per 100,000 




Of those who have experienced a myocardial infarction, nearly 25 percent of men 
and 38 percent of women will die within one year.  Additionally, people with a previous 
MI have a risk of sudden death 4-6 times higher than in the general population.  Around 
half of men and women under the age of 65 who have had an AMI will die within 8 
years.1  According to the Framingham Heart study, within six years, 18 percent of men 
and 35 percent of women will have another heart attack; seven percent of men and six 
percent of women will experience sudden death; and about 22 percent of men and 46 
percent of women will develop heart failure.  Angina pectoris will develop in 27 percent 
of men and 14 percent of women within six years after an AMI.  “Only 20 percent of 
coronary attacks are preceded by long-standing angina.”1   
 
Acute Myocardial Infarction – Etiology and Treatment       
 
Etiology – Coronary artery disease (CAD) is the primary factor leading to a possible 
AMI.  The disease process usually begins early in life, with fatty streaks of deposits 
developing on the endothelium.  These deposits can then, in turn, develop into 
atherosclerotic plaques, depending on risk factors.10  Risk factors attributed to the 
progression of these plaques include:  hypertension, diabetes mellitus, smoking, and 
hyperlipidemia.  With the progression of these plaques, narrowing of the arteries and 
thrombogenic formations occur, causing an AMI.  The thrombotic process is a complex 
process and involves activation of platelets, thrombin, and fibrin.10  Thrombus formations 




Treatment – The primary goals in the management of patients with MI are to:  minimize 
the infarction size, salvage ischemic myocardium, prevent and minimize complications, 
and improve outcomes.10  Patients presenting to the emergency room may receive 
thrombolytic therapy or undergo percutaneous transluminal coronary angioplasty 
(PTCA).  In addition to these procedures, patients may need oxygen and pain 
management.  Pharmaceutical management may include: therapy with nitroglycerin to 
relieve chest discomfort and salvage ischemic myocardium; lidocaine to manage 
ventricular tachycardia and ventricular fibrillations; and early administration of β-
adrenergic blockers to reduce the incidence of ventricular arrhythmias, recurrent 
ischemia, reinfarction, and mortality.10  Post MI management may include the use of β-
adrenergic blockers, calcium channel blockers, amiodarone, angiotensin-converting 
enzyme inhibitors (ACEI), cholesterol medications, aspirin and/or other antiplatelet 
drugs.10    
 
Sudden Cardiac Death  
 
Sudden Cardiac Death – Sudden cardiac death is the unexpected stopping of the 
heartbeat and is often associated with coronary heart disease.  Sudden cardiac death 
occurs on average around the age of 60, with women lagging 20 years behind men.1,11  
The most common cause of sudden cardiac arrest is a heart attack that results in 
ventricular fibrillation or pulse-less ventricular tachycardia.  Various heart medications 
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and other drugs (including illicit drugs) can induce abnormal heart rhythms.  Additional 
causes of cardiac arrest include respiratory arrest, electrocution, drowning, choking, 
trauma, and unknown causes.   
 
Sixty-three percent of women and 50 percent of men who die from sudden cardiac 
death have had no previous symptoms of the disease.1  People with a previous heart 
attack are 4-6 times more likely to experience sudden cardiac death than the general 
population; with 7 percent of men and 6 percent of women experiencing sudden death six 
years post myocardial infarction (MI).11  Roughly 80 percent of all sudden cardiac arrests 
occur at home, and 60 percent are witnessed by someone.  It is estimated that 95 percent 
of sudden cardiac arrest victims die before reaching the hospital.1  Survival is directly 
linked to the amount of time between the onset of sudden cardiac arrest and defibrillation.  
Victims located in communities with public access defibrillators have an increased 
survival probability.  With immediate CPR and defibrillation within 3-5 minutes, survival 
rates have been reported as high as 48-74 percent.  
 
No statistical data are available on the exact number of sudden cardiac arrests that 
occur each year.  However, roughly 250,000 people die yearly of coronary heart disease 
without being hospitalized, equaling about half of all CHD related deaths.1  The CDC 
estimates that in 1999, 728,743 people died of heart disease and congenital 
malformations of the heart in an emergency department (16.5%) or before reaching the 





Incidence/Mortality – Stroke is the third leading cause of death; it accounted for roughly 
1 of every 14 deaths in the United States in 2000.1  Of the nearly 700,000 yearly 
occurrences of new (71%) and recurrent (29%) strokes experienced in the US, roughly 
30% will die within one year.1,13  Approximately 8 – 11% of individuals who experience 
an AMI will have an ensuing stroke within six years.  Fourteen percent of individuals 
who survive a first stroke or transient ischemic attack (TIA) will experience a subsequent 
attack within one year.  With regards to stroke related mortality, about 50 percent 
occurred outside the hospital.1  Age-adjusted stroke incidence rates (per 100,000) for the 
first occurrence of a stroke are 167 for white males, 138 for white females, 323 for black 
males, and 260 for black females.1  There is a steep rise in incidence with age, with 75% 
of all first stokes occurring after the age of 65 (in the white population).13   
 
Etiology/Treatment – There are three pathological types of strokes:  ischemic (88% of all 
strokes), intracerebral hemorrhage (9%), and subarachnoid hemorrhage (3%).  Not 
considered a pathological type of stroke, a transient ischemic attack (TIA) differs from an 
ischemic stroke in three facets, duration (less than 24 hours), differential diagnosis, and 
ease of diagnosis.13  Regarding ischemic strokes, roughly 50 percent of occurrences can 
be attributed to atherothrombotic disease (in the white population), 25 percent to 
intracranial small vessel disease, and 20 percent from emboli from the heart.13  In the 
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event of an ischemic stroke, antiplatelet therapy or anticoagulation therapy are typically 
the first line agents, followed by risk factor modifications.   
 
Risk Factors - There are a number of modifiable risk factors for ischemic stroke, most of 
which are associated with atherosclerosis.  Factors include: hypertension, hyperlipidemia, 
smoking, physical activity, obesity, asymptomatic carotid stenosis, alcohol consumption, 
and atrial fibrillation.  Non-modifiable risk factors for stroke include:  older age, male 
sex, nonwhite race, the presence of coronary heart disease or congestive heart failure, and 
a family history of stroke or TIA.14 
 
Congestive Heart Failure  
 
Prevalence/Incidence/Mortality – An estimated 4,900,000 Americans are estimated to 
have congestive heart failure (CHF).1  The Framingham study estimates that at the age of 
40, the lifetime risk of developing CHF for men is 21.0 percent and 20.3 percent for 
women.  At the age of 80, the lifetime risk drops slightly to 20.2 percent and 19.3 
percent, respectively.  Of those who have CHF under the age of 65, approximately 80 
percent of men and 70 percent of women will die within eight years and fewer than 15 
percent of all men and women diagnosed with CHF will live longer than 8-12 years.  The 
one-year mortality rate of people diagnosed with CHF is 20 percent.1  In the year 2000, 
the overall death rate for CHF was 18.7 per 100,000, with a rate of 19.5 for white males, 
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20.4 for black males, 18.1 for white females, and 19.3 for black females.  In 2000, there 
were 990,000 hospital discharges for CHF.1 
 
Age/Gender/Race - As seen with the other cardiovascular conditions, the prevalence and 
incidence rates of CHF increases with age (Appendix H).1  According to the 
Cardiovascular Health Study, annual incidence rates of new and recurrent CHF events are 
as follows: 
 
• Non-black men  
o Age 65-74 – 21.5 per 1,000 
o Age 75-84 – 43.3 per 1,000 
o Age 85 +   – 73.1 per 1,000 
• Non-black women 
o Age 65-74 – 11.2 per 1,000 
o Age 75-84 – 26.3 per 1,000 
o Age 85 +   – 64.9 per 1,000 
• Black Men 
o Age 65-74 – 21.1 per 1,000 
o Age 75-84 – 52.0 per 1,000 
o Age 85 +   – 66.7 per 1,000 
• Black Women 
o Age 65-74 – 18.9 per 1,000 
o Age 75-84 – 33.5 per 1,000 




Etiology – Congestive heart failure (CHF) is a condition when the heart is unable to 
provide sufficient amounts of blood to meet the metabolic needs of the body.  Congestive 
heart failure is not a specific disease state, but a clinical syndrome caused by various 
cardiovascular disorders.10  According to the Framingham Study, it is estimated that 
ischemic heart disease is the underlying cause of CHF in 47 percent of females and 59 
percent of males.15  Furthermore, roughly 22 percent of males and 46 percent of female 
patients who experienced an AMI will develop CHF within six years.1  Hypertension is 
implicated as the suspect etiology in 37 percent of females and 30 percent of males.15  
Other etiologies include cardiomyopathies and valvular heart diseases.10   
 
Precipitating Factors – Patients with a diagnosis of CHF can be symptom free when they 
are in a “compensated” state of heart failure.  However, there are many factors that can 
decompensate a patient.  A study evaluating 101 patients admitted to the hospital with 
CHF found that noncompliance with their medications and/or diet was the most common 
precipitating factor.  Uncontrolled hypertension, despite medications, was the second 
leading cause, followed by arrhythmias.10   
 
Treatment – Treatment of acute and severe heart failure will vary depending on the 
patient’s cardiac index and pulmonary capillary wedge pressure.  Positive ionotropic 
agents (e.g., dopamine, dobutamine, amrinone, milrinone) and/or vasodilators (e.g., 
nitroglycerin, nitroprusside, hydralazine) may be needed to increase cardiac output.  In 
order to decrease intravascular volume and preload, diuretics are usually required.  For 
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the treatment of acute and severe heart failure, intravenous loop diuretics (e.g., 
furosemide and bumetanide) are usually the drugs of choice.10   
Regarding the long-term management of chronic heart failure, the first step is to 
correct any underlying disorders such as anemia or hyperthyroidism.  In CHF patients, 
compensatory mechanisms such as sodium and water retention will occur, leading to 
systemic and pulmonary congestion.  Therefore, diuretics are vital in the prevention of 
decompensation.  Other pharmacological agents include ACEI and β-adrenergic blockers.  
Digital glycosides are used in the long-term management to increase cardiac index, and to 
decrease systemic vascular resistance and pulmonary capillary wedge pressure.  
However, digitalis glycosides have not been shown to reduce CHF-related mortality.16  In 
addition to the pharmacological agents, patients should follow recommended exercise 




CARDIOVASCULAR RISK FACTORS 
 
Since the 1960s, several intervention studies and clinical trials, demonstrating the 
beneficial effects of reducing risk factors for cardiovascular disease, have been 
conducted.2  Public health efforts to reduce tobacco use, reductions in the consumption of 
saturated fats and cholesterol, and the increase of hypertensive patients receiving 
treatment have all contributed to the reduction of morbidity and mortality of 
cardiovascular diseases and stroke events (Appendix I).  Additionally, improvements in 
detection, medical care, medications, emergency services, and an increase in coronary-
care units have contributed to the reduction in cardiovascular events.2 
 
Several prospective cohort studies have shown that the risk of developing a 
cardiovascular disease is directly related to a complex relationship of several factors. 17  
Major positive risk factors for the development of CHD are:  older age (≥ 45 years of age 
for men and ≥ 55 years for women), smoking, hypertension, low HDL concentration, 
hyperlipidemia, and a family history of premature heart disease.17  Of note, diabetes is no 
longer a separate risk factor and according to the Adult Treatment Panel III guidelines, 
diabetes is considered a CHD risk equivalent (risk for major coronary events equal to that 
in established CHD).  Through the use of medications and preventative programs (e.g., 





 “Smoking acts both independently of, and synergistically with, other major risk 
factors for coronary heart disease.”18  Smoking can disrupt the endothelium and 
precipitate coronary spasms, thereby possibly contributing to a myocardial infarction in 
patients with minimal atherosclerosis.19  The progression of atherosclerosis is directly 
related to the total pack-years of smoking.18  Roughly 20 percent of all cardiovascular 
related deaths are smoking-related.20  The Centers for Disease Control estimates that 25.0 
million adult men (25.7 % of US males) and 22.6 million women (21.5% of US women) 
were smokers in 2001.  Race and gender smoking prevalence rates are detailed in 
Appendix J.20   
 
The smoking prevalence rates are higher among those with 9-11 years of 
education (35.4%) versus those with greater than 16 years of education (11.6%) and were 
the highest among those living below the poverty level (33.3%).20  Even individuals who 
do not smoke may be at an increased risk from second-hand smoke.  Studies have found 
that exposure to passive smoke may increase the risk of death from CHD by up to 30 
percent.20  Individuals who smoke or are exposed to smoke can return to baseline risk 
levels over time and become equivalent to non-smokers.  The excess risk is decreased by 
50 percent one year post smoking cessation and can return to baseline levels within 15-20 
years.18,20  Smoking among people 18 and older has declined about 44 percent since 




In addition to cardiovascular disease, smoking has been shown to be a significant 
risk factor in the development of several medical conditions.  Most notable of these 
conditions are lung cancer, aerodigestive cancer, and chronic obstructive pulmonary 
disease (COPD).  The hazards associated with smoking depend on several factors such as 
age at onset, number of cigarettes per day, cigarette characteristics, and degree of 
inhalation.22  These factors can vary over time, making the determination of smoking 
prevalence and associated risk very difficult.  Therefore, current smoking prevalence 
alone would be an insufficient indicator for the accumulated risk from smoking.22  
However, “the absolute age-sex-specific lung cancer rates can be used to indicate the 
approximate proportions of deaths due to tobacco not only from lung cancer itself but 
also, indirectly, from vascular disease and from various other categories of disease.”23   
 
Cholesterol  
In addition to smoking, high cholesterol has been identified as an independent risk 
factor for developing coronary heart disease.  Clinical trials utilizing lipid lowering 
agents for the primary and secondary prevention of coronary heart disease related events 
have found significant reductions in morbidity and mortality.17  Roughly 105 million 
Americans age 20 and older have borderline high (200-239 mg/dl) to high (≥ 240 mg/dl) 
total cholesterol levels and, of those, about 42 million Americans have total cholesterol 
levels greater than or equal to 240 mg/dl.  Similar trends in overall elevated total 
cholesterol levels in adults aged 20-74 are noted between different racial/ethnic and 
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gender groups (Appendix K).24  However, beginning at the age of 50, the number of 
women with total cholesterol levels greater than or equal to 200 mg/dl will exceed men.     
   
Hypertension  
Large population studies have shown hypertension to increase the risk of 
developing various cardiovascular diseases.  Hypertensive patients are shown to have 
accelerated development of macrovascular lesions, leading to an increased risk/incidence 
of coronary heart disease, peripheral arterial and cerebrovascular diseases.25  The risk can 
be elevated by as much as two to three times (Appendix L).26  Hypertension has been 
implicated in 35 percent of all atherosclerotic events and in 49 percent of all cases of 
heart failure.  Several studies have shown that the risk from elevated blood pressure can 
be partially reversed through appropriate therapies.26     
  
Prevalence of high blood pressure is shown to increase with age (Appendix M).27  
Of those with hypertension, 31.6 percent are unaware they have it; 27.4 percent are 
controlled with antihypertensive medications; 26.2 percent are not controlled with 
medication; and 14.8 percent are not receiving any hypertensive medication(s).  Racial 
disparities have been noted.  For example, African-Americans have a higher prevalence 
of hypertension (Appendix B, Chart 12); develop hypertension at an earlier age; and have 
higher levels of blood pressures.  In addition to racial/ethnic disparities, people with 
lower education and income tend to have higher levels of hypertension when compared to 





Diabetes has been shown to increase the risk of cardiovascular morbidity and 
mortality.  The abnormal metabolic conditions accompanying diabetes, chronic 
hyperglycemia, dyslipidemia, and insulin resistance, lead to an increase risk of 
macrovascular complications.28  Diabetic patients have a two to four-fold increase in risk 
of developing coronary artery disease.  Seventy-five percent of diabetics die from some 
form of heart or blood vessel disease.29  In one study, the seven-year incidence of 
developing a first MI was 20 percent in the diabetic population as compared to 3.5 
percent in the control group. 28  Post MI diabetic patients, as compared to nondiabetic 
patients, are at an increased risk of reinfarction, CHF, and death.  A previous history of 
an MI and a diagnosis of diabetes have been associated with a 45 percent recurrence rate 
as compared to 18.8 percent in nondiabetic patients.28  Furthermore, diabetic patients 
without a previous MI are at the same risk for a future MI as nondiabetic patients with a 
previous MI.28  For this reason, diabetes is classified as a risk equivalent for CAD.  
 
In addition to the effects on CAD, diabetes adversely affects cerebrovascular 
arterial circulation.  The risk of stroke in diabetic patients is increased by 150 to 400 
percent.28  Patients presenting with stroke are three times more likely to have a diagnosis 
of diabetes.  Diabetes also doubles the risk of recurrence and increases total and stroke 




An estimated 10.9 million Americans are diagnosed with diabetes and an additional 
5.7 million Americans have undiagnosed diabetes.  The risk for diabetes for Mexican 
Americans and African Americans is almost twice that for non-Hispanic whites.29  For 
Americans 20 and older, the following have diagnosed and undiagnosed (in parentheses) 
diabetes: 
 
• Non-Hispanic whites 
o Men – 5.4% (3.0%)  
o Women – 4.7% (2.1%) 
• African Americans  
o Men – 7.6% (2.8%) 
o Women – 9.5% (4.7%) 
• Mexican Americans 
o Men – 8.1% (5.8%) 
o Women – 11.4% (3.9%)            
 
Obesity  
Obesity (defined as a BMI of 30 kg/m2 or higher) is a condition affecting roughly 
20 percent of the US population and 22.7 percent of the Texas population.30    Obesity 
has been associated with an increased risk of developing cardiovascular disease and 
diabetes.30,31  Obesity has been linked to increased levels of dyslipidemia, higher blood 
pressures, and glucose intolerance.32  Clustering of cardiovascular risk factors has been 
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found in obese men and women.  In a study conducted by Kannel et al., 56% of obese 
men and 62.4% of obese women were found to have ≥ 2 cardiovascular risk factors.32 
 
Metabolic Syndrome  
Metabolic syndrome is the association of several different risk factors, enhancing 
the tendency of developing cardiovascular complications.  This syndrome is associated 
with insulin resistance, hypertension, central obesity, and dyslipidemia.25  Patients with 
this syndrome are at an increased risk of developing non-insulin dependent diabetes 
mellitus and at an increased cardiovascular risk.       
 
An estimated 47 million U.S. residents have metabolic syndrome, 21.8 percent of 
adults.  The prevalence of this syndrome increases with age, with a prevalence of 6.7 
percent for people aged 20-29; 43.5 percent for ages 60-69; and 42.0 percent for those 70 
and older.1  Men and women and those of different race/ethnicity have a similar 
prevalence of this syndrome.  
 
Arthritis 
With regards to cardiovascular risk, rheumatoid arthritis (RA) has been associated 
with an increased comorbidity and mortality resulting from cardiovascular disease.33  
Patients with RA have been found to have elevated levels of inflammation and 
thrombogenic factors, key factors in the development of cardiovascular disease.33  In a 
large observational cohort study, RA patients were found to have a significant increase in 
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mortality (relative risk (RR) 1.60; 95% CI, 1.55-1.63) and thromboembolic events (RR 
1.47; 95% CI, 1.41-1.54) when compared with nonarthritic patients. 33  A similar trend 
was also found when arthritic patients were compared with osteoarthritis patients, 
mortality (RR 1.72; 95% CI, 1.67-1.78) and thromboembolic events (RR 1.31; 95% CI, 
1.25-1.39).33 
 
Arthritis and chronic joint symptoms affect nearly 70 million Americans, making 
arthritis one of the most prevalent diseases and causes of disability in the United States.34  
The prevalence of arthritis or chronic joint symptoms (CJS) among U.S. adults ranges 
from 19% in adults age 18 – 44 to 58.8% in adults age 65 and older.34  
 
Rheumatoid arthritis (RA) and osteoarthritis (OA) are two of the most prevalent 
joint disorders.  Rheumatoid arthritis is a systemic inflammatory disease marked by 
symmetrical joint involvement.  Rheumatoid arthritis patients experience chronic 
inflammation of the synovial tissue lining the joint, eventually leading to erosion of bone 
and cartilage.10  Symptoms of RA develop slowly over several weeks to months.  
Symptoms include: fatigue, weakness, loss of appetite, joint pain, muscle pain and 
stiffness.  Osteoarthritis is believed to be caused by a combination of abnormal 
biomechanical stresses on the joint and abnormal biochemical and metabolic changes in 
the chondrocyte and articular cartilage.35    Osteoarthritis usually presents with a localized 
deep aching pain associated with the affected joint.  The pain is not related to the 
destruction of cartilage.  Rather, the pain is from stimulation of nerve endings by 
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mechanical and chemical irritants related to the joint pathology.10  To alleviate the pain 
associated with RA and OA, several pharmacological and non-pharmacological 
treatments are available.  Among the pharmacological treatments, nonsteriodal anti-
inflammatory drugs are the class of medications most commonly used to treat joint pain 





NSAIDs/COX-2 INHIBITORS AND CARDIOVASCULAR RISK 
 
Background 
 Nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most commonly 
prescribed medications in the world.  NSAIDs annually account for roughly 70 million 
prescriptions and 30 billion over-the-counter (OTC) medications sold in the United States 
(US) yearly.36  With the ever-increasing age of the US population, utilization of these 
agents is expected to increase.  Since the 1960s, more than 30 NSAIDs have been 
introduced into the US market.37  Two of the newest NSAIDs, known as COX-2 
inhibitors, were introduced into the market in 1999 under the trade names of Vioxx 
(rofecoxib) and Celebrex (celecoxib).38 Today, there are four COX-2 selective inhibitors 
approved for use in various markets around the world.39 A fifth COX-2 inhibitor, 
lumiracoxib, is currently in phase three development.  A listing of available NSAID and 
COX-2 inhibitors is found in Appendix N.        
One of the primary limitations regarding the use of traditional NSAIDs is the risk 
associated with the development of gastrointestinal ulcers.  Long-term use of NSAIDs is 
associated with a two-to-five fold increase in relative risk (RR) and a 30% attributable 
risk for serious GI-related adverse effects (i.e., ulcer perforation, upper gastrointestinal 
bleeding, and death).40  The gastrointestinal toxicity is caused by the inhibition of COX-1 
mediated prostaglandin production.  Over a decade ago, it was discovered that two 
isoforms existed of the cyclooxygenase enzyme, COX-1 and COX-2.41  While COX-1 is 
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responsible for mediating the integrity of the gastrointestinal mucosa and platelet 
aggregation, COX-2 is primarily involved in the mediation of inflammation and pain.42  
Traditional NSAIDs (e.g., ibuprofen and naproxen) have been shown to inhibit the 
activity of COX-1 and COX-2.  In an effort to minimize the gastrointestinal toxicity, 
while providing relief from pain and inflammation, researchers developed anti-
inflammatory agents that targeted the COX-2 enzyme while minimizing the inhibition of 
the COX-1 isoform.  Due to this selective targeting, the GI protective prostaglandins 
(PGE2) mediated by the COX-1 enzyme are not inhibited.  However, by exclusively 
inhibiting the COX-2 isoform and not the COX-1 isoform, selective COX-2 inhibitors 
may favor a prothrombotic state.43  The proposed mechanism of action for this 
prothrombotic state results from PGI2 inhibition, an inhibitor of platelet aggregation, and 
unopposed Thromboxane (TX) A2 production, a promoter of platelet aggregation.  
Traditional NSAIDs do not share this same characteristic due to their ability to inhibit 
COX-1 mediated TXA2 (see Figure 1).  Some researchers have even hypothesized that 
select NSAIDs (i.e., naproxen) may offer cardioprotective effects.44-46  Prevention of 
nonfatal myocardial infarctions by aspirin’s ability to inhibit COX-1 mediated 












Note:  PG = prostaglandin; TX = thromboxane; COX = cyclooxygenase  
COX-1 
Found in most tissues, 
GI tract, platelets, and 
kidneys.  
COX-2 
Found in select tissues 
– e.g., inflammatory 
cells and kidneys 
Traditional 
NSAIDs
PGE2 – (GI) cytoprotection 
PGI2 – inhibitor of platelet 
aggregation, vasodilatation 
TXA2 – promotes platelet 
aggregation 
 
PGI2 – inhibitor of platelet    
aggregation, vasodilatation 
Inhibit Inhibit





Studies that evaluated the impact of COX-2 selective NSAIDs for their 
cardiovascular and GI safety will be summarized.  Results from two major clinical trials, 
the Vioxx Gastrointestinal Outcomes Research Study (VIGOR) and the Celecoxib Long-
Term Arthritis Safety Study (CLASS), two meta-analysis studies, and six retrospective 
studies (assessing COX-2 cardiovascular risk) will be evaluated.  The use of naproxen as 
a comparator NSAID in the VIGOR trial has been implicated as a possible reason for the 
significant cardiovascular risk associated with rofecoxib.  Therefore, several 
observational studies assessing naproxen for possible cardioprotective effects will also be 





Concern regarding the negative cardiovascular effects of this new class of drug 
became prominent when the VIGOR study was published in November 2000.42  The trial 
was designed to assess the gastrointestinal safety of rofecoxib (Vioxx®).  The study 
comprised 8,076 patients diagnosed with rheumatoid arthritis (RA).  Patients were at least 
fifty years of age and were randomly assigned to receive 50 mg of rofecoxib daily or 500 
mg of naproxen twice daily.  Aspirin use was not allowed in the study; therefore, patients 
requiring aspirin therapy were excluded.  Baseline characteristics were similar in both 
groups.  Over the nine month follow-up period, the rate of GI events was significantly 
lower for the rofecoxib treatment group (RR, 0.5; 95% CI, 0.3-0.6).  However, the 
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incidence of myocardial infarction was significantly lower in the naproxen group as 
compared to the rofecoxib treatment group (0.1% vs. 0.4% respectively, RR 0.2; 95% CI, 
0.1-0.7).         
 
Due to the excessive cardiovascular events experienced in the VIGOR study, 
serious cardiovascular events were evaluated by an Independent Adjudication 
Committee.48  Ninety-eight events were sent for adjudication, 65 in the rofecoxib group 
and 33 in the naproxen group.  Forty-five patients in the rofecoxib group and 19 patients 
in the naproxen group met the criteria for a serious thrombotic cardiovascular event.  The 
overall cardiovascular event rate was nearly double in the rofecoxib group (1.67 per 100 
patient-years at risk) as compared to the naproxen group (0.70 per 100 patient-years at 
risk).  Separating patients into specific cardiovascular categories (cardiac, 
cerebrovascular, and peripheral vascular) revealed varying levels of cardiovascular risk 
between the categories.  A higher cardiac event rate was found in the rofecoxib group 
(1.04 per 100 patient-years at risk) as compared to the naproxen group (0.36 per 100 
patient-years at risk).  In contrast, a significant difference was not noted between the 
rofecoxib group and the naproxen group for cerebrovascular and peripheral vascular 
events.  Results are presented in Appendix O. 
 
Four percent of the VIGOR study population met the Food and Drug 
Administration (FDA) criteria for use of aspirin for secondary cardiovascular 
prophylaxis.  During the study, 33 percent of the myocardial infarctions occurred in this 
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group.  To assess the impact of patients meeting FDA criteria for prophylactic aspirin 
use, patients were stratified into the following categories: “all patients,” “aspirin 
indicated,” and “aspirin not indicated.”  In the initial analysis of the entire study 
population, the rate of myocardial infarctions (MI) was significantly lower in the 
naproxen group as compared to the rofecoxib group (RR 0.20; 95% CI, 0.07-0.58).  
Patients taking naproxen in the “aspirin indicated” group were significantly less likely to 
have an MI as compared to the rofecoxib group (RR 0.00; 95% CI, 0.00-0.60).  Patients 
taking rofecoxib in the “aspirin not indicated” group had an insignificant trend towards 
an increased rate of MIs as compared to the naproxen group (RR 3.03; 95% CI, 0.97 – 
9.09).  The event rate for cardiovascular deaths and cerebrovascular accidents was also 
evaluated.  No significant results were found in these categories.  However, the 
composite endpoint (cardiovascular deaths, MI, and CVA) in all three groups 
demonstrated an unfavorable trend for rofecoxib.  Results are summarized in Appendix P.                  
 
CLASS Study 
 Contrasting with the VIGOR study, the CLASS study found no significant 
increase in cardiovascular risk.49  The CLASS study was a double-blind, randomized 
controlled trial designed to evaluate the gastrointestinal toxicity associated with celecoxib 
(800 mg/day) as compared to ibuprofen (2400 mg/day) or diclofenac (150 mg/day).49  
The trial consisted of 8,059 patients who were at least 18 years old and who were 
diagnosed with osteoarthritis (OA) or rheumatoid arthritis (RA).  In this study, as 
compared to the VIGOR study, patients were permitted to receive ≤ 325 mg/day of 
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aspirin for cardiovascular prophylaxis.  Aspirin users comprised roughly 20% of the 
study population.  Approximately 57% of the patients (n=4,573) were enrolled for the 
entire six months of the treatment.   
The annualized incidence rate of upper GI ulcer complications for celecoxib vs. 
comparator NSAIDs was 0.76% vs. 1.45% (RR 0.53; 95% CI, 0.26 – 1.11).  When 
symptomatic ulcers were included in the analysis, the annualized incidence rate for 
celecoxib vs. NSAIDs changed to 2.08% vs. 3.54% (RR 0.59; 95% CI, 0.38-0.94).  When 
patients taking aspirin were factored out, the annualized incidence of upper GI ulcer 
complications of celecoxib vs. NSAIDs was 0.44% vs. 1.27%, respectively (RR 0.35; 
95% CI, 0.14-0.98).  In non-aspirin users, when symptomatic ulcers were included in the 
analysis, the rates changed to 1.40% vs. 2.91% (RR 0.48; 95% CI, 0.28-0.89).   
When accounting for simultaneous aspirin administration, the relative risk for 
developing upper GI complications increased to 4.5 (P = 0.01, a 95% CI was not 
provided).  In contrast, no significant increase in upper GI complications was found 
among patients taking aspirin and nonselective NSAIDs (RR, 1.7; P = 0.29).  Similar GI 
event rates were noted between patients taking nonselective NSAIDs plus aspirin and 
patients taking celecoxib plus aspirin.  Therefore, patients taking low dose aspirin with 
celecoxib (or possibly other COX-2 inhibitors) may loose or diminish their GI advantage.       
During the study, no significant difference was found regarding the incidence of 
cardiovascular events between celecoxib and comparator NSAIDs.  Since 22 percent of 
the patients in the CLASS study were on low-dose aspirin, a subgroup analysis was 
performed to assess the cardiovascular safety of patients not taking aspirin.  Results 
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indicated no significant increase in cardiovascular events among “non-aspirin” patients 
taking celecoxib versus those taking diclofenac and ibuprofen.  Cardiovascular 
thromboembolic adverse events occurring in the CLASS study are summarized in 
Appendix Q.   
 
Comments - VIGOR and CLASS  
 
 The primary objective of the two major COX-2 clinical trials, CLASS and 
VIGOR, was to determine if celecoxib or rofecoxib had an improved GI safety profile as 
compared to traditional NSAIDs. The CLASS study failed to demonstrate a statistically 
significant difference in complicated GI events between celecoxib and comparator 
NSAIDs.  In contrast, the VIGOR study showed significant reductions in complicated 
upper GI events when compared to naproxen.  Concerning the cardiovascular safety 
profile, the VIGOR study found a significant increase in cardiovascular events among 
patients taking rofecoxib as compared to naproxen.  In contrast, the CLASS study did not 
show significant differences in cardiovascular event rates between celecoxib and 
comparator NSAIDs.   
 One possible reason for this difference is the varying COX-1/COX-2 selectivity 
ratio between celecoxib and rofecoxib.  Selective COX-2 inhibitors do not exclusively 
inhibit the COX-2 isoform; they have varying degrees of selectivity for COX-1 and 
COX-2.  As the selectivity for the COX-2 isoform increases, the GI toxicity decreases 
and the cardiovascular event rate increases.  Rofecoxib has been found to be more 
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specific for the COX-2 enzyme as compared to celecoxib.50  This speculated mechanism 
of action could explain the difference found between rofecoxib and celecoxib.  Other 
possible explanations for the difference between the two clinical studies (VIGOR and 
CLASS) include the use of aspirin in the CLASS study and the use of different 




CLASS and VIGOR vs. Placebo group 
In an effort to clarify the relationship between the cardiovascular risk associated 
with COX-2 inhibitors, Mukherjee et al. compared the cardiovascular event rates of the 
CLASS and VIGOR studies against the combined placebo groups (non-aspirin users) 
from four aspirin primary prevention trials.41  The four aspirin studies included: the US 
Physicians’ Health Study, the UK Doctors Study, the Thrombosis Prevention Trial, and 
the Hypertension Optimal Treatment Trials.51  The total combined population consisted 
of 48,540 patients, with 25,133 treated with aspirin and 23,407 in the placebo group.  The 
annualized MI incidence rate for the placebo group (0.52%) was significantly lower than 
the annualized incidence rates for patients in the VIGOR (0.74%, p = 0.04) and CLASS 
(0.80%, p = 0.02) studies.   
Major limitations exist when conducting an evaluation of this nature.  Of 
particular concern are the heterogeneous factors between the three groups, VIGOR, 
CLASS and placebo.  For example, the VIGOR study used RA patients exclusively as 
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compared to the CLASS study which incorporated both RA (27%) and OA (73%) 
patients.  Rheumatoid arthritis patients have been associated with a 32 percent increased 
risk of developing cardiovascular disease as compared to patients diagnosed with OA.33,52 
 
Rofecoxib Clinical Trials     
                   
 Due to the negative findings from the VIGOR study, Konstam et al. assessed 
cardiovascular (CV) thrombotic events across 23 phase IIb through V rofecoxib studies.53  
The purpose of the meta-analysis was to determine if there was an excess of 
cardiovascular thrombotic events (i.e., CV, hemorrhagic, unknown death, nonfatal MI, 
and nonfatal stroke) in patients treated with rofecoxib versus those treated with placebo 
or traditional NSAIDs.  The analysis consisted of 28,465 patients studied in various 
patient populations and conditions.  Study populations and conditions included: 
rheumatoid arthritis, osteoarthritis, Alzheimer’s, and chronic low back pain.  Comparator 
medications included: naproxen, ibuprofen, nabumetone, and diclofenac.  Results from 
the meta-analysis did not indicate a significant difference in CV thrombotic events 
between rofecoxib and placebo (RR, 0.84; 95% CI, 0.51-1.38) or between rofecoxib and 
non-naproxen NSAIDs (RR, 0.79; 95% CI, 0.40-1.55).  However, when compared with 
naproxen, rofecoxib showed a significant increase in risk (RR, 1.69; 95% CI 1.07-2.69).  
The authors concluded that the difference in cardiovascular events between the rofecoxib 
and naproxen group may have been due to the antiplatelet effects of naproxen.   
 
35
As discussed in the previous study, the limitation regarding heterogeneity 
between study groups can pose significant problems when combining studies.  When 
interpreting the results of the comparison between rofecoxib and placebo, it is important 
to note that over 50 percent of the patient-years at risk consist of Alzheimer’s patients.  
The large percentage of Alzheimer’s patients is due to the long duration of Alzheimer 
studies and the limited use of placebo groups in RA and OA studies.  With regards to the 
comparison between rofecoxib and non-naproxen NSAIDs, only patients with 
osteoarthritis were studied.  It is important to keep in mind that the negative 
cardiovascular results found between rofecoxib and naproxen, in this meta-analysis, was 
primarily driven by the VIGOR study.  The VIGOR study was the only rofecoxib clinical 
trial to show a significant difference in the cardiovascular event rate.  Other factors that 
need to be considered when evaluating this meta-analysis are:  study duration; proximity 
between enrollment and cardiovascular event; and disease specific events (not just the 
aggregate of CV events).  See Appendix R for study results.   
  
Naproxen Use and Cardiovascular Protection  
      
 As a result of the VIGOR study, there was a renewed interest in the 
cardiovascular effects of traditional NSAIDs, with a specific focus on naproxen.  Results 
from the VIGOR study indicated one of three possibilities: (1) rofecoxib increased 
cardiovascular risk; (2) naproxen offers significant cardioprotective benefits; (3) or a 
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combination of the two.  Four recent studies have been published regarding the 




 A matched case control study conducted by Raheme et al. evaluated the effect of 
naproxen vs. other NSAIDs in the prevention of acute myocardial infarction (AMI).44  
The study was comprised of 14,163 subjects taking naproxen and 14,160 patients taking 
other NSAIDs.  Patients were at least 65 years of age and hospitalized for an AMI in 
Québec between January 1, 1992 and December 31, 1994.  An acute myocardial 
infarction was considered the index date.  One control was randomly selected for each 
case and assigned a corresponding index date.  Patients were evaluated one year prior to 
the index date and were classified into four different categories: 
 
• Concurrent exposure – Prescription with a duration that covered or overlapped the 
index date 
• Chronic exposure – Receiving at least 60 days of medication, consisting of at least 
one refill and not exceeding a 25% gap in coverage.  
• Concurrent-chronic exposure – Patients receiving “chronic exposure” and 
exposure on the index date. 
• Interrupted-chronic exposure – Patients with chronic exposure without exposure 




Adjusting for baseline factors, the AMI incidence rate for interrupted-chronic users of 
naproxen was not significantly different from patients taking other NSAIDs (adjusted 
Odds Ratio (OR), 0.98; 95% CI, 0.73-1.33).  However, naproxen showed a significant 
cardioprotective effect when concurrent users (patients taking naproxen at the time of an 
AMI) of naproxen were compared with other concurrent NSAIDs users (adjusted OR, 
0.79; 95% CI, 0.63-0.99).  Concurrent-chronic users of naproxen showed a similar trend 
when compared with other concurrent-chronic users of other NSAIDs (adjusted OR, 




 Solomon et al. conducted a similar study, evaluating 4,425 cases (17,700 control 
patients) of AMI in the New Jersey Medicaid or Medicare and Pharmaceutical Assistance 
for the Aged and Disabled programs.45  A case control study design was used.  Patients 
were evaluated between January 1, 1991 and December 31, 1995.  Twenty-five percent of 
cases and controls had filled an NSAID prescription six months prior to the AMI index 
date or the randomly assigned index date for the control group.  No relationship was 
found between (all) NSAID use and AMI risk during the prior six month period (OR, 
1.00; 95 % CI, 0.92-1.08) or with concurrent NSAID use on the index date (OR, 1.04; 
95% CI, 0.92-1.18).  When individual NSAIDs (naproxen, fenoprofen, etodolac, and 
ibuprofen) were evaluated during the six month period, only naproxen use showed a 
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significant reduction in AMI risk as compared to control (OR, 0.84; 95% CI, 0.72-0.98).  
In contrast, fenoprofen was associated with an increased risk of an AMI (OR, 1.95; 95% 
CI, 1.16-3.30).  Ibuprofen and etodolac showed no significant associations with risk of an 




The third case control study evaluating this issue, conducted by Watson et al., 
found results similar to the previous two case control studies.46  The study utilized the 
British General Practice Research Database and evaluated overall thromboembolic 
cardiovascular events (myocardial infarction, sudden death, and stroke).  Patients aged 40 
to 79 years with rheumatoid arthritis were evaluated over a one-year time frame; patients 
not receiving a prescription for naproxen during the study period were classified as the 
control group.  Three categories of naproxen use were utilized:   
 
• Current – Naproxen use ≤ 30 days from the Index date 
• Past – Naproxen use > 30 days but < 365 days 
• None – Use ≥ 365 days 
  
Patients were aged 40 to 79 years and had a current diagnosis of rheumatoid arthritis.   
Risk of acute thromboembolic cardiovascular events for current naproxen use on the 
index date was significantly lower than the control group (adjusted OR, 0.61; 95% CI, 
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0.39-0.94), while past naproxen use was not significantly different from control (OR, 
0.87; 95% CI, 0.65-1.16). 
   
Study 4 
 
The final study was an observational cohort study consisting of Tennessee 
Medicaid patients evaluated between January 1, 1987 and December 31, 1998.47  The 
purpose of this study was to evaluate NSAIDs and the risk associated with serious 
coronary heart disease (i.e., acute MI or death from coronary heart disease).  The 
population consisted of 362,882 case and control subjects, matched for age, sex, and date 
NSAID use began.  The control group was randomly drawn from the population and 
excluded patients taking NSAIDs.  Study results found no significant difference between 
(all) NSAID users and the control group (RR, 1.05; 95% CI, 0.97-1.14).  Similar results 
were found when only naproxen was compared to the control group (RR 0.95; 95% CI, 
0.82-1.09).   However, when directly comparing naproxen users with ibuprofen users, a 
significant reduction in coronary heart disease was found (RR, 0.83; 95% CI 0.69-0.98).   
 
All four of these studies lend support to the concept that naproxen may provide 
some level of cardiovascular protection.  However, it is unlikely that the four to five-fold 
increase in MI risk found in the VIGOR study can be accounted for by this benefit 
alone.43,47  One possible reason for the difference in cardiovascular risk between 
concurrent (patients taking naproxen at the time of cardiovascular event) and non-
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concurrent users of naproxen is the limited ability (~ 8 hours) of naproxen to inhibit 
platelet thromboxane generation for long periods of time.50,52  The short duration of 
naproxen’s antiplatelet effects suggests that inconsistent naproxen use may not provide 
prophylactic cardioprotective effects.  Limitations among these studies include: the 
inability to control for OTC products, particularly aspirin; patient differences between 
case and control groups; and lifestyle factors such as smoking and obesity.  Unmeasured 
potential confounders between NSAID users and nonusers may have been minimized by 
comparing two different NSAID groups.               
 




 To address the concern regarding the possible cardiovascular risk associated with 
COX-2 inhibitors, a retrospective cohort study was conducted among Tennessee 
Medicaid (TennCare) patients.54  Patients in the study were between 50-84 years of age 
and enrolled in TennCare between January 1999 and June 2001.  The study evaluated 
378,776 patients, of whom 202,916 were control patients; 22,337 were taking celecoxib; 
24,132 were taking rofecoxib; and 129,391 patients were taking naproxen or ibuprofen.  
Patients were classified into four categories: 
 
• Non-User – No NSAID exposure within 365 days of enrollment. 
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• Current exposure – Use of an NSAID on that day according to days of supply 
• Former exposure – No use of an NSAID on that day.  
• New User – Patients who began use of an individual NSAID during the follow-up 
period.    
 
The primary endpoint assessed was serious coronary heart disease.  Results were 
adjusted for age, sex, and comorbidities.  Results indicated no associated increased risk of 
serious CHD from ibuprofen, naproxen, or celecoxib when compared to the control 
population.  Additionally, patients taking less than or equal to 25 mg of rofecoxib where 
not found to be at an increased risk.  However, for patients taking greater than 25 mg of 
rofecoxib, the risk ratio compared to non-users increased to 1.7 (95 % CI, 0.98-2.95, p = 
0.058) and for new users of rofecoxib compared with non-users, the risk ratio increased 
to 1.93 (95% CI, 1.09-3.43, p = 0.024).  Similar results were found when high-dose 
current and new users of rofecoxib were compared with celecoxib (adjusted RR, 1.78; 
95% CI, 0.99-3.21, p = 0.056 / adjusted RR, 2.20; 95% CI, 1.17-4.10, p=0.014, 
respectively).  Of note, only 3,887 patients in the study received doses greater than 25 mg 
of rofecoxib.  Results (for new users) and study variables are provided in Tables 1.1 – 










A second retrospective cohort study was conducted using the administrative 
health care data from Ontario, Canada, from April 1998 to March 2001.55  Patients 
included in the study were 66 years of age and older and were initiated on either 
celecoxib (n = 15,271), rofecoxib (n = 12,156), naproxen (n = 5,669), or non-naproxen 
NSAIDs (33,868).  Additionally, 100,000 randomly selected control subjects not taking 
any NSAIDs during the study were selected.  Subjects receiving NSAIDs were required 
to receive continuous exposure of the drug during the study.  Information was obtained 
from pharmacy refill records and a 20 percent grace period was allowed on the previous 
day supply to refill the next prescription.  Also, patients in the nonselective NSAID group 
were allowed to switch between different nonselective NSAIDs.  Patients were followed 
up to a year after the index date.  The primary outcome assessed was the incidence of 
acute myocardial infarctions.  Results were adjusted for age, sex, and cardiovascular risk 
factors.  No significant increase in cardiovascular risk was found in any of the four 
subgroups when compared with the control group or each other.  Additionally, patients 
taking naproxen did not show a significant reduction in MI incidence as compared to the 
control group (Adjusted rate ratio – 1.0; 95% CI – 0.6-1.7).  Results and study variables 








 The study conducted by Solomon et al. evaluated the association between COX-2 
inhibitors and acute myocardial infarctions in older adults.56  The case-control study was 
comprised of 54,475 patients 65 years of age and older (mean age ~ 80) enrolled in the 
New Jersey and Pennsylvania Pharmaceutical Assistance Programs during 1998, 1999, 
and 2000.  The 10,895 AMI cases were matched by age, gender, and month of index date 
to controls.   Confounding factors were controlled for by using logistic regression 
models; a detailed list of confounding factors can be found in Table 1.1.  Study groups 
consisted of celecoxib and rofecoxib users subdivided by dose (any, high, and low dose) 
and duration (≤ 30 days; 31-90 days; and > 90 days) of exposure.  Rofecoxib and 
celecoxib were compared to non-NSAID users, each other, ibuprofen, naproxen, and 
“other” NSAIDs.  Results indicated that short term use (< 90 days) of rofecoxib was 
associated with an increased risk of an AMI compared to similar celecoxib users (results 
in Table 1.2).  Long-term use of rofecoxib (> 90 days) was not associated with an 
increased risk when compared to celecoxib (adjusted OR, 0.96; 95% CI – 0.72-1.25).  
High dose rofecoxib (> 25 mg) was associated with a higher cardiovascular risk than low 
dose rofecoxib users (≤ 25 mg) when compared to high dose and low dose celecoxib 
users, respectively.  No duration category for celecoxib was associated with an increased 





Study 4  
 
David Graham and colleagues conducted a nested case-control study among 6 
million California Kaiser Permanente members to evaluate the cardiovascular risk 
associated with NSAIDs and COX-2 inhibitors.57  The “nested” population was 
comprised of 1,394,764 men and women 18 - 84 years of age who received a COX-2 
inhibitor or non-selective NSAID between 1999 and 2001.  There were 8,199 AMI events 
and 1,524 sudden cardiac deaths.  These events were matched to controls based on index 
date, birth year, gender, and health plan region.  The study groups were current users of 
NSAIDs/COX-2 inhibitors (exposure overlaps index date), recent users (1-60 days prior 
to index date), and those with remote exposure (> 60 days prior to index date).  
Covariates were controlled for in the model and are listed in Table 1.1.  Study results 
revealed no cardio-protective effects of naproxen, rather they reveal an increase in 
cardiovascular risk (Adjusted OR – 1.18; 95% CI – 1.04-1.35).  High dose rofecoxib (> 
25 mg / daily) was associated with a 3 fold increase in risk.  No significant increase in 
risk was found with low dose rofecoxib when compared to the control group (aOR – 
1.29; 95% CI – 0.93 – 1.79).  Lastly, a higher cardiovascular risk was found with low 
dose rofecoxib when compared to celecoxib (results not provided).  Study results and 
study variables are provided in Tables 1.1 – 1.2.   
 The study also involved a telephone survey of randomly selected controls exposed 
to celecoxib, ibuprofen, naproxen, rofecoxib, or remotely exposed controls in order to 
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evaluate the use of low-dose aspirin, OTC-NSAIDs, smoking history, and family history 




 Two articles reported results from a study that used prescription event monitoring 
data in England to assess the cardiovascular safety of celecoxib and rofecoxib as 
compared to meloxicam.58,59  Subjects were identified from prescriptions written by 
general practitioners between December 1996 – March 1997 for meloxicam; May 2000 – 
December 2000 for celecoxib; and July 1999 – November 1999 for rofecoxib.  General 
practitioners were sent a questionnaire requesting information about patient factors and 
events occurring during and after exposure.  Endpoint events occurring over nine months 
were divided into three separate categories, cerebrovascular events, cardiovascular 
events, and peripheral venous thrombotic events.  After adjusting for age and sex, the 
cerebrovascular event rate was 1.66 times (95% CI, 1.10 – 2.51) higher for celecoxib 
users and 1.68 times (95% CI 1.15 – 2.46) higher for rofecoxib users, as compared to 
meloxicam users.  No difference in cardiovascular events were found between celecoxib 
or rofecoxib and meloxicam (RR 1.72; 95 % CI 0.87 – 3.40 / RR 1.38; 95% CI 0.71 – 
2.67, respectively).  Regarding peripheral venous thrombotic events, no significant 
difference between celecoxib and meloxicam were found (RR 1.06; 95% CI, 0.51 – 2.19) 
and a reduced risk (RR 0.29; 95% CI, 0.11 – 0.78) was found with rofecoxib as compared 
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to meloxicam.  Due to methodological concerns (non-responders and only two covariates 
used, age and sex), results and study variables were not provided in Tables 1.1 – 1.2.        
Study 6  
 Kimmel et al. conducted a case-control study evaluating the cardiovascular safety 
of celecoxib and rofecoxib.60 Patients (1718) who experienced a myocardial event and 
control subjects (6800) were evaluated for exposure to study medications via telephone 
interviews.  The study had a 50 percent response rate.  When compared to non-NSAID 
subjects, the study found a cardioprotective effect with celecoxib (aOR, 0.43; 95% CI, 
0.23 – 0.79) and traditional NSAIDs (aOR, 0.61; 95% CI 0.52 – 0.71).  Naproxen 
specifically was found to decrease cardiovascular risk by nearly 2 fold (aOR, 2.08; 95% 
CI, 1.37 – 3.13)  Rofecoxib was not associated with an increased risk when compared to 
non-NSAID subjects (aOR, 1.16; 95% CI, 0.70 – 1.93).  However, when compared to 
naproxen, rofecoxib was associated with an increased risk (aOR, 3.39; 95% CI 1.37 – 
8.40).  Celecoxib vs. ibuprofen and diclofenac did not reveal a cardioprotective or 
cardionegative effect (aOR, 0.77; 05% CI, 0.40 – 1.48).  Recall bias and low response 
rate may limit the interpretability of these results.  Therefore, results and study variables 

















Table 1.1  Retrospective COX-2 studies – Study variables. 
 
Study 1 
Ray et al. 54 
Study 2 
Mamdani et al. 55 
Study 3 
Solomon et al. 56 
Study 4 
Graham et al. 57 
Demographics Demographics Demographics Demographics 
Age  Age Age Age 
Sex  Sex Sex Sex 
Ethnicity  -- Ethnicity  -- 
Health care use Health care use Health care use Health care use 
Hospital admissions 
(non-cardiovascular) 
Any Hospital visit No. Physician visits Hospital admissions 
(non-cardiovascular) 
ER visits -- Hospitalized past year Cardiovascular ER 









AMI Malignancy AMI AMI / 
Revascularization 





Revascularization Other ischemic heart 
disease 
Heart failure Heart failure Heart failure Heart failure 
PVD Noninfarct CAD Stroke Cardiac arrhythmia 
RA Stroke RA PVD 
-- -- OA Stroke 
Drugs – past yr. Drugs – past 120 dys. Drugs – past yr. Drugs – past yr. 
Current aspirin use  No. different drugs No. different drugs ACE inhibitor 
Anti-arrhythmic Aspirin Diabetes (? Drug) ARB 
ACE inhibitor Anti-arrhythmic Hypertension (? Drug) Anti-arrhythmic 
Anticoagulant ACE inhibitor Statin Anticoagulant  
Aspirin Anticoagulant Anticoagulant  B-blocker 









Digitalis glycoside B-blocker -- Hypoglycemic agent 
Antidiabetic agent Digitalis glycoside -- Lipid-drug  
Lipid-drug Antidiabetic agent -- Loop diuretic  
Loop diuretic  Lipid-drug -- Nitrate 
Nitrate Loop diuretic  -- Platelet inhibitor 
Other Antihypertensive Other Antihypertensive -- Thiazide diuretic  
Platelet inhibitor Nonloop diuretics  -- Steroid high dose  
Thiazide diuretic  Estrogen -- HRT 
Oestrogen -- -- -- 
Abbreviations:  IHD – ischemic heart disease; AMI – acute myocardial Infarction; HRT – hormone 
replacement therapy; No. – number; PVD – peripheral vascular disease; RA – rheumatoid arthritis; CAD – 
coronary artery disease; ER – emergency room; yr. – year; ACE – Angiotensin-converting Enzyme ; ARB 









Table 1.1  Continued – Retrospective COX-2 studies – Study variables. 
 
Study 1 
Ray et al. 54 
Study 2 
Mamdani et al. 55 
Study 3 
Solomon et al. 56 
Study 4 
Graham et al. 57 
Exclusion Criteria  Exclusion Criteria  Exclusion Criteria Exclusion Criteria 
Cancer None Cancer None 
HIV -- HIV -- 
Renal failure -- Coagulopathy -- 
Liver injury -- -- -- 
Respiratory failure -- -- -- 
Serious immunological 
disorder 
-- -- -- 
End point(s)  End point(s) End point(s) End point(s) 
AMI AMI AMI AMI 
Death – IHD  -- Sudden cardiac death 
Other  Other Other Other 
-- Long-term care Nursing home resident Treated by 
rheumatologist 
-- Low-income status -- Health plan region 
   Smoking-related 
diagnoses  
Abbreviations:  IHD – ischemic heart disease; AMI – acute myocardial Infarction; HRT – hormone 
replacement therapy; No. – number; PVD – peripheral vascular disease; RA – rheumatoid arthritis; CAD – 
coronary artery disease; ER – emergency room; yr. – year; ACE – Angiotensin-converting Enzyme ; ARB 
























Table 1.2  Summary of results from studies one through four.  
 
Study 1…. Ray et al. 54 Person-years Events Adjusted RR 95% CI 
Non-users* 237,975 3,085 1.00 -- 
Ibuprofen  4,319 52 1.01 0.77-1.33 
Naproxen  6,489 72 0.92 0.73-1.16 
Celecoxib 4,509 55 0.88 0.67-1.16 
Rofecoxib ≤ 25 mg 3,430 47 1.02 0.76-1.37 
Rofecoxib > 25 mg  500 12 1.93 1.09-3.42 
Study 2…. Mamdani et al. 55 Person-years Events Adjusted RR 95% CI 
Non-users* 51,194 419 1.00 -- 
Non-selective NSAIDs 11,085 134 1.2 0.9-1.4 
Naproxen 1,559 15 1.0 0.6-1.7 
Celecoxib 7,004 75 0.9 0.7-1.2 
Rofecoxib 4,806 58 1.0 0.8-1.4 
Study 3….Solomon et al. 56 Number  Events Adjusted OR 95% CI 
Rofecoxib (celecoxib*) 941 225 1.24 1.05-1.46 
Celecoxib (non-user*) 2,140 425 0.93 0.84-1.02 
Rofecoxib (non-user*) 941 225 1.14 1.00-1.31 
Celecoxib (naproxen*) 2,140 425 0.95 0.74-1.21 
Rofecoxib (naproxen*) 941 225 1.17 0.90-1.52 
Celecoxib (ibuprofen*) 2,140 425 0.98 0.76-1.26 
Rofecoxib (ibuprofen*) 941 225 1.21 0.92-1.58 
Celecoxib (other NSAID*) 2,140 425 0.95 0.82-1.10 
Rofecoxib (other NSAID*) 941 225 1.17 0.99-1.38 
Rofecoxib ≤ 25 mg (celecoxib ≤ 200 mg*) -- -- 1.21 1.01-1.44 
Rofecoxib > 25 mg (celecoxib > 200 mg*) -- -- 1.70 1.07-2.71 
Rofecoxib (celecoxib*) 1 to 30 days -- -- 1.40 1.12-1.75 
Rofecoxib (celecoxib*) 31 to 90 days -- -- 1.38 1.11-1.72 
Rofecoxib (celecoxib*) > 90 days -- -- 0.96 0.72-1.25 
Study 4….Graham et al. 57 Cases Control Adjusted OR 95% CI 
Remote use* (> 60 days prior to index) 4,699 19,876 1.00 -- 
Recent use (1-60 days prior to index) 1,728 6,339 1.14 1.06-1.22 
Current use (overlapped index date)     
Celecoxib 126 497 0.86 0.69-1.07 
Ibuprofen 674 2,606 1.09 0.99-1.21 
Naproxen 369 1,416 1.18 1.04-1.35 
Rofecoxib ≤ 25 mg 58 190 1.29 0.93-1.79 
Rofecoxib > 25 mg 10 8 3.15 1.14-8.75 
Other NSAIDs 1,864 535 1.16 1.04-1.30 
Abbreviations: PVT – peripheral venous thrombosis; CI – confidence interval; OR – odds ratio; RR – risk 
ratio 




Rofecoxib Withdrawal  
 
 On September 30, 2004 Merck and Co. withdrew rofecoxib from the market due 
to excess risk of myocardial infarctions and stroke.61  The decision to remove rofecoxib 
from the market resulted from negative cardiovascular findings in the APPROVe trial 
(Adenomatous Polyp Prevention On Vioxx), testing rofecoxib for adenomatous polyposis 
prevention.  The study began in 2000 and consisted of 2,600 individuals with colon 
polyps.  Of note, the study did not allow patients to have any cardiovascular disease.61  
Patients received either 25 mg of rofecoxib or a placebo.  Participants were between 40 – 
96 years of age, with approximately 62% male and 38% female.  Aspirin use < 325 mg 
per day was permitted during the study.62  Results indicated that 3.5 percent of 
individuals assigned to rofecoxib had a myocardial infarction or stroke, as compared to 
1.9 percent of individuals assigned to the placebo group.61  Although some cardiovascular 
events occurred during the first 18 months of the study, the link was not statistically 
evident until after 18 months of chronic use.62 
 
Celecoxib Cardiovascular Safety  
             
 Just ten weeks after rofecoxib was withdrawn from the market, Pfizer announced 
that patients taking celecoxib in a long-term cancer prevention trial experienced a 2.5-
fold increase in risk of experiencing a cardiovascular event compared to those taking a 
placebo.  Patients in the Adenoma Prevention with Celecoxib (APC) trial were taking 400 
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mg and 800 mg of celecoxib daily.  In contrast, a second long-term study, the Prevention 
of Spontaneous Adenomatopus Polyps (PreSAP) trial, has not revealed an increased risk 
in patients taking 400 mg daily of celecoxib as compared to those taking placebo.  The 
two studies, comprising 3,600 patients, are following patients over a five-year period. 
From these two studies, nearly 2,400 patients evaluated in the cardiovascular analysis had 
completed at least two years of treatment. 63 
 
Biological Plausibility  
  
 Inhibition of the COX-1 enzyme has been shown to increase the risk of upper GI 
bleeding by inhibition of thromboxane (TX) A2 mediated platelet function and 
impairment of prostaglandin (PG) E2 mediated cytoprotection (see Figure 1).50  Whereas, 
“selective COX-2 inhibition blocks PGI2 [for explanatory purposes, PGI2 serves to inhibit 
platelet aggregation and acts as a mediator of inflammation64] formation without 
inhibiting platelet derived TXA2, thereby increasing platelet activation, adhesion, and 
aggregation with a resultant possibility for thrombosis and ischemic events.”43  Large 
clinical trials have demonstrated aspirin’s ability to prevent myocardial infarctions and 
ischemic strokes through inhibition of platelet COX-1.50  Traditional NSAIDs are also 
believed to provide varying levels of cardiovascular protection through the inhibition of 
COX-1.  Even though celecoxib and rofecoxib specifically target the COX-2 isoform, 
they do have varying levels of COX-1 inhibition.50,65  The biochemical selectivity of 
rofecoxib for COX-2 as compared to COX-1 has been shown to be up to nine times 
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greater than celecoxib.50  Additionally, celecoxib demonstrated a dose-dependent 
inhibition of platelet COX-1 up to 800 mg.50,65  In contrast, rofecoxib did not demonstrate 
a dose response relationship with platelet COX-1 activity up to 1000 mg.  The high dose 
of celecoxib (800 mg) in the CLASS study may have provided sufficient inhibition of 
COX-1 to prevent a significant number of cardiovascular events.     
Results from the CLASS study failed to show a significant difference in rates of 
complicated GI and cardiovascular events between celecoxib and comparator NSAIDs.  
Results may reflect the inadequate selectivity of celecoxib for the COX-2 enzyme.  In 
contrast, rofecoxib demonstrated a significantly lower incidence of endoscopic ulcers 
when compared with naproxen.  However, rofecoxib did demonstrate a higher incidence 
of cardiovascular events as compared to naproxen.  Results (GI and cardiovascular) from 
the VIGOR study may reflect the enhanced selectivity of rofecoxib for the COX-2 
isoform.           
Further research supporting negative cardiovascular effects of COX-2 inhibition 
revealed that COX-2 may be a significant factor in late phase ischemic preconditioning 
(ischemic preconditioning is a process whereby brief episodes of sublethal ischemia 
render the myocardium resistant to subsequent ischemic stress).  The inhibition of COX-2 
activity may add to myocardial cell death by obliterating the innate defensive response of 
the heart against ischemia and reperfusion injury.66    
Unlike aspirin and traditional NSAIDs, in vitro studies have found that celecoxib 
and rofecoxib do not inhibit platelet aggregation or prolong bleeding time.67   
Interestingly, one study suggests that ibuprofen and celecoxib may antagonize the COX-1 
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inhibition produced by aspirin.  Celecoxib, with some COX-1 selectivity may compete 
with aspirin’s platelet inhibitory effects.  In contrast, rofecoxib was not shown to interfere 
with aspirin’s antiplatelet effects.  This could be problematic when evaluating 
cardiovascular risk among patients taking aspirin for cardiovascular protection.  Of note, 
one study did not demonstrate the same association with celecoxib and aspirin.67    
One theory explaining the association between rofecoxib and cardiovascular risk, 
is the effect of rofecoxib on human low density lipoprotein (LDL) oxidation.  LDL 
oxidation is an important contributor to atherosclerosis.68  This effect is believed to be 
related to the chemical structure and not related to COX-2 inhibition.  Etoricoxib and 
rofecoxib exhibited prooxidant activity; whereas, celecoxib, valdecoxib and traditional 
NSAIDs were not associated with changes in lipid peroxidation rates.          
Another possible factor explaining the difference in cardiovascular events 
between rofecoxib and celecoxib is the propensity of these agents to alter blood pressure 
and cause edema.  Even though both agents have been found to affect blood pressure and 
edema, a randomized double-blind study comparing the two found significantly higher 
levels of edema and elevated blood pressure in the rofecoxib group.69  Data also suggest 
that COX-2 inhibitors may provide significant attenuation of the antihypertensive effects 








    
The clinical trials to date were not designed to adequately evaluate the 
cardiovascular risk profiles of the COX-2 inhibitors.  The low cardiovascular risk (less 
than one percent per year) and the short follow-up period in both the VIGOR and CLASS 
trials (9 and 6 months, respectively), limit the ability to detect moderate differences of 
major cardiovascular events between COX-2 inhibitors and traditional NSAIDs.33,50  The 
negative results of the VIGOR study could be explained by chance, selective inhibition of 
COX-2, prooxidant activity, effects on hypertension and edema, cardioprotective effects 
of naproxen, or a combination of these factors.      
To date, no prospective studies have been specifically conducted to evaluate the 
cardiovascular risks associated with COX-2 inhibitors.  In addition to celecoxib, 
rofecoxib, and valdecoxib, several NSAIDs possess some COX-2 selectivity (e.g. 
diclofenac and etodolac).  To date, no study has specifically examined etodolac’s or 
diclofenac’s cardiovascular risk.   
Several researchers have indicated the need for larger, more rigorous, prospective 
randomized studies to evaluate the potential cardiovascular effects of selective COX-2 
medications.  However, large prospective experimental studies can be costly and time 
consuming.  Historical cohort studies and case control studies can be a timely and 
effective method for evaluating the potential cardiovascular risks associated with COX-2 
inhibitors.   
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Information obtained from epidemiological studies evaluating the possible 
cardiovascular risk associated with COX-2 inhibitors will help researchers and clinicians 
determine appropriate therapeutic regimens for the treatment of patients.  Additionally, 
the information obtained will allow evaluation of the potential tradeoffs associated with 
COX-2 inhibitors in relation to GI and cardiovascular events.             
Researchers have advocated the use of aspirin in patients with increased 
cardiovascular risk taking COX-2 inhibitors.  However, it is possible that concomitant 
use of aspirin may not fully offset the increased risk of selective COX-2 inhibitors.  
Limited data are available regarding the gastrointestinal effects of combining aspirin with 
COX-2 inhibitors.  The addition of aspirin could negate the gastrointestinal benefits that 
COX-2 inhibitors provide.    
Due to the rising popularity of this new class of medication, future research 
evaluating the cardiovascular differences between the COX-2 inhibitors and traditional 
NSAIDs is warranted.  Additionally, further research is needed to evaluate the possible 




PURPOSE – OBJECTIVES - HYPOTHESES 
 
Purpose of the Study  
 
The purpose of this study was to evaluate the association of cardiovascular events 
with COX-2 inhibitors.  In particular, the study describes and compares cardiovascular 
events occurring in patients taking traditional NSAIDs and those taking COX-2 
inhibitors.  Furthermore, cardiovascular risk differences or similarities between naproxen 
and other traditional NSAIDs/COX-2 inhibitors will be evaluated.  In order to obtain a 
better understanding of the group dynamics, the cardiovascular profiles associated with 
each study group will be assessed.  Prior aspirin use and duration of NSAID therapy will 













The objectives of this study were: 
I. To evaluate serious cardiovascular events (AMI, stroke, cardiovascular mortality) 
associated with use of COX-2 inhibitors;      
II. To determine if naproxen offers greater cardioprotective benefits compared to other 
NSAIDs; and  
III. To determine if duration of naproxen/COX-2 inhibitor use has an effect on 
cardiovascular outcomes (protective for naproxen and cardio-negative for COX-2 
inhibitors).     
 
Hypotheses   
 
The hypotheses in this study will take the null form.  The following hypotheses were 
tested: 
OBJECTIVE I  
 
Ho1: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking rofecoxib 
versus patients taking a traditional NSAID (i.e., ibuprofen), while 





Ho2: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking celecoxib 
versus patients taking a traditional NSAID (i.e., ibuprofen), while 
controlling for various covariates.  Overall use 
 
Ho3: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking etodolac versus 
patients taking a traditional NSAID (i.e., ibuprofen), while controlling for 





Ho4: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking naproxen 
versus patients taking another traditional NSAID (i.e., ibuprofen), while 






Short-term exposure  
 
Ho5: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking celecoxib short 
term (≤ 180 days) and patients taking ibuprofen short-term, while 
controlling for various covariates.   
 
Ho6: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking rofecoxib short 
term (≤ 180 days) and patients taking ibuprofen short-term, while 
controlling for various covariates. 
Ho7: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking etodolac short 
term (≤ 180 days) and patients taking ibuprofen short-term, while 





Ho8: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking naproxen short 
term (≤ 180 days) and patients taking ibuprofen short-term, while 
controlling for various covariates. 
 
Long-term exposure  
 
Ho9: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking celecoxib long-
term (> 180 days) and patients taking ibuprofen long-term, while 
controlling for various covariates.   
 
Ho10: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking rofecoxib long-
term (> 180 days) and patients taking ibuprofen long-term, while 





Ho11: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking etodolac long-
term (> 180 days) and patients taking ibuprofen long-term, while 
controlling for various covariates. 
Ho12: There is no difference in the risk of experiencing a serious cardiovascular 
event (defined as acute myocardial infarction, death from coronary heart 
disease, or cerebrovascular event) between patients taking naproxen long-
term (> 180 days) and patients taking ibuprofen long-term, while 
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 Prescription and health care services utilization and mortality data were collected 
and analyzed to meet the objectives and test the hypotheses outlined in Chapter One.  
This chapter describes the data sources, study population, study design, study variables, 




 The study used a population-based retrospective cohort study design using the VA 
Heart of Texas Health Care Network databases.  Patients selected for the study were 35 
years of age or older and dispensed a traditional NSAID or COX-2 inhibitor during the 
study period.  The lower occurrence of cardiovascular events in patients younger than 35 
years of age necessitated the removal of these patients from the study population.  The 
study period extended from January 1, 1999 through December 31, 2001.  Mortality data 
provided by the Texas Department of Health and Medicare claims data were used to 
capture additional outcome measures.  Analysis of events in relation to person-time for 
cardiovascular and cerebrovascular events and cardiovascular-related mortality were 





DATA SOURCES  
 
Veterans Administration  
 
 The Department of Veterans Affairs (VA) database offers extensive information 
concerning health services provided to Veterans.  The ability to examine a large number 
of patients and the availability of clinical laboratory data make the VA database 
extremely useful for evaluating drug-related adverse events.  Other strengths of this 
database include: the lack of recall and interviewer bias, the capture of prescription 
claims, the low cost, and the ability to compare similar populations groups.  However, 
there are still weaknesses associated with the database.  Weaknesses include: availability 
of alternative health care coverage, generalizability, compliance issues, inability to 
capture over-the-counter medications, and the use of a drug formulary.     
 
Medical Insurance  
One methodological concern is the ability of Veterans to receive healthcare from 
sources outside the VA healthcare system.  The largest provider of health coverage 
outside the VA healthcare system is Medicare, providing coverage to roughly 25 percent 
of Veterans.  An additional 15.7 percent of Veterans receive some form of health 
coverage other than the VA or Medicare.  The remaining 56 percent of Veterans do not 
receive any additional healthcare coverage outside the VA Health Care System.1  Of note, 
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only 0.1 percent of Veterans have additional prescription coverage.1  A detailed listing of 
health care coverage is provided in Table 2.1. 
 
Table 2.1 – U.S. Veterans Insurance Coverage for Fiscal Year 2000 
 
Type of Insurance* No. (%) 
No Insurance  19,817,247 (56.1) 
Medicare 8,950,800 (25.3) 
Medicare Supplemental  1,040,101 (2.9) 
Major Medical  3,462,186 (9.8) 
PPO/HMO 1,438,686 (3.9) 
Medicaid 130,215 (0.3) 
Prescription 51,759 (0.1) 
All Other  381,237 (1.6) 
Missing 825 (0.0) 
Source:  VA Information Resource Center (VIReC)1 
* Coverage provided by sources outside the VA Health Care System   
 
Generalizability  
Utilizing databases can raise concerns regarding the generalizability of the results 
to other populations.  However, using a single database does have advantages.  By using 
the same database for cases and controls, factors such as socioeconomic status may be 
controlled.2  One of the primary differences between the Veteran population and other 
populations is the disproportionate number of men compared to women.  Women only 
comprise roughly 5 percent of the Veteran population.1  The disproportionate number of 
men to women may be advantageous because other studies evaluating COX-2 inhibitor 
related cardiovascular risk consisted primarily of women (COX-2 inhibitor study groups 
~ 70% women).3,4  Furthermore, the level of comorbidities may be higher in the VA 




Pharmacy data  
Regarding prescription coverage, even though automated pharmacy claims are 
one of the best sources of information on drug use, information concerning compliance 
and use of drugs from outside sources may be lacking.2  Areas of concern are drugs taken 
intermittently for symptomatic relief (i.e., NSAIDs), compliance, over-the-counter drugs 
(OTC), and drugs not on the formulary.2      
 
Compliance and duration of therapy  
To treat painful symptoms, NSAIDs are often used.  These medications are 
usually provided to patients on an as needed basis or as a scheduled regimen.  However, 
many patients will not utilize this therapeutic option to its maximum potential.  For 
example, compliance rates among arthritis patients taking (traditional) NSAIDs range 
from 54% to 85%.5,6  Furthermore, treatment duration may vary between users of 
traditional NSAIDs and COX-2 inhibitors.  A study using the provincial health care 
database in Quebec, Canada to evaluate new users of NSAIDs and COX-2 inhibitors 
found a longer duration of treatment with COX-2 inhibitors than traditional NSAIDs.  
More specifically, the median duration of treatment for patients prescribed celecoxib was 







Over-the-counter drug use  
Regarding automated pharmacy claims data, one factor that may not be accounted 
for is the use of OTC medications, particularly aspirin and NSAIDs.  One benefit of using 
the VA pharmacy database is the fact that OTC aspirin and NSAID use is accounted for 
in their database.  However, even though patients have a financial incentive to obtain 
aspirin and OTC medications through the VA, patients may still obtain these products 
from other sources.         
 
VA Formulary Criteria for COX-2 inhibitors  
One of the primary limitations surrounding the use of prescription claims data 
obtained from the VA is the restricted formulary.  In particular, COX-2 inhibitors are 
limited to individuals with a high risk of developing NSAID-induced GI injury.  Many 
patients are required to receive prior treatment with traditional NSAIDs or preferential 
COX-2 inhibitors.  (Preferential COX-2 inhibitors are NSAIDs with relative COX-2 
selectivity.  Drugs included in this category are etodolac, nabumetone, and salsalate.8)  
The requirement of prior NSAID exposure limited the number of individuals with an 
adequate washout period (period of no NSAID/COX-2 inhibitor use) prior to 
NSAID/COX-2 inhibitor exposure.  A detailed listing of the VA formulary concerning 
COX-2 inhibitors is provided in Table 2.2.8               
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Table 2.2 – Recommendations for the Use of NSAIDs or COX-2 Inhibitors in  
              Veteran Patients (Formulary):  
 
 
• Individuals with a higher risk for NSAID-induced GI injury: 
 
o Prior history of a hospital admission for a serious gastrointestinal event 
(gastroduodenal perforation, ulcer or bleed). 
o Concurrent use of warfarin (reinforce to patients to report any signs and 
symptoms of bleeding. In addition, patients and their INRs should be 
monitored more closely when any new drug is initiated). Both celecoxib 
and rofecoxib may increase INR and may increase the risk for bleeding. 
o Additionally, high risk patients with OA must receive a therapeutic trial of 
acetaminophen 4000 mg qd prior to a COX-2 inhibitor. 
 
• Other individuals (Patients not having a history of hospital admission for a significant 
gastrointestinal event or those not receiving warfarin must have a GI risk score calculated) 
 
o No risk (GI score 0-10) – Use formulary traditional NSAIDs. 
o Moderate risk (GI score 11-15) – Use formulary traditional NSAIDs. 
o Significant risk (GI score 16-20) – Use “preferential COX-2 inhibitors” 
(e.g. etodolac or diclofenac). 
 If no response or intolerant, then traditional NSAID (ibuprofen, 
naproxen, etc) plus proton pump inhibitor (PPI) or misoprostol or a 
COX-2 inhibitor. 
 In patients receiving low dose aspirin for cardiovascular 
prophylaxis, a non-selective NSAID plus a PPI or misoprostol is 
preferred since the GI safety of the COX-2 inhibitors is reduced or 
lost. 
o Substantial risk (GI score > 20) – Salsalate, traditional NSAID 
(ibuprofen, naproxen, etc) plus PPI or misoprostol, or a COX-2 inhibitor. 
 In patients receiving low dose aspirin for cardiovascular 
prophylaxis, a non-selective NSAID plus a PPI or misoprostol is 






Texas Department of Health 
 
Mortality data from the Texas Department of Health was required to capture fatal 
cardiovascular events occurring outside the VA healthcare system.  The VA medical 
databases only capture mortality if someone died at the hospital.  Patients meeting the 
study criteria within the VA database were linked via Social Security Numbers (SSN) to 
the Texas Department of Health mortality database to extract the required information.  
Mortality data were collected from the Texas Department of Health from January 1997 




Another limitation regarding the use of VA healthcare databases is the ability of 
Veterans to receive health care coverage outside the VA health care system.  Veterans 
over the age of sixty-five are eligible to receive medical services through Medicare.  As 
previously discussed, roughly 25% of Veterans receive additional coverage from 
Medicare.1  In order to minimize missing information due to utilization of outside 
healthcare coverage, patients over the age of sixty-five meeting the study criteria were 
evaluated separately in a sensitivity analysis.  Medicare data were collected from January 







The study encompasses patients receiving health care services from the VA Heart 
of Texas Health Care Network, termed Veterans Integrated Service Network (VISN) 17.  
VISN 17 serves a population of 1 million veterans living in 134 counties across central 
Texas.  The network consists of seven medical centers and 58 clinic sites.9  These sites 
are organized under three health care systems: the VA North Texas Health Care System, 
the VA Central Texas Health Care System, and the South Texas Veterans Health Care 
System.  A more detailed representation of the VISN 17 health care system profile is 
provided in Table 2.3 and Figure 2.1. 




Table 2.3 – Veterans Integrated Service Network (VISN) 17 
 
VA North Texas Health Care System  
 
• Medical Centers 
o Dallas VA Medical Center (Dallas, TX) 
o Sam Rayburn Memorial Veterans Center (Bonham, TX) 
• Fort Worth Outpatient Clinic (Fort Worth, TX) 
• Numerous Community-Based Outpatient Clinics  
 
VA Central Texas Health Care System 
 
• Medical Centers 
o Olin E Teague Veterans’ Center (Temple, TX) 
o Waco VA Medical Center (Waco, TX) 
o Thomas T. Connally VA Medical Center (Marlin, TX) 
• Austin Outpatient Clinic (Austin, TX) 
• Numerous Community-Based Outpatient Clinics  
 
VA South Texas Health Care System 
 
• Medical Centers 
o Kerville VA Medical Center (Kerville, TX) 
o Audie L. Murphy Memorial Veterans Hospital (San Antonio, TX) 
• Outpatient Clinics 
o Frank M. Tejeda VA Outpatient Clinic (San Antonio, TX) 
o Corpus Christi Clinic (Corpus Christi, TX) 
o McAllen Clinic (McAllen, TX) 
o Laredo Clinic (Laredo, TX) 
o Victoria Clinic (Victoria, TX) 














INVESTIGATIONAL REVIEW BOARD & DATA USE AGREEMENTS  
 
1. University of Texas at Austin - Approved 
2. University of Texas at San Antonio- Approved  
3. Veterans Administration – North - Approved 
4. Veterans Administration – Central - Approved  
5. Veterans Administration – South - Approved 
6. Texas Tech University - Approved  
7. Texas Department of Health – Bureau of Vital Statistics - Approved  










The primary study objective was to compare the incidence of cardiovascular 
events and death from coronary heart disease in Veterans dispensed NSAIDs and COX-2 
inhibitors.  To meet this objective, a population-based retrospective cohort study design 




Study period  
The administrative health care databases within VISN 17 allowed for cohort 
identification and selection.  The initial selection criterion required the administration and 
use of any NSAID or COX-2 inhibitor between September 30, 1995 through April 1, 
2004.  Due to this restrictive criterion, a control group consisting of patients not receiving 
NSAIDs or COX-2 inhibitors was not available for comparative analyses.  From this 
initial cohort, the sample was further restricted and inclusion and exclusion criteria were 
applied in order to define the final study cohorts. 
 
 The baseline study period was restricted to January 1, 1999 through December 31, 
2001.  This time period was chosen to correspond with the approval of the first COX-2 
inhibitor introduced into the U.S. market and completeness of available data (Medicare 
and TDH data).  Additionally, reports linking cardiovascular risk to COX-2 inhibitors 
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became prominent in the years following 2001.  This information could cause a 
channeling effect.  Therefore, caution should be used in analyzing data after 2001.    Due 
to the concern of channeling, the 2002 data were only incorporated into the study design 
as a sensitivity analysis.   Celecoxib was approved December 31, 1998 and rofecoxib was 
approved May 20, 1999.10  Data from January 1, 1998 to December 31, 1998 were used 
to evaluate prior cardiovascular conditions, NSAID/COX-2 inhibitor exposure, and 
confounding factors.   
 
Study groups  
Patients were stratified into five different study groups determined by NSAID and 
COX-2 inhibitor exposure.  The study groups include: naproxen, ibuprofen, etodolac 
celecoxib, and rofecoxib.  Ibuprofen served as the control for the other four study groups.  
Additionally, naproxen and etodolac also served as a control group in several sensitivity 
analyses.  The initial prescription during the study period was used as the index date.  
Patients were not allowed to receive the study drug one year prior to the index date.  
Additionally, patients who received a prescription for other COX-2 inhibitors or NSAIDs 
in the six months prior to their index date were not allowed in the study (wash-out 









































Duration of Exposure 
 
Duration of cohort involvement started on the index date and lasted until the 
individual experienced a censorship point: study end-point event, exposure to another 
NSAID or COX-2 inhibitor, death (non-cardiovascular related death), discontinued study 
medication, or reached the end of the study (December 31, 2001).  Patients were allowed 
to re-enter the cohort or join a new cohort so long as the patient met the inclusion criteria.  
Patients who died or experienced a study endpoint were not allowed to re-enter the 
cohort.  Due to the short nature of the study, the follow-up period was not limited, thus 
allowing patients to be followed the entire duration of the study.               
 
The study groups were restricted to patients being dispensed enough drug for at 
least 30 days of observation and receiving at least one subsequent prescription.  This 
restriction was used to exclude sporadic users of NSAIDs and to ensure exposure to the 
study medication.  Drug therapy must have begun on or after the start date (January 1, 
1999); patients who started therapy prior to this date were not evaluated.  Patients who 
were dispensed more than one study drug on the index date were excluded.   Patients 
were allowed a 20% grace period on the previous days supply to refill the next 
prescription.  Inpatient pharmacy data were available for a portion of the population; 
patients receiving a study drug while admitted to the hospital were allowed a 10-day 




As mentioned in Chapter One, on September 30, 2004, rofecoxib was voluntarily 
withdrawn from the market due to a recent prospective, randomized, placebo-control 
trial, the APPROVe (adenomatous Polyp Prevention on VIOXX) trial.11,12  In this trial 
involving 2,600 patients with a history of colorectal adenomas (without any 
cardiovascular disease), an increase in cardiovascular risk was found after 18 months of 
continuous therapy.  Of those taking 25 mg of rofecoxib, 3.5 percent of these patients had 
a stroke or myocardial infarction, as compared to 1.9 percent of patients in the placebo 
group.  Results from the first 18 months did not show any increased risk of confirmed 
cardiovascular events.          
 
Therefore, in order to assess the cardiovascular effect of long-term exposure vs. 
short-term exposure to COX-2 inhibitors, the study sample was first restricted to those 
receiving greater than 180 days of study medications.  During the previous 180 days, if a 
patient experienced a study endpoint (i.e., AMI, stroke, and/or AMI related death), he or 
she was excluded from the long-term analysis.  Additionally, patients receiving short-
term (≤ 180 days) therapy were evaluated separately for an increased cardiovascular risk.  
The 180 day time period was chosen due to the short duration (less than 6 months) of 
many of the clinical trials evaluating COX-2 inhibitors.  This decision was made prior to 








Age – The lower occurrence of cardiovascular events in patients younger than 35 years of 
age necessitated the removal of these patients from the study population.  Based on 
national Veterans demographic information, patients under the age of 35 comprise only a 
small proportion of the total population, roughly 2.5%.1  Information regarding age-
related cardiovascular events can be found in Chapter One. 
 
Exposure – Patient observations with less than 30 days of study medication were 
excluded.  Additionally, only observation periods with two or more prescriptions were 
considered.   
 
Washout period – Patients who received a study drug one year prior to the index date 
were excluded.  Additionally, patients exposed to other NSAIDs or COX-2 inhibitors 
within the six months prior to the index date were excluded.     
 
One-year baseline period – Patient observations without at least one year of prior health 









Acute Myocardial Infarction (AMI) – AMI was defined as a patient who received an ICD-
9 diagnosis code of 410.xx.  Research conducted within the VA healthcare system found 
a 96.9% positive predictive value of acute myocardial infarction coding in the primary 
position.16  Patients discharged alive were required to have a length of stay no less than 
three days and no greater than 180 days.  The results from this study are similar to other 
studies validating the positive predictive value of MI ICD-9 codes.  Of note, duration of 
stay and position of the ICD-9 code were not available and were not assessed, thus 
decreasing the positive predictive value of the AMI diagnosis.    
 
Death from AMI – ICD-10 codes: I21 – I22.  
 
Death from “major cardiovascular diseases” – ICD-10 codes: I00 – I78. 
 
Death from “ischemic heart disease” – ICD-10 codes:  I20 – I25.    
 
Cerebrovascular Disease – A study conducted within the VA healthcare system 
assessing code veracity of stroke-related ICD-9 codes has been conducted.  When a high 
sensitivity model was used, results yielded 89% sensitivity, 57% specificity, 60% positive 
predictive value, and 88% negative predictive value.  When a high specificity algorithm 
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was used, the results change to: 59% sensitivity, 84% specificity, 72% positive predictive 
value, and 74% negative predictive value.17 
 
ICD-9 codes high sensitivity model (using all fields): 430, 431, 432.0, 432.1, 432.9, 
434.00 - 434.01, 434.10-434.11, 436 
 
ICD-9 codes high-specificity model (using all fields): 431, 433.01, 433.11, 433.21, 
433.31, 433.81, 433.91, 434.00 - 434.01, 434.10-434.11   
  
Confounding Variables   
The assessment period was one year prior to enrollment (except age) for all covariates. 
 
Neoplasm18 – ICD-9 codes: 140.00 – 239.9, 795.0 - 795.1, V10.00 - V10.99, V71.1, 
V12.72.  
 
Human Immunodeficiency Virus (HIV)18 – ICD-9 codes:  042.00 - 044.99, V08, 795.71, 
79.53, 279.10, 279.19, 795.8. 
 
Renal Failure18,19 – ICD-9 codes: 584.5 - 585, 586, 792.5, V42.0, V45.1, V56.0-V56.32, 




Respiratory failure, insufficiency, arrest18 – ICD-9 codes:  518.5, 518.81 – 518.84, 799.1, 
V461 – V462  
 
Diabetes18 – A diagnosis of diabetes required at least one of two criteria:  1) receiving 
one or more of the following IDC-9 codes:18  250.00-250.99, 790.2, 791.5 - 791.6;  
and/or use of a diabetic medication.            
 
Age20 – Age was assigned at the time of enrollment.  Age was treated as a continuous 
variable.  Participants 35 years of age and older were included.  For descriptive purposes 
age was subdivided into four different categories:  < 64 years of age; 65 – 74 years of 
age; 75 – 84 years of age; and ≥ 85 years of age.            
 
Sex – Male/Female 
 
Race1 – was not included due to missing data.     
 
Rheumatoid arthritis18 – The following ICD-9 Codes were used to define RA: 714.0 –
714.9, 720.0     
 
Osteoarthritis arthritis18 – The following ICD-9 Codes were used to define OA: 715.00 – 




Systemic lupus erythematosus and connective tissue disorders18 – The following ICD-9 
Codes were used to define systemic lupus erythematosus and connective tissue disorders: 
710.0 – 710.9  
 
Heart Failure18,21 – Heart failure was defined as one or more health care visits for heart 
failure - ICD-9 codes:  428.0 – 428.9, 402.01, 402.11, 402.91, 404.01, 404.11, 404.13, 
404.91, 404.93.       
 
Previous AMI21 – The assessment period was one year prior to enrollment into the study.  
The following ICD-9 Codes were used to define previous AMI:  410.xx. 
 
Previous cerebrovascular disease17 – The high-specificity model was used to assess prior 
cerebrovascular disease (with the exception of one sensitivity analysis, in that case the 
high-sensitivity model was used).    
 
ICD-9 codes high-specificity model (using all fields): 431, 433.01, 433.11, 433.21, 
433.31, 433.81, 433.91, 434.00 - 434.01, 434.10-434.11   
 
Peripheral vascular disease21,22 – The following ICD-9 codes were used to define 
peripheral vascular disease: 440.2, 443.1, 443.9, 444.22, 444.81.  Additionally, cilostazol, 
cyclandelate, or pentoxifylline drug use served as an indicator for peripheral vascular 




Angina21 – The following ICD-9 codes were used to define angina: 411 or 413.  
Additionally, patients dispensed a nitrate were classified as having angina.  
 
Atrial fibrillation – The following ICD-9 code was used to define atrial fibrillation: 
427.31  
 
Chronic obstructive pulmonary disease18,22 – The following ICD-9 codes were used to 
define COPD: 490 – 492.8, 496  
 
Baseline Laboratory and Patient Vitals Information 
 
Limited baseline laboratory and patient vitals information were available.  Not 
every patient within the VA healthcare system was assessed for hypertension (BP), 
diabetes (glucose), and dyslipidemia (cholesterol values); subsequently, these factors 
were not included into the model.  Additionally, factors such as height and weight (body 
mass index (BMI)) were not available for all patients and were not included.  If these 
values were incorporated into the study model, the sample size would be severely 
reduced.  Furthermore, patients for whom this information is available may represent a 
healthier population (e.g., regular doctor visits) or a sicker population (e.g., required to 
use medical services).  Methods to deal with missing values, such as multiple imputation 
or list-wise deletion, require the assumption of “missing at random.”  As described 
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previously, patients not utilizing VA healthcare services are more than likely not missing 
at random.  Baseline information will be provided for the following factors in order to 
delineate any major differences between the study groups.  The assessment period was 
365 days prior to enrollment for all laboratory and patient vitals information.            
 
Hypertension20 –  Multiple readings were averaged to obtain an aggregate score.  Patients 
were placed into five categories (for descriptive purposes) based on Framingham risk 
stratification and JNC 7 classification.20,23  The blood pressure categories are presented in 
Table 2.4.  
 
   Table 2.4 – JNC 7 Classification of High Blood Pressure 
BP Classification  Group SBP mmHg DBP mmHg 
Normal I < 120 and < 80 
II 120-129 or 80-84 Prehypertension III 130-139 or 85-89 
Stage 1 Hypertension IV 140-159 or 90-99 
Stage 2 Hypertension V ≥ 160 or ≥ 100 
  
 
Cholesterol24 – Multiple readings were averaged to obtain an aggregate score.  
Cholesterol was divided into four different categories.  These four categories include: 1) 
total cholesterol, 2) low density lipoprotein (LDL), 3) high density lipoprotein (HDL), 
and 4) triglycerides.  Categories were further subdivided based on Framingham risk 
categories and the Third Report of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III) final report.20,24  The subcategories (for descriptive 




   
 Table 2.5 – ATP III / Framingham Classification of Total Cholesterol (mg/dl) 
Classification Group Total Cholesterol Level 
I < 160 Desirable 
II 160-199 
Borderline high III 200-239 





   Table 2.6 – ATP III / Framingham Classification of LDL Cholesterol (mg/dl) 
Classification Group LDL Cholesterol Level 
Optimal  I < 100 
Near optimal/above optimal II 100-129 
Borderline high III 130-159 
High IV 160-189 





   Table 2.7 – ATP III / Framingham Classification of HDL Cholesterol (mg/dl) 
Classification Group HDL Cholesterol Level 
I < 35 Low£ 
II 35-44 
III 45-49  IV 50-59 
High V ≥ 60 






   Table 2.8 – ATP III Classification of Serum Triglycerides (mg/dl) 
Classification Group Triglyceride Level 
Normal  I < 150 
Borderline-high II 150-199 
High III 200-499 






Body mass index25 – Multiple readings were averaged to obtain an aggregate score.  
Height and weight were used to calculate body mass index (BMI).  The following 
formula was used:   
 
BMI = (weight in pounds / (height in inches) x (height in inches)) x 703 
 
Patients were placed into four different categories based on BMI (for descriptive 
purposes).     
  
• Underweight – Below 18.5 
• Normal – 18.5 – 24.9 
• Overweight – 25.0 – 29.9 





To further control for differences in baseline risk for cardiovascular disease, prescription 
drugs were evaluated.  The assessment period was 365 days prior to enrollment.  The 





     
 
      Table 2.9   Baseline Medications 
 
ACE inhibitors / ARBS Lipid-lowering drugs 
Antiarrhythmics Loop diuretics 
Antiplatelets Methotrexate 
Antirheumatics Nitrates† 
Aspirin Other anticoagulants 
β-Blockers Other antihypertensives 
Calcium channel antagonists Peripheral vascular disease drugs† 
Corticosteroids (oral/injectable) Thiazide diuretics 
Digoxin Warfarin 
Estrogen*  
Hypoglycemic agents†  
† Hypoglycemic, nitrates, and peripheral vascular disease drugs were combined with  
corresponding medical diagnoses. 
      * Not included in model, only baseline descriptive information. 
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Statistical Analyses  
 
A historical cohort study design was used to analyze the cardiovascular effects of COX-2 
inhibitors.  An alpha level of 0.05 was used to test for statistical significance.  Analyses 
were conducted using SPSS and SAS software.  Frequency distributions and means for 
the study variables were examined.  Analysis of events in relation to person-time was 
analyzed via the Cox proportional hazard model.  The Wald test was used to determine 
statistical differences between individual NSAIDs/COX-2 inhibitors.  The proportional 
hazards assumption for each variable was assessed in each analysis for any violations.   
 
Proportional Hazards Assumption  
 
 Proportional hazards definition – “the hazard for any individual is a fixed 
proportion of the hazard for any other individual”.13  In other words, one of the key 
assumptions for the Cox regression model is that the ratio of the hazards is constant over 
time.  Violation of the proportional hazard assumption is equivalent to the interaction 
between one or more covariates and time.  Several methods are used to assess the 
proportional hazard assumption.  Two of these methods include graphical evaluation and 
the incorporation of a time-dependent covariate representing the interaction of the 
original covariate and time.  The initial step usually involves assessing the transformed 
Kaplan-Meier curves.  If the hazards are proportional, the survival curves should be 
parallel.  If the graphical results do not look parallel, then one will generate a time 
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dependent covariate by creating interactions between predictors and survival time.  If the 
results are significant then those predictors are not proportional.  Subsequently, “the 
method of diagnosis is also the cure.”13  Even in the event that the proportional hazard 
assumption is violated for some variable, the coefficient estimated for the variable will 




Due the large number of covariates in the model, multicollinearity was checked.  
Multicollinearity is an unacceptably high level of intercorrelation among independent 
variables, causing the effects of the independent variables to be inseparable.14  In the 
presence of multicollinearity, the estimates are unbiased; however, evaluation of the 
relative strength of the explanatory variables and their joint effects are unreliable.14  To 
assess multicollinearity, correlation matrixes were created for all of the variables.  A 











The Cox proportional hazard equation used to analyze the data can be expressed as the 
following: 
 
ln hi(t) = ln λo(t) + β1x1 + β2x2 + β3x3 + β4x4 + β5x5 + β6x6 + β7x7 + β8x8 + β9x9 + β10x10 + 
β11x11 + β12x12 + β13x13 + β14x14 + β15x15 + β16x16 + β17x17 + β18x18 + β19x19 + β20x20 + 
β21x21 + β22x22 + β23x23 + β24x24 + β25x25 + β26x26 + β27x27 + β28x28 + β29x29 + β30x30 + 
β31x31 + β32x32 + β33x33 + β34x34 + β35x35 + β36x36  
                                                                                                                         
Where: 
 
hi(t) = The hazard for individual i at time t;   
 
λo(t) = baseline hazard function;  
 
x1 = rofecoxib versus ibuprofen;   
β1 = eβ1 – the ratio of the estimated hazard; 
 
x2 = celecoxib versus ibuprofen;  
β2 = eβ2 – the ratio of the estimated hazard; 
 
x3 = naproxen versus ibuprofen;   
β3 = eβ3 – the ratio of the estimated hazard; 
 
x4 = etodolac versus ibuprofen;   
β4 = eβ4 – the ratio of the estimated hazard; 
 
x5 = age of the patient; 
β5 = eβ5 – the ratio of the estimated hazard; 
 
x6 = gender of patient; 
β6 = eβ6 – the ratio of the estimated hazard; 
 
x7 = renal failure diagnosis; 
β7 = eβ7 – the ratio of the estimated hazard; 
 
x8 = cancer diagnosis; 
β8 = eβ8 – the ratio of the estimated hazard; 
 
x9 = chronic obstructive pulmonary disease; 
β9 = eβ9 – the ratio of the estimated hazard; 
 
x10 = HIV diagnosis;              
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β10 = eβ10 – the ratio of the estimated hazard; 
 
Cox proportional hazard equation continued  
 
x11 = respiratory failure diagnosis;              
β11 = eβ11 – the ratio of the estimated hazard; 
 
x12 = diabetes diagnosis;              
β12 = eβ12 – the ratio of the estimated hazard; 
 
x13 = rheumatoid arthritis diagnosis;  
β13 = eβ13 – the ratio of the estimated hazard; 
 
x14 = osteoarthritis diagnosis;  
β14 = eβ14 – the ratio of the estimated hazard; 
 
x15 = systemic lupus erythematosus and connective tissue disorders diagnosis;  
β15 = eβ15 – the ratio of the estimated hazard; 
 
x16 = heart failure diagnosis;  
β16 = eβ16 – the ratio of the estimated hazard; 
 
x17 = prior myocardial infarction;  
β17 = eβ17 – the ratio of the estimated hazard; 
 
x18 = previous cerebrovascular incident;  
β18 = eβ18 – the ratio of the estimated hazard; 
 
x19 = peripheral vascular disease;  
β19 = eβ19 – the ratio of the estimated hazard; 
 
x20 = angina;  
β20 = eβ20 – the ratio of the estimated hazard; 
 
x21 = atrial fibrillation diagnosis;  
β21 = eβ21 – the ratio of the estimated hazard; 
 
x22 = thiazide diuretic use;  
β22 = eβ22 – the ratio of the estimated hazard; 
 
x23 = angiotensin converting enzyme (ACE) inhibitor use;  
β23 = eβ23 – the ratio of the estimated hazard; 
 
x24 = antiarrhythmic medication use;  
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β24 = eβ24 – the ratio of the estimated hazard; 
 
Cox proportional hazard equation continued  
 
x25 = anticoagulant medication use;  
β25 = eβ25 – the ratio of the estimated hazard; 
 
x26 = antiplatelet medication use;  
β26 = eβ26 – the ratio of the estimated hazard; 
 
x27 = antirheumatic medication use;  
β27 = eβ27 – the ratio of the estimated hazard; 
 
x28 = aspirin use;  
β28 = eβ28 – the ratio of the estimated hazard; 
 
x29 = β-blocker use;  
β29 = eβ29 – the ratio of the estimated hazard; 
 
x30 = calcium channel antagonist use;  
β30 = eβ30 – the ratio of the estimated hazard; 
 
x31 = digoxin use;  
β31 = eβ31 – the ratio of the estimated hazard; 
 
x32 = lipid-lowering medication use;  
β32 = eβ32 – the ratio of the estimated hazard; 
 
x33 = loop diuretic use;  
β33 = eβ33 – the ratio of the estimated hazard; 
 
x34 = methotrexate use;  
β34 = eβ34 – the ratio of the estimated hazard; 
 
x35 = corticosteroid use (oral/injectable);  
β35 = eβ35 – the ratio of the estimated hazard; 
 
x36 = other antihypertensive medication use;  




Sample Size Considerations 
 
The sample size required for a cohort study depends on five factors.15  The first factor is 
the alpha (α) value or type I error permitted.  Type one error is the probability of finding 
a difference when one does not exist.  For sample size estimation, the conventional α 
value of 0.05 will be used.  The second factor to consider is the beta (β) value or type II 
error permitted.  Type II error is the probability of finding no difference when a 
difference does exist.  The conventional β value of 0.2 will be used for the sample size 
calculation.  The third variable needed to calculate the sample size is the minimum 
relative risk one wants to detect.  For estimation purposes, the minimum relative risk to 
be detected will be 1.25 (arbitrarily chosen).  The expected incidence of the event in the 
control group is the fourth variable required.  The rarer the event, the larger the sample 
size required.  For estimation purposes (based on annual coronary event rates), the 
incidence in the control group will be 0.01 and 0.05 (to provide a range).  The fifth 
variable used in estimating the sample size is the ratio of control subjects to exposed 
subjects.  Additional power is obtained when the ratio of control subjects to exposed 
subjects increases.  However, a limit is reached once the ratio reaches a 3:1 to 4:1 ratio.  
Due to the large number of patients in the control group (ibuprofen), a 4:1 ratio will be 
used in the sample size calculation.  The equation used to estimate the sample size can be 


































p = the incidence of the disease in the unexposed group; 
R = the minimum relative risk to be detected; 
α = the type I error rate; 
β = the type II error rate; 
Z1-α & Z1-β = the unit normal derivative corresponding to α and β; 







Using p = 0.01 or 0.05; R = 1.25; α = 0.05; β = 0.2; K = 4:1 the formula indicates that a 
sample size between 3,247 and 16,990 was needed in the exposed group.   
   










The first model (Model I) provides an overall evaluation of the relationship between 
NSAID/COX2 inhibitor use and cardiovascular/cerebrovascular events (Figure 2.3).  
NSAID users were defined as someone who began taking a traditional NSAID or COX-2 
inhibitor during the time they were eligible for the study and had not taken that drug in 
the prior 365 days.  The control group used was ibuprofen users.  Study endpoints used 
were: acute myocardial infarction, death from acute myocardial infarction, and 
cerebrovascular disease.  Sensitivity analyses for Model I include: 
 
1. Expansion of the mortality definition to take account of:  
a) death from major cardiovascular diseases; or 
b) death from ischemic heart disease. 
2. Restriction of the population to individuals 65 years of age and older.  This 
allowed for Medicare enrollment and focused on an older population.  
3. Assessment of cerebrovascular events using high-specificity and high-sensitivity 
models (discussed in “study endpoints”). 
4. Use of naproxen and etodolac as the comparator group for celecoxib and 
rofecoxib. 
5. Incorporation of one additional year of data into the model (2002). 
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The second model (Model II) assessed the relationship between long-term use of 
NSAID/COX2 inhibitor and cardiovascular/cerebrovascular events (Figure 2.4).  The 
interval of continuous NSAID/COX-2 use was extended from 30 days to greater than 180 
days of exposure (events may not occur within the prior 180 days).  The control group 
used was ibuprofen users.  Study endpoints were: acute myocardial infarction, death from 
acute myocardial infarction, and cerebrovascular disease.  Sensitivity analyses for Model 
II include: 
 
1.  Expansion of the mortality definition to take account of:  
a. death from major cardiovascular diseases; or 
b. death from ischemic heart disease. 
2. Restriction of the population to individuals 65 years of age and older.  This 
allowed for Medicare enrollment and focused on an older population.  
3. Assessment of cerebrovascular events using high-specificity and high-sensitivity 
models (discussed in “study endpoints”). 
4. Use of naproxen and etodolac as the comparator group for celecoxib and 
rofecoxib. 
5. Incorporation one additional year of data into the model (2002). 
6. Allowing individuals who had an event in the first 180 days to be included in the 
model, primarily to further evaluate naproxen’s cardioprotective abilities.     
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The third model (Model III) assessed the relationship between short-term use of 
NSAID/COX2 inhibitor and cardiovascular/cerebrovascular events (Figure 2.5).  This 
analysis restricted the exposure period to the first 180 days of COX-2/NSAID therapy.  
Additionally, this analysis excluded individuals exposed to > 180 days of study 
medication.  The control group was ibuprofen users.  Study endpoints were: acute 
myocardial infarction, death from acute myocardial infarction, and cerebrovascular 
disease.  Sensitivity analyses for Model III include: 
 
1.  Expansion of the mortality definition to take account of:  
a. death from major cardiovascular diseases; or 
b. death from ischemic heart disease. 
2. Restriction of the population to individuals 65 years of age and older.  This 
allowed for Medicare enrollment and focused on an older population.  
3. Assessment of cerebrovascular events using high specificity and high sensitivity 
models (discussed in “study endpoints”). 
4. Use of naproxen and etodolac as the comparator group for celecoxib and 
rofecoxib. 
5. Incorporation of one additional year of data into the model (2002). 
6. Allowing individuals with long-term exposure to be incorporated into the model, 
but analysis limited to their first 180 days of exposure. 
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Censoring and Drug Use Evaluation Periods   
 
 In order to provide the reader with a better understanding of the short-term and 
long-term models and corresponding sensitivity analyses, a conceptual diagram was 
created to illustrate the process.  Figure 2.6 shows five possible observations occurring in 
the study.  The figure is divided in short-term and long-term use.  Overall use (model I) is 
a combination of long-term and short-term use.  The index date is the initial exposure to 
the study drug.  The X represents an endpoint event.  The end of the line is when the 
observation was censored for some other reason.    
 
Censoring  
 There are several reasons an observation was censored from the study.  These are 
as follows: 
a. Reached the end of the study;  
b. Exposure to another NSAID; 
c. Death (not due to a cardiovascular event); 
d. Discontinued study medication; and 







Model I (overall use/any exposure) – captures all exposure periods and events occurring 
during the study period, lines one, two, three, four, and five were evaluated.  See Figure 
2.6.  
 
Model II – Limits exposure to long-term use observations, exposure periods greater than 
180 days.  Additionally, the model only evaluates events that have not occurred during 
the first 180 day period.  Therefore, only lines one and two were included in the analysis.  
See Figure 2.6. 
 
Model II – sensitivity analysis – Limits exposure to long-term use observations, exposure 
periods greater than 180 days.  However, this model includes events occurring during the 
first 180 day exposure period.  Lines one, two, and three were incorporated into the 
analysis.  See Figure 2.6. 
 
Model III – Limits exposure to short-term use observations, exposure periods less than 
180 days.  Additionally, the model excludes individuals who are exposed to the study 








Model III – sensitivity analysis – Limits exposure to short-term use observations, 
exposure periods less than 180 days.  However, this model includes individuals who are 
exposed to the study medication over long periods of time but analysis is restricted to 
the first 180 days of exposure.  Therefore, lines one, two, three, four, and five were 
evaluated, but only data from the first 180 days were analyzed.  See Figure 2.6.  




      Figure 2.6  Conceptual model describing the censoring process and drug use  
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 This chapter reports the study findings.  The chapter first provides an overview of 
the criteria used to select the study population and the resulting effect on sample size.  
Details regarding overall and drug-specific baseline information for medical conditions, 
medications, and laboratory data will be subsequently provided.  Lastly, the study results 
and sensitivity analyses will be presented.          
 
Study Cohort  
       
 The original cohort encompassed individuals exposed to NSAIDs, COX-2 
inhibitors, and salicylic acid drugs (not including aspirin) from September 1995 through 
May 2004.  This cohort consisted of 166,515 unique individuals.  Patients in this study 
were allowed to have multiple exposure periods, consisting of different study drugs along 
with the same drug multiple times.  Therefore, the total number of observations (not 
unique individuals) for this sample was 337,152.  However, due to the limited available 
data (Medicare & TDH) and concern regarding a channeling effect, the sample was 
restricted to individuals exposed to these agents from January 1, 1999 through December 
31, 2001.  This restricted cohort consisted of 84,677 unique individuals and 122,683 
observations.  When additional study restrictions were applied (age ≥ 35, ≥ 2 
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prescriptions, ≥ 30 days of exposure, ≥ 6 months washout period, and ≥ 1 year prior use 
of VA health care services) the cohort was reduced to 13,394 individuals, and 13,758 
observations (Figure 3.1).   
 
Of note, this chart does not include the exclusion criterion – “patients who 
experience a study endpoint will not re-enter the cohort.”  This criterion was not included 
because several endpoints were evaluated and the final number varied with each 
assessment.  For the primary endpoint, (acute myocardial infarction (AMI), stroke, and 
death from AMI) only nine observations were censored (i.e., did not re-enter cohort).  
This is the same number of censored patients when death from ischemic heart disease 
(IHD) or death from a major cardiovascular event was evaluated.  For the high stroke 
sensitivity model, fifteen observations were censored and seven observations were 
censored for the AMI plus AMI death model.       
 
Medicare data for the year 2002 became available after the preliminary analyses 
were completed.  Reports linking cardiovascular risk to COX-2 inhibitors became 
prominent in the years following 2001.  This information could cause a channeling effect.  
Therefore, caution should be used in analyzing data after 2001.    Due to the concern of 
channeling, the 2002 data were only incorporated into the study design as a sensitivity 





Figure 3.1   Study restrictions and resulting cohort size.  
 
 
Abbreviations: Obs. – observations; Ind. – unique individuals; mo. – months; yr. – years; Rx’s - 
prescriptions.  
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Important – The final cohort of 13,758 observations listed in Figure 3.1 will be used to 
describe the demographic, study medication use, and baseline characteristics.   
 
Demographic findings 
 Of the 13,758 eligible observations, 12,888 (93.7%) were men and 870 were 
women (6.3%).  The overall mean age of study subjects was 61.2 years of age (SD - 
12.6).  The age distribution was bimodal, with peaks in the mid 50s and early 70s (see 
Figure 3.2).  Patients taking celecoxib and rofecoxib were, on average, about seven years 
older than patients taking ibuprofen, etodolac, and naproxen (Table 3.1).   
Race/ethnicity data from the VA were limited; with data available for only 65 
percent of subjects.  Of this 65 percent, 81.2 percent were white, 13.7 percent were black, 
and 2.2 percent were Hispanic (see Table 3.2).  A majority of the racial/ethnic data were 
provided by the Medicare data.  For subjects 65 years of age and older, race/ethnicity 
data were available for 98.1 percent of this subgroup.  Specific details can be found in 
Table 3.2.  Due to the limited availability, race/ethnicity was not incorporated into the 
study model.   
Study subjects were gathered for three separate regions across Texas; north, 
south, and central.  As seen in Table 3.3, 41.0 percent of the study population was from 
the north region, 28.8 percent from the central region, and 30.2 percent from the southern 
region.  A few patients used VA healthcare services from more than one region.  For 
these patients, health care profiles were merged together into a single profile and 
arbitrarily assigned a region.                   
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Figure 3.2  Age distribution of eligible study subjects who received a NSAID,  
       COX-2 inhibitor, or salicylic acid drug during the study period.  
 























Table 3.1  Baseline age for subjects taking celecoxib, etodolac, ibuprofen, naproxen  
       and rofecoxib.  
Categories Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
Mean Age (SD)* 67.5 (11.8) 61.6 (12.5) 58.8 (12.3) 60.3 (12.1) 66.8 (12.4) 
      
< 65 36.7% 58.4% 66.8% 63.1% 40.7% 
65 - 74 32.2% 22.9% 20.3% 22.5% 27.2% 
75 - 84 27.5% 17.2% 11.7% 13.2% 28.0% 
>= 85 3.6% 1.5% 1.1% 1.2% 4.1% 
Total (N) 1530 2373 4483 3241 567 





Figure 3.3  Age distribution of eligible study subjects who received an NSAID,  
       COX-2 inhibitor, or salicylic acid drug during the study period.  
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Table 3.2   Racial/Ethnic distribution among eligible study subjects who received an 
                   NSAID/COX-2 inhibitor or salicylic acid drug during the study period.  
Racial / Ethnic Group All Study Subjects*    N (%) 
White 7,262 (81.2) 
Black 1,225 (8.9) 
Hispanic 308 (2.2) 
Other 148 (1.1) 
Total 8,943 (100) 
Racial / Ethnic Group Study subjects ≥ 65 years of age*    N (%) 
White 4,721 (86.0) 
Black 494 (9.0) 
Hispanic  223 (4.1) 
Other 49 (0.9) 
Total 5,487 (100) 





Table 3.3  Regional distribution of NSAID/COX-2 inhibitor use; north, south, 
      and central VA regions.    
Region No. Study Subjects (%) 
North  5,646 (41.0) 
Central  3,959 (28.8) 
South  4,153 (30.2) 




















NSAID, COX-2 inhibitor, and salicylic acid drug use 
 
 The distribution of subjects obtaining NSAID/COX-2 inhibitors during the study 
period revealed that a majority of the subjects received either ibuprofen (32.6%) or 
naproxen (23.6%).  The remaining subjects received etodolac (17.2%), celecoxib 
(11.1%), rofecoxib (4.1%), or other study drugs (other categories < 3% of total each).  
See Table 3.4 for more details.  The original study design involved evaluation of 
celecoxib, rofecoxib, naproxen, and ibuprofen.  The design did allow for additional study 
groups to be added if sufficient numbers allowed.  Etodolac is one of these additional 
study groups, comprising roughly 17 percent of total drug use.      
 
Regional contributions for the top five drugs (ibuprofen, naproxen, etodolac, 
celecoxib, and rofecoxib) were evaluated.  Similar percentages were found with regards 
to the amount of ibuprofen and naproxen, with each region contributing between 28 to 40 
percent.  Disproportionate contributions were found with etodolac, celecoxib, and 
rofecoxib.  North Texas contributed the largest percent of etodolac (~ 73%) to the study, 
followed by central (~ 25%), and south Texas (~ 2%).  The southern region contributed 
the largest percentage of celecoxib and rofecoxib observations (51% and 62%, 
respectively), followed by central, and north Texas.  See Table 3.5 for more details.  
Regional prescribing patterns are presented in Table 3.6.  Ibuprofen was the most 
commonly prescribed study drug within all three regions.  Following ibuprofen, naproxen 
was the second most prescribed study drug in the central and south regions; whereas, 
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etodolac was the second most prescribed drug in the north.  Etodolac was infrequently 
prescribed in the south region.                      
 
 One of the study objectives was to evaluate the association between 
cardiovascular events and long-term (> 180 days) and short-term (≤ 180 days) exposure 
to NSAIDs and COX-2 inhibitors.  A majority of subjects for the five study groups are 
short-term users.  Roughly, 25 – 40 percent of subjects used these drugs long-term.  See 
Table 3.7 for more details.  Of note, this includes all exposure times and does not censor 
observations with end-point events occurring during the first 180 days.  Person-years 
were also calculated for each study drug and are provided in Table 3.7.   
 
Table 3.4  Frequency and Percent of NSAID, COX-2 inhibitors, and salicylic acid 
     medications prescribed to eligible subjects during the study period.  
Drug Frequency Percent 
Ibuprofen 4,483 32.6 
Naproxen  3,241 23.6 
Etodolac 2,373 17.2 
Celecoxib 1,530 11.1 
Rofecoxib 567 4.1 
Piroxicam  414 3.0 
Indomethacin 389 2.8 
Salicylic Acid Drugs 388 2.8 
Sulindac 300 2.2 
Other NSAIDs 42 0.3 
Diclofenac  21 0.2 
Nabumentone  6 0.0 
Meloxicam 4 0.0 
Total 13,758 100 







Table 3.5  Percent of study drug (celecoxib, etodolac, ibuprofen,   
       naproxen, and rofecoxib) from each region.   
Region Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
  North 17% 73% 40% 38% 17% 
  Central 32% 25% 30% 28% 21% 
  South  51% 2% 30% 34% 62% 
Total (%)* 1,530 (100) 2,373 (100) 4,483 (100) 3,241 (100) 567 (100) 
*Total N = 12,194 
 
Table 3.6  Percent of study drugs (celecoxib, rofecoxib, etodolac, ibuprofen, and 
naproxen) within each region.   
Region Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib Total (%)* 
  North 5% 34% 35% 24% 2% 5,091 (100) 
  Central 14% 17% 39% 26% 3% 3,479 (100) 
  South  21% 1% 37% 31% 10% 3,624 (100) 
*Total N = 12,194 
 
Table 3.7  Duration of therapy patterns for celecoxib, rofecoxib, etodolac, 
      ibuprofen, and naproxen.   
Exposure  Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
    0 - 90 days 29.9 % 41.4 % 51.1 % 46.7 % 32.6 % 
> 90 – 180 days 29.5 % 30.5 % 24.4 % 26.7 % 30.7 % 
> 180 – 365 days 20.5 % 20.0 % 16.6 % 17.3 % 24.9 % 
≥ 365 days 20.1 %   8.1 %   7.9 % 9.4 % 11.8 % 
Mean (SD) 234.3 (213) 159.0 (130) 152.2 (154) 164.2 (164) 188.6 (149) 
Person-Years 964.1 1021.5 1850.7 1438.8 285.5 
Events* 39 23 38 29 17 
Total (N) 1,530 2,373 4,483 3,241 567 
* Number of primary endpoint events (acute myocardial infarction, death from acute myocardial infarction, 
















Baseline medical conditions 
 
Entire study cohort  
 
 The following baseline medical conditions were derived from VA and Medicare 
ICD-9 billing codes.  The assessment period was one year prior to the index date (start of 
study medication).  Exact codes used to delineate the medical conditions can be found in 
Chapter Two.  Sixteen baseline medical conditions were evaluated, ranging from prior 
cardiovascular events through terminal conditions.  The predominant medical conditions 
were: osteoarthritis (13.2%), cancer (12.8%), and diabetes (11%).  Very few patients had 
a diagnosis for HIV or “systemic lupus erythematosus and connective tissue disorders.”  
The percent and frequency of baseline medical conditions can be found in Table 3.8.    
 
A study within the VA healthcare system assessing code veracity of stroke-related 
ICD-9 codes has been conducted.  When a high-sensitivity model was used, results 
yielded 89% sensitivity, 57% specificity, 60% positive predictive value, and 88% 
negative predictive value.  When a high-specificity algorithm was used, the results 
change to: 59% sensitivity, 84% specificity, 72% positive predictive value, and 74% 
negative predictive value.1  When using the high-sensitivity model, 157 prior stroke cases 
were found.  The high-specificity model restricted the 157 stroke cases found in the high-




Table 3.8  Frequency and percent of subjects with a baseline medical diagnosis 
      in the year prior to the index date.  N = 13,758 
Medical Condition Frequency Percent 
Atrial fibrillation 310 2.3 
Angina 625 4.5 
Cancer 1,763 12.8 
COPD 894 6.5 
Diabetes 1,509 11.0 
Heart failure 577 4.2 
HIV 18 0.1 
Lupus* 27 0.2 
Osteoarthritis 1,815 13.2 
PVD 392 2.8 
Renal failure 85 0.6 
Respiratory failure 73 0.5 
Rheumatoid arthritis 186 1.4 
Prior AMI 139 1.0 
Prior stroke sensitivity 157 1.1 
Prior stroke specificity  40 0.3 
Abbreviations:  COPD – chronic obstructive pulmonary disease; HIV - human immunodeficiency virus; 
PVD – peripheral vascular disease; AMI – acute myocardial infarction. 
 * Systemic lupus erythematosus and connective tissue disorders diagnosis  
 
 
A post-hoc analysis was conducted to evaluate the different types of cancer 
represented in the cancer category.  Cancer diagnoses were subdivided into 25 different 
categories based on an algorithm developed by the Agency for Health Care Research and 
Quality.2 Of the 1,763 observations with a cancer diagnosis in the year prior to the index 
date, 751 (43 %) had multiple classifications of cancer.  Nearly 26 percent of the cases 
were benign neoplasms, followed by unspecified cancers (~ 16%), skin cancer (~ 14%), 
prostate cancer (~ 10%), lung cancer (~ 4%), head and neck cancer (3.9%), and colon 






Table 3.9  Frequency and percent of cancer categories for study subjects diagnosed 
      in the year prior to the index date. 
Cancer category Frequency Percent 
Head and neck cancer 98 3.9 
Esophageal cancer  12 0.5 
Stomach cancer 7 0.3 
Colon cancer 86 3.4 
Rectum/anus cancer 44 1.8 
Liver and intrahepatic bile duct cancer 8 0.3 
Pancreas cancer 4 0.2 
GI/peritoneal cancer 16 0.6 
Bronchial/lung cancer 93 3.7 
Other respiratory cancer 9 0.4 
Bone and connective tissue cancer 23 0.9 
Melanomas of skin cancer 44 1.8 
Other skin cancer 355 14.2 
Female cancers* 41 1.6 
Prostate cancer 260 10.4 
Testicular cancer 4 0.2 
Other male genital cancers 8 0.3 
Bladder cancer 56 2.2 
Kidney/renal pelvis cancer 15 0.6 
Other urinary organ cancer 4 0.2 
Brain/nervous system cancer  12 0.5 
Thyroid cancer 1 0.0 
Hodgkins disease 15 0.6 
Non-Hodgkins lymphoma 48 1.9 
Leukemias 28 1.1 
Multiple myeloma 12 0.5 
Cancer; other and unspecified malignancy 76 3.0 
Secondary malignancies 43 1.7 
Malignant neoplasm without site specification 33 1.3 
Neoplasms of unspecified nature or uncertain behavior 398 15.8 
Benign neoplasm of uterus 5 0.2 
Other and unspecified benign neoplasm 650 25.9 
Total ξ  2508 100 
* Breast, uterus, cervical, ovarian, and other female cancers 







Baseline medical conditions by study drug  
 
 In order to obtain a better understanding of the study groups, demographic and 
baseline information was subdivided by study medication.  The following drugs were 
evaluated: celecoxib, rofecoxib, naproxen, ibuprofen, and etodolac.  In every category  
(except HIV) detailed in Table 3.10, a higher percentage of subjects with prior medical 
conditions were found in the celecoxib and rofecoxib groups as compared to the 
ibuprofen, naproxen, and etodolac groups.  Patients taking celecoxib and rofecoxib had 
higher percentages of cancer, diabetes, arthritis, and cardiovascular conditions.   
 
One of the study objectives required subjects to be exposed to the study 
medication for greater than 180 days without an endpoint event occurring during the 
initial 180 day period.  Table 3.11 details the baseline medical conditions for long-term 
users.  No major differences were found in this restricted sample as compared to the 
entire study population.  Similar to the “any exposure” model, long-term users of 
celecoxib and rofecoxib were found to have higher percentages of baseline values as 












 Table 3.10   Percent of subjects classified with a baseline medical condition in the  
          year prior to their index date by study drug.   
 
CELECOXIB 
N = 1530 
ETODOLAC 
N = 2373 
IBUPROFEN 
N = 4483 
NAPROXEN 
N = 3241 
ROFECOXIB 
N = 567 
Atrial 
fibrillation 6.7% 2.1% 1.0% 1.4% 5.6% 
Angina 8.0% 5.2% 2.8% 4.0% 8.5% 
Cancer 19.5% 13.8% 10.2% 11.2% 20.5% 
COPD 9.9% 7.1% 5.1% 5.4% 13.2% 
Diabetes 15.6% 11.3% 8.9% 10.2% 17.5% 
Heart Failure 8.3% 4.1% 3.0% 3.1% 9.0% 
HIV 0.0% 0.0% 0.2% 0.1% 0.4% 
Lupus* 0.5% 0.1% 0.1% 0.1% 1.1% 
Osteoarthritis 24.7% 13.8% 8.5% 11.0% 24.0% 
PVD 5.2% 2.4% 2.1% 2.6% 5.3% 
Renal failure 1.1% 0.7% 0.3% 0.3% 2.5% 
Respiratory 
Failure 1.0% 0.6% 0.4% 0.3% 1.2% 
Rheumatoid 
arthritis 3.1% 1.6% 0.7% 0.8% 2.6% 
Prior AMI 1.6% 1.1% 0.8% 0.8% 1.9% 
Prior Stroke 
Sensitivity  2.5% 1.3% 0.7% 0.7% 2.6% 
Prior Stroke 
Specificity  0.6% 0.3% 0.3% 0.2% 0.5% 






















Table 3.11  Long-term NSAID/COX-2 inhibitor users classified with a baseline  
              medical condition in the year prior to the index date by study drug.   
 
CELECOXIB 
N = 611 
ETODOLAC 
N = 656 
IBUPROFEN 
N = 1085 
NAPROXEN 
N = 849 
ROFECOXIB 
N = 206 
Atrial 
fibrillation 6.6% 1.5% 1.0% 1.9% 3.4% 
Angina 6.9% 5.6% 3.7% 4.6% 6.3% 
Cancer 20.6% 13.2% 10.0% 12.9% 20.4% 
COPD 10.2% 7.0% 5.5% 6.2% 10.7% 
Diabetes 16.2% 12.8% 8.1% 12.4% 15.5% 
Heart Failure 8.2% 4.4% 3.8% 3.6% 5.3% 
HIV 0% 0% 0% 0.1% 0% 
Lupus* 0.01% 0.5% 0.2% 0.1% 1.0% 
Osteoarthritis 24.1% 16.4% 10.6% 13.5% 22.8% 
PVD 5.6% 1.7% 1.7% 2.6% 6.8% 
Renal 1.5% 0.5% 0.2% 0.4% 2.4% 
Respiratory 
Failure 0.01% 0.3% 0.5% 0.1% 0.5% 
Rheumatoid 
arthritis 4.4% 1.8% 1.1% 0.9% 1.9% 
Prior AMI 1.6% 0.9% 0.5% 0.8% 2.4% 
Prior Stroke 
Sensitivity  2.1% 1.1% 0.8% 1.1% 2.9% 
Prior Stroke 
Specificity  0.2% 0.3% 0.3% 0.4% 1.0% 











Baseline medications  
 Subjects were assessed one year prior to the index date for exposure to twenty 
different categories of medications (Table 3.12).  Many of the subjects received 
antihypertensive medications, with roughly 20 percent of subjects receiving beta-
blockers, 25 percent receiving calcium channel blockers, 30 percent receiving ACE 
inhibitors/ARBs, 27 percent receiving a diuretic (two categories combined), and 18.3 
percent receiving some other form of antihypertensive drug.  Of the 13,758 observations, 
40 percent received at least one antihypertensive medication.  Of this 40 percent, nearly 
60 percent received more than one type of antihypertensive therapy in the year prior to 
their index date.  This number could be higher if subjects received multiple medications 
from the same category.  Other pertinent categories include aspirin, cholesterol 
medications, diabetes medications, and nitrates.  Roughly, 28 percent of subjects received 
aspirin therapy in the year prior to their index date, 30.8 percent received a cholesterol 
medication, 18.3 received a diabetic medication, and 16.1 percent received a nitrate.  
Evaluation of concurrent aspirin therapy was considered post hoc; however, when 
assessed very few patients received concurrent therapy.  Therefore, concurrent aspirin 
















Table 3.12  Frequency and percent of subjects who received a baseline medication 
        in the year prior to the index date.  N = 13,758 
Medication Frequency Percent 
Antiarrhythmic 191 1.4 
Aspirin 3,886 28.2 
ß - Blocker 2,692 19.6 
Calcium channel blocker 3,461 25.2 
Diabetes drug 2,523 18.3 
Digoxin 732 5.3 
Estrogen* 383 2.8 
Other HTN drugs 2,516 18.3 
Loop diuretic  1,522 11.1 
Methotrexate 71 0.5 
Nitrate 2,219 16.1 
PVD drug 108 0.8 
Warfarin  591 4.3 
ACE inhibitor/ARBS 4,077 29.6 
Antiplatelet  464 3.4 
Antirheumatic 38 0.3 
Steroid 855 6.2 
Cholesterol drug 4,234 30.8 
Diuretic other  2,220 16.1 
Other anticoagulant 120 0.9 


















Baseline medications by study drug  
 
Baseline medications were subdivided by study medication (ibuprofen, naproxen, 
etodolac, celecoxib, and rofecoxib) for evaluation.  A similar trend to the baseline 
medical conditions was found with the baseline study medications (Table 3.13).  
Celecoxib and rofecoxib subgroups were found to have a higher percentage of patients 
receiving baseline medications as compared to etodolac, ibuprofen, and naproxen 
subjects.  One interesting finding is the disproportionate number of patients taking 
warfarin in the celecoxib and rofecoxib study groups as compared to ibuprofen, 
naproxen, and etodolac study groups (Table 3.13).  When the cohort was restricted to 
long-term users of study medications, no major differences were found between overall 





















Table 3.13  Percent of subjects who received baseline medications in the year prior 
               to their index date by study drug.    
 CELECOXIB 
N = 1530 
ETODOLAC 
N = 2373 
IBUPROFEN 
N = 4483 
NAPROXEN 
N = 3241 
ROFECOXIB 
N = 567 
Antiarrhythmics 3.7% 1.2% 0.8% 1.3% 3.2% 
Aspirin 31.8% 27.6% 26.5% 28.5% 31.6% 
B-Blocker 23.9% 20.7% 16.9% 18.4% 28.0% 
Ca-Blocker 32.4% 25.6% 21.9% 24.4% 29.8% 
Diabetes Drug 20.0% 18.3% 16.8% 19.0% 22.6% 
Digoxin 12.2% 5.3% 3.5% 4.1% 9.5% 
Estrogen 2.6% 2.8% 2.8% 3.0% 3.7% 
Other HTN 
Drugs 24.2% 20.9% 15.0% 16.9% 22.9% 
Loop Diuretics 18.1% 11.6% 8.9% 8.8% 16.8% 
Methotrexate 1.3% 0.5% 0.3% 0.4% 0.9% 
Nitrate 22.4% 16.8% 14.1% 14.4% 22.6% 
PVD drug 1.2% 0.7% 0.6% 0.8% 1.6% 
Warfarin 14.1% 3.6% 1.9% 2.4% 13.1% 
ACE/ARBs 33.7% 31.2% 26.3% 29.7% 33.3% 
Antiplatelet 5.9% 3.0% 2.7% 2.9% 6.5% 
Antirheumatic 0.7% 0.3% 0.2% 0.2% 0.2% 
Steroid 9.3% 5.9% 5.6% 5.0% 8.1% 
Cholesterol 
drug 37.6% 33.3% 25.9% 31.6% 37.9% 
Diuretic Other 17.5% 18.6% 14.3% 15.5% 16.8% 
Other 























Table 3.14  Long-term NSAID/COX-2 inhibitor users who received a baseline  
         medication in the year prior to their index date by study drug.    
 CELECOXIB 
N = 611 
ETODOLAC 
N = 656 
IBUPROFEN 
N = 1085 
NAPROXEN 
N = 849 
ROFECOXIB 
N = 206 
Antiarrhythmics 3.4% 1.4% 0.8% 1.6% 1.5% 
Aspirin 30.6% 30.9% 30.3% 32.4% 33.0% 
B-Blocker 22.6% 20.2% 18.9% 18.4% 28.6% 
Ca-Blocker 34.9% 26.3% 26.2% 28.7% 22.8% 
Diabetes Drug 19.8% 21.0% 18.3% 20.9% 21.4% 
Digoxin 12.9% 5.9% 4.2% 5.4% 7.8% 
Estrogen 1.6% 2.7% 2.3% 3.2% 2.4% 
Other HTN Drugs 25.5% 26.6% 16.8% 21.6% 20.9% 
Loop Diuretics 17.5% 12.9% 9.4% 10.4% 14.6% 
Methotrexate 0.0% 1.1% 0.6% 0.8% 0.0% 
Nitrate 21.9% 17.8% 17.0% 16.6% 21.4% 
PVD drug 1.5% 0.9% 0.9% 1.4% 1.0% 
Warfarin 15.9% 4.0% 1.4% 2.1% 16.0% 
ACE/ARBS 32.2% 34.4% 30.6% 35.3% 34.5% 
Antiplatelet 6.4% 4.0% 2.9% 2.1% 7.8% 
Antirheumatic 0.0% 0.3% 0.2% 0.2% 0.5% 
Steroid 8.0% 4.9% 4.9% 4.7% 6.8% 
Cholesterol drug 40.6% 38.1% 31.6% 37.3% 40.8% 
Diuretic Other 19.0% 20.5% 16.0% 17.2% 20.4% 
Other 



















Combined medical condition and medication 
 
 For three conditions (diabetes, angina, and peripheral vascular disease), the 
medical diagnoses and use of a related medication were merged together into a single 
category.  Regarding diabetes, when using only hypoglycemic medications for 
classification purposes, 18.3 percent of the observations received a diagnosis for diabetes.  
When classification of diabetes via medication use was merged with a medical diagnosis 
for diabetes, 21.5 percent of the observations were subsequently classified as diabetic (a 
difference of 3.2%).  Elevated serum glucose (≥ 200 mg/dl) was also considered as a 
classification criteria for diabetes.  However, this did not yield a significant increase in 
classification (~ 1% increase) and therefore was not used.  With respect to angina, 16.1 
percent of the study subjects received a nitrate medication.  When use of a nitrate was 
merged with a diagnosis of angina, 17.7 percent of the observations were classified with 
angina (~ 1.6% increase).  The final category, peripheral vascular disease, comprised a 
small percentage of the population.  When “PVD medications” (0.8%) were merged with 









Patient vitals & laboratory data 
 
In the original study design, laboratory values and patient vitals were to be used 
as covariates in the study model.  However, due to the limited availability of readings and 
small sample size, they were excluded from the model.  If the patient vitals and 
laboratory values were used, the study population would be reduced by 64 percent and an 
insufficient number of subjects would be available to conduct the study.  Additionally, 
subjects with available vital and laboratory data may not be representative of the entire 
population.  Despite these limitations, the laboratory data were assessed to determine if 
clinically significant differences were found between the study medications (e.g., to 
determine if celecoxib and rofecoxib subjects had higher cholesterol, blood pressure, and 
body mass index values as compared to the other study groups).    
 
Laboratory values and patient vitals were assessed and analyzed for outlying 
values.  Laboratory values and patient vitals from the original cohort of 166,515 
individuals were evaluated.  Values outside the plausible range were removed from 
analysis.  Systolic blood pressure (SBP) values less than 50 millimeters of mercury 
(mmHg) and diastolic blood pressure (DBP) values less than 30 mmHg were removed.  
Values in this range represent a small proportion of the values, less than 0.1 percent of 
diastolic readings and less than 0.1 percent of systolic readings.  Height values less than 
47 inches (3.9 feet) were deleted, representing less than 0.1 percent of values.  Weight 
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values less than 70 pounds and greater than 900 pounds were deleted, representing less 
than 0.1 percent of readings.  Body mass index (BMI) was assessed; values less than 6.5 
units were deleted, representing less than 0.1 percent of readings.  Extreme height, 
weight, and BMI values were then assessed individually and records were assessed for 
consistent values across time.  Values with improbable deviations over time were 
removed (e.g., weight varying by 100 lbs from one month to the next).  Lastly, 
cholesterol readings were assessed for outlying values.  Total cholesterol values less than 
40 mg/dl and greater than 750 mg/dl were deleted (< 1% of values).  High density 
lipoprotein (HDL) values greater than 150 mg/dl were deleted (< 1% of values).  Low 
density lipoprotein (LDL) values less than 22 mg/dl and greater than 260 mg/dl were 
deleted (< 1% of values).  Triglyceride values less than 10 mg/dl and greater than 3000 
mg/dl were deleted (< 1% of values).                     
 
 Patient vital and laboratory readings occurring in the year prior to the index date 
were averaged into a single value.  Median values along with the lowest and highest 
reading were also obtained.  The range of values in Table 3.15 detail the lowest and 
highest value assigned to any observation.  No clinically significant differences were 
found between mean and median measurements.  Therefore, only mean values will be 
used and presented in this paper.  Only a single measurement of height was available for 




 Blood pressure (BP) readings were available for approximately 60 percent of the 
observations.  Of these observations, the average SBP was 139 mmHg (SD, 17.9) and the 
average DBP value was 76 mmHg (SD, 18.1).  Based on JNC-7 criteria, the average 
blood pressure reading is in the prehypertension stage (SBP, 120 – 139; DBP, 80 – 89).  
Cholesterol values were available for roughly 45 to 57 percent of the observations (exact 
percent depends on the type of cholesterol evaluated).  The average total cholesterol 
value is in the desirable range according to ATP III guidelines, at 192 mg/dl (SD, 39.7).  
The average HDL value is low (< 45 mg/dl) according to ATP III guidelines.  The 
average LDL value is in the “near optimal/ above optimal” range, at 112 mg/dl (SD, 
32.9).  According to ATP III guidelines, the average triglyceride value is in the 
borderline-high category, at 191 mg/dl (SD, 145.2).  The average subject within the study 
cohort was overweight, with a BMI of 29.2 (SD, 5.9).  Calculated BMI values were 
available for 57% of the population.  Further details are available in Table 3.15.     
 
Baseline laboratory and patient vitals by study drug 
 
 Baseline laboratory data and patient vitals were assessed by study drug.  When 
comparing values across the study groups, similar values were found.  Blood pressure, 
cholesterol, and body mass index values only varied by a few points between the 
categories.  However, slightly lower total cholesterol and LDL values were found with 
celecoxib and rofecoxib as compared to the other study groups.  Results can be found in 




In addition to segmenting laboratory values and patient vitals by study drug, 
values were restricted to patients receiving greater than 180 days of study medication 
(long-term users).  This was done to evaluate if long-term users were comparable (in 
terms of baseline laboratory and vitals) to the population as a whole.  Results are not 
shown; however, no clinically significant differences were found between the restricted 
sample and the principle study population.  The subset of patients receiving short-term 
therapy was not assessed.            





      Table 3.15  Baseline patient vitals and laboratory data.   
Category N* Mean SD Min Max 
SBP mean 8219 139.0 17.9 56 267 
DBP mean 8219 75.7 10.4 30 177 
Total Cholesterol mean 7852 191.7 39.7 40 667 
HDL mean 6434 44.9 13.1 5 136 
LDL mean 6229 112.1 32.9 22 259 
TG mean 7102 191.1 145.2 20 2800 
Weight mean (lbs) 7929 201.1 44.0 77.5 633 
BMI mean 7867 29.2 5.9 . . 
Height (inches)§ 7870 69.5 3.2 . . 
         Abbreviations: SBP – systolic blood pressure; DBP – diastolic blood pressure; HDL – high density 
           Lipoprotein; LDL – low density lipoprotein; TG – triglyceride; BMI – body mass index.   
          * Numbers based on available data  











Table 3.16  Baseline blood pressure values for subjects taking celecoxib, etodolac, 
        ibuprofen, naproxen and rofecoxib.  
Categoriesξ Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
SBP mean (SD) 139.6 (18.3) 139.0 (17.8) 138.5 (18.1) 139.2 (17.2) 139.9 (18.0) 
DBP mean (SD) 73.7 (9.8) 75.6 (10.5) 76.6 (10.4) 76.1 (10.2) 73.5 (10.3) 
      
I      Normal 17.1% 14.6% 15.5% 13.8% 13.5% 
II     Pre-HTN 15.1% 17.4% 17.2% 17.5% 14.4% 
III   Pre-HTN 20.3% 21.6% 21.9% 21.3% 22.6% 
IIII  Stage 1 HTN  34.8% 33.9% 33.0% 35.7% 35.6% 
IV    Stage 2 HTN 12.7% 12.5% 12.5% 11.7% 13.8% 
Total (N)* 929 1683 2523 1874 340 
Abbreviations: SBP – systolic blood pressure; DBP – diastolic blood pressure; SD – standard deviation 
* Number of subjects with available readings.  
ξ BP values for categories I – IV can be found in Table 2.4 
 
Table 3.17  Baseline total cholesterol values for subjects taking celecoxib, etodolac, 
        ibuprofen, naproxen and rofecoxib.  
Categories Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
Total Cholesterol 
mean (SD) 187.3 (36.9) 192.3 (39.6) 192.3 (40.0) 193.8 (40.6) 187.4 (44.7) 
      
< 160  22.7% 19.2% 20.3% 19.0% 24.2% 
160 - 199 43.2% 40.9% 39.7% 39.3% 42.7% 
200 - 239 26.1% 29.1% 29.6% 30.2% 23.7% 
240 - 279 6.6% 7.9% 7.8% 8.7% 7.4% 
≥ 280 1.4% 2.9% 2.7% 2.7% 1.9% 
Total (N)* 1075 1298 2326 1864 417 
* Number of subjects with available readings.  
 
Table 3.18  Baseline high density lipoprotein (HDL) values for subjects taking 
        celecoxib, etodolac, ibuprofen, naproxen and rofecoxib.  
Categories Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
HDL mean (SD) 45.5 (13.2) 43.7 (12.8) 45.2 (13.4) 45.2 (13.2) 45.4 (12.5) 
      
< 35 18.7% 22.7% 19.5% 18.3% 18.7% 
35 - 44 35.7% 37.5% 37.0% 39.4% 34.9% 
45 - 49 15.6% 15.5% 14.6% 14.8% 13.1% 
50 - 59 18.7% 15.1% 16.7% 16.1% 21.1% 
≥ 60 11.3% 9.2% 12.3% 11.5% 12.2% 
Total (N)* 886 1180 1825 1528 327 









Table 3.19  Baseline low density lipoprotein (LDL) values for subjects taking 
        celecoxib, etodolac, ibuprofen, naproxen and rofecoxib.  
Categories Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
LDL mean (SD) 106.5 (31.8) 112.4 (32.4) 113.6 (33.3) 114.2 (33.5) 108.1 (32.4) 
      
< 100 44.2% 35.4% 35.1% 35.1% 41.9% 
100 - 129 35.1% 36.7% 35.3% 35.1% 35.7% 
130 - 159 15.6% 20.7% 21.3% 20.8% 16.8% 
160 - 189 3.3% 5.6% 6.3% 6.5% 4.7% 
≥ 190 1.7% 1.6% 2.0% 2.5% 0.9% 
Total (N)* 886 1138 1767 1468 322 
* Number of subjects with available readings.  
 
Table 3.20  Baseline triglyceride values for subjects taking celecoxib, etodolac,  
         ibuprofen, naproxen and rofecoxib.  
Categories Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
TG mean (SD) 190.0 (130.9) 193.9 (143.7) 189.9 (151.2) 189.2 (140.2) 188.3 (197.0) 
      
< 150 48.4% 45.3% 50.7% 48.2% 52.2% 
150 - 199 17.2% 20.5% 16.6% 19.0% 17.5% 
200 - 499 31.6% 31.3% 29.2% 29.6% 28.3% 
≥ 500 2.8% 2.9% 3.5% 3.2% 1.9% 
Total (N)* 955 1261 2075 1675 360 
* Number of subjects with available readings.  
 
Table 3.21  Baseline body mass index (BMI) for subjects taking celecoxib, etodolac,  
        ibuprofen, naproxen and rofecoxib.  
Categories Celecoxib Etodolac Ibuprofen Naproxen Rofecoxib 
BMI mean (SD) 29.2 (5.5) 29.5 (6.0) 28.9 (6.0) 29.3 (5.7) 29.0 (5.9) 
      
< 18.5 0.7% 1.3% 1.6% 0.8% 1.5% 
18.5 - 24.9 19.1% 21.2% 24.6% 22.2% 24.4% 
25 - 29.9 42.5% 35.0% 36.4% 36.7% 37.7% 
> 30 37.7% 42.4% 37.4% 40.3% 36.4% 
Total (N)* 899 1633 2379 1795 332 












ANALYTICAL RESULTS  
 
OBJECTIVE I – To evaluate serious cardiovascular events (AMI, stroke, or 
     cardiovascular mortality) associated with use of COX-2 inhibitors. 
Study 
Hypotheses Description 
Fail to Reject /Reject 
Null Hypotheses  
Ho1 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking rofecoxib versus patients taking a traditional NSAID (i.e., 
ibuprofen), while controlling for various covariates. Overall use (short-
term and long-term use) 
Fail to Reject 
Ho2 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking celecoxib versus patients taking a traditional NSAID (i.e., 
ibuprofen), while controlling for various covariates.  Overall use 
Fail to Reject 
Ho3 
There is no difference in the overall risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking etodolac versus patients taking a traditional NSAID (i.e., 
ibuprofen). “any exposure” model 
Fail to Reject 
 
OBJECTIVE II – To determine if naproxen offers greater cardioprotective benefits  
        compared to other NSAIDs.  
Study 
Hypotheses Description 
Fail to Reject /Reject 
Null Hypotheses  
Ho4 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking naproxen versus patients taking another traditional NSAID (i.e., 
ibuprofen), while controlling for various covariates.  Overall use 
Fail to Reject 
 
 
Regarding objective one, the unadjusted model found an associated risk for 
serious cardiovascular events with celecoxib and rofecoxib when compared to ibuprofen 
(RR, 2.04; 95% CI, 1.30 – 3.20; p < 0.01 / RR, 2.88; 95% CI, 1.63 – 5.11; p < 0.01, 
respectively).  However, there were no significant differences found with naproxen or 
etodolac.  See Table 3.22 for further details.  
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When adjusting for various covariates, the Cox regression model revealed that 
overall, recipients of etodolac, celecoxib, and rofecoxib were not associated with an 
increased risk of serious cardiovascular events when compared to ibuprofen users (See 
Table 3.23).  With regards to the study medications, all results were not statistically 
significant.  Results yielded an adjusted risk ratio (aRR) of 1.13 (95% CI, 0.70 – 1.83; p 
= 0.61) for celecoxib users; 1.59 (95% CI, 0.87 – 2.90; p = 0.13) for rofecoxib users, and 
0.82 (95% CI, 0.48 – 1.40; p = 0.47) for etodolac users.  When compared to ibuprofen, 
naproxen was not found to be cardioprotective (or cardionegative) in the all-inclusive 
model (aRR, 0.86; 95% CI, 0.53 – 1.40; p = 0.54).          
 
Several covariates in the model were statistically significant.  These included:  
COPD, osteoarthritis, prior AMI and stroke, ß-blocker, loop diuretic, methotrexate, 
antiplatelet, and age.  Other covariates were not statically significant; however, they may 
have contributed to the overall fit of the model.  Some variables had little to no 
contribution to the model (HIV, lupus, and antirheumatics).  This is primarily due to the 













Table 3.22   Un-adjusted association between exposure to NSAIDS & COX-2 
                    inhibitors and serious cardiovascular events (defined as acute 
        myocardial infarction, death from coronary heart disease, or  
        cerebrovascular event) – Ibuprofen Comparison. 
 
Exposure (reference group) 
 
Risk Ratio  
(95% CI) 
  Lower        Upper 
 
Sig. (p) 
Any exposure      
Celecoxib (ibuprofen) 2.04 1.30 3.20  < 0.01 
Etodolac   (ibuprofen) 1.08 0.64 1.81     0.78 
Rofecoxib (ibuprofen) 2.88 1.62 5.11  < 0.01 
Naproxen  (ibuprofen) 0.99 0.61 1.60     0.96 
Total population: 12,188; Ibuprofen – 4,481; Naproxen – 3,240; Celecoxib – 1,530; Etodolac – 2,371;  




Table 3.23  Adjusted association between exposure to NSAIDS & COX-2 
                    inhibitors and serious cardiovascular events (defined as acute 
        myocardial infarction, death from coronary heart disease, or  
        cerebrovascular event) – Ibuprofen Comparison. 
Exposure (reference group) Adjusted Risk Ratio (95% CI) Sig. (p) 
Celecoxib (ibuprofen) 1.13 (0.70 – 1.83) 0.61 
Etodolac   (ibuprofen) 0.82 (0.48 – 1.40) 0.47 
Rofecoxib (ibuprofen) 1.59 (0.87 – 2.90) 0.13 
Naproxen  (ibuprofen) 0.86 (0.53 – 1.40) 0.54 
Covariates    
Diabetes 1.32 (0.92 – 1.90) 0.13 
Angina 1.16 (0.76 – 1.78) 0.48 
PVD 1.48 (0.87 – 2.49) 0.15 
Atrial Fibrillation  1.29 (0.66 – 2.52) 0.45 
Cancer 0.89 (0.58 – 1.37) 0.60 
COPD 1.98 (1.27 – 3.10) < 0.01 
Heart failure  1.27 (0.75 – 2.16) 0.38 
HIV 0 .            . 
Lupus* 0 .            . 
Osteoarthritis 1.85 (1.27 – 2.68) < 0.01 
Renal failure  0.56 (0.15 – 2.05) 0.38 
Respiratory failure 0.74 (0.20 – 2.78) 0.65 
Rheumatoid arthritis 0.84 (0.29 – 2.37) 0.74 
Prior AMI 3.98 (2.10 – 7.60) < 0.01 
Prior Stroke (specificity model) 4.07 (1.42 – 11.67) 0.01 
Antiarrhythmic 1.41 (0.67 – 2.94) 0.37 
Aspirin 1.07 (0.74 – 1.56) 0.72 
B-blocker 1.51 (1.03 – 2.22) 0.03 
Ca-blocker 0.96 (0.67 – 1.37) 0.80 
Digoxin 1.03 (0.60 – 1.75) 0.92 
Other HTN Meds 0.69 (0.45 – 1.04) 0.08 
Loop diuretic 1.58 (1.03 – 2.41) 0.03 
Methotrexate 5.90 (1.72 – 20.22) < 0.01 
Warfarin 0.99 (0.54 – 1.79) 0.96 
ACE/ARBS 1.21 (0.84 – 1.73) 0.31 
Antiplatelet 1.79 (1.07 – 2.99) 0.03 
Antirheumatic 0 .       .   
Steroid 0.47 (0.21 – 1.06) 0.07 
Cholesterol drug 0.91 (0.63 – 1.31) 0.62 
Diuretic other 0.74 (0.47 – 1.18) 0.20 
Anticoagulant 0.34 (0.05 – 2.50) 0.29 
Sex (male) 0.69 (0.25 – 1.89) 0.47 
Age  1.04 (1.02 – 1.05) < 0.01 
Total population: 12,188; Ibuprofen – 4,481; Naproxen – 3,240; Celecoxib – 1,530; Etodolac – 2,371;  
   Rofecoxib – 566.  Endpoint events – 146; censored 12,042.     






OBJECTIVE III – To determine if duration of naproxen/COX-2 inhibitor use has an  
          effect on cardiovascular outcomes (protective for naproxen and  
          cardio-negative for COX-2 inhibitors).  Compared to ibuprofen 
 
 
Important reminder to the reader - in this analysis patients are excluded if an endpoint 
event occurred during the first 180 days.      
 
The following analysis evaluates the cardiovascular risk associated with long-
term exposure to study medications.  The unadjusted model revealed a 3.72-fold (95% 
CI, 1.47 – 9.39; p = 0.01) increased risk of serious cardiovascular events in subjects using 
celecoxib long-term as compared to long-term ibuprofen users.  Similarly, long-term 
users of rofecoxib were found to be 7.46 times (95% CI, 2.59 – 21.54; p = < 0.01) more 
likely to experience a serious cardiovascular event when compared to long-term users of 
ibuprofen. Results for the unadjusted model are listed in Table 3.24.        
Study 
Hypotheses Description 




There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking celecoxib long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates.  
Reject 
Ho10 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking rofecoxib long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates. 
Reject 
Ho11 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking etodolac long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates. 
Fail to Reject 
Ho12 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking naproxen long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates. 
Fail to Reject 
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After controlling for confounders, long-term use of celecoxib was associated with 
an increased risk of serious cardiovascular events when compared to persons taking 
ibuprofen long-term (aRR, 3.64; 95% CI, 1.36 – 9.70; p = 0.01).  See Table 3.25    
Furthermore, long-term rofecoxib use was found to have roughly twice the magnitude of 
risk (aRR, 6.64; 95% CI, 2.17 – 20.28; p = < 0.01).    After long-term exposure, subjects 
taking etodolac were not associated with an increased or decreased risk of serious 
cardiovascular events when compared to ibuprofen users (aRR, 1.26, 95% CI, 0.35 – 
4.56; p = 0.73).  Similarly, after long-term use, naproxen was not found to be 
cardioprotective or cardionegative (aRR, 1.15, 95% CI, 0.35 – 3.77; p = 0.81).  




Table 3.24  Un-adjusted association between long-term exposure to NSAIDS & 
        COX-2 inhibitors and serious cardiovascular events (defined as acute 
        myocardial infarction, death from coronary heart disease, or  
        cerebrovascular event) – Ibuprofen Comparison. ξ 
 
Exposure (reference group) 
 
Risk Ratio  
(95% CI) 
  Lower        Upper 
 
Sig. (p) 
Any exposure      
Celecoxib (ibuprofen) 3.72 1.47 9.39 0.01 
Etodolac   (ibuprofen) 1.25 0.35 4.44 0.73 
Rofecoxib (ibuprofen) 7.46 2.59 21.54 < 0.01 
Naproxen  (ibuprofen) 1.18 0.38 3.66 0.77 
Total population: 3,407; Ibuprofen – 1,085; Naproxen – 849; Celecoxib – 611; Etodolac – 656; Rofecoxib 
– 206.  Endpoint events – 42; censored 3,275.    










Table 3.25  Adjusted association between long-term exposure to NSAIDS & COX-2 
                    inhibitors and serious cardiovascular events (defined as acute 
        myocardial infarction, death from coronary heart disease, or  
        cerebrovascular event) – Ibuprofen comparison.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 3.64 1.36 9.70 0.01 
Etodolac   (ibuprofen) 1.26 0.35 4.56 0.73 
Rofecoxib (ibuprofen) 6.64 2.17 20.28 < 0.01 
Naproxen  (ibuprofen) 1.15 0.35 3.77 0.81 
Covariates     
Diabetes 1.38 0.67 2.83 0.39 
Angina 0.58 0.23 1.45 0.25 
PVD 0.24 0.03 1.97 0.18 
Atrial Fibrillation  3.27 0.93 11.45 0.06 
Cancer 0.50 0.19 1.28 0.15 
COPD 1.85 0.73 4.72 0.20 
Heart failure  3.11 1.12 8.65 0.03 
HIV 0 . .        . 
Lupus* 0 . .        . 
Osteoarthritis 0.93 0.41 2.12 0.86 
Renal failure  0.34 0.03 3.50 0.36 
Respiratory failure 0 . .        . 
Rheumatoid arthritis 1.98 0.43 9.13 0.38 
Prior AMI 9.65 2.39 38.95 < 0.01 
Prior Stroke (specificity model) 0 . .        . 
Antiarrhythmic 0.43 0.06 3.24 0.41 
Aspirin 0.71 0.32 1.54 0.38 
B-blocker 0.79 0.34 1.87 0.60 
Ca-blocker 0.73 0.36 1.50 0.39 
digoxin 0.91 0.31 2.68 0.87 
other HTN Meds 0.47 0.20 1.10 0.08 
loop diuretic 4.13 1.95 8.76 < 0.01 
methotrexate 0 . .        . 
warfarin 0.21 0.05 0.87 0.03 
ACE/ARBS 0.96 0.47 1.98 0.91 
Antiplatelet 2.78 1.08 7.15 0.03 
Antirheumatic 0 . .         . 
Steroid 0.76 0.17 3.43 0.72 
cholesterol drug 1.12 0.57 2.21 0.74 
diuretic other 1.22 0.54 2.77 0.63 
Anticoagulant 0 . .        . 
Sex (male) 0.54 0.07 4.06 0.55 
Age  1.03 1.00 1.06 0.09 
Total population: 3,407; Ibuprofen – 1,085; Naproxen – 849; Celecoxib – 611; Etodolac – 656; Rofecoxib 
– 206.  Endpoint events – 42; censored 3,275.    
* Systemic lupus erythematosus and connective tissue disorders diagnosis 




OBJECTIVE III – short-term use  
  
 To further delineate the temporal relationship between NSAID and COX-2 
inhibitor use and cardiovascular risk, observations with less than or equal to 180 days of 
exposure were evaluated.  Observations exceeding 180 days of exposure were not 
evaluated.  The unadjusted model found a significant increase in serious cardiovascular 
risk among short-term users of rofecoxib as compared to short-term users of ibuprofen.  
All other comparisons were not statistically significant.  Results for the unadjusted model 
are listed in Table 3.26.  With regards to the adjusted model, short-term use of any 
NSAID or COX-2 inhibitor was not associated with an increase or decreased risk of 








There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking celecoxib short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
Ho6 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking rofecoxib short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
Ho7 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking etodolac short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
Ho8 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking naproxen short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
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Table 3.26   Un-Adjusted association between short-term exposure to NSAIDS & 
        COX-2 inhibitors and serious cardiovascular events (defined as acute 
        myocardial infarction, death from coronary heart disease, or  
        cerebrovascular event) – Ibuprofen Comparison.ξ 
 
Exposure (reference group) 
 
Risk Ratio  
(95% CI) 
  Lower        Upper 
 
Sig. (p) 
Any exposure      
Celecoxib (ibuprofen) 1.80 0.88 3.67 0.10 
Etodolac   (ibuprofen) 0.93 0.45 1.93 0.85 
Rofecoxib (ibuprofen) 3.03 1.34 6.85 0.01 
Naproxen  (ibuprofen) 0.71 0.34 1.48 0.36 
Total population: 8,730; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 908; Etodolac – 1,705; 
Rofecoxib – 358.  Endpoint events – 63; censored 8,667.     




Table 3.27  Adjusted association between short-term exposure to NSAIDS & COX-2 
                    inhibitors and serious cardiovascular events (defined as acute 
        myocardial infarction, death from coronary heart disease, or  
        cerebrovascular event) – Ibuprofen Comparison.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.67 0.31 1.47 0.32 
Etodolac   (ibuprofen) 0.63 0.30 1.34 0.23 
Rofecoxib (ibuprofen) 1.40 0.59 3.33 0.44 
Naproxen  (ibuprofen) 0.60 0.29 1.26 0.18 
Covariates     
Diabetes 0.89 0.50 1.58 0.68 
Angina 1.08 0.56 2.09 0.82 
PVD 1.82 0.86 3.85 0.12 
Atrial Fibrillation  1.40 0.54 3.63 0.49 
Cancer 1.22 0.67 2.25 0.51 
COPD 2.43 1.24 4.75 0.01 
Heart failure  1.44 0.64 3.22 0.37 
HIV 0 . .         . 
Lupus* 0 . .         . 
Osteoarthritis 2.35 1.33 4.14 < 0.01 
Renal failure  1.33 0.24 7.20 0.74 
Respiratory failure 1.67 0.37 7.66 0.51 
Rheumatoid arthritis 0.37 0.04 3.11 0.36 
Prior AMI 1.99 0.65 6.06 0.23 
Prior Stroke (specificity model) 4.35 0.93 20.45 0.06 
Antiarrhythmic 1.93 0.70 5.33 0.20 
Aspirin 1.59 0.90 2.83 0.11 
B-blocker 1.92 1.06 3.45 0.03 
Ca-blocker 0.76 0.43 1.35 0.35 
digoxin 0.80 0.33 1.96 0.63 
other HTN Meds 0.51 0.24 1.05 0.07 
loop diuretic 0.66 0.32 1.34 0.25 
methotrexate 10.38 2.10 51.26 < 0.01 
warfarin 1.74 0.73 4.14 0.21 
ACE/ARBS 1.89 1.08 3.32 0.03 
Antiplatelet 1.46 0.63 3.39 0.37 
Antirheumatic 0 . .         . 
Steroid 0.38 0.11 1.34 0.13 
cholesterol drug 0.93 0.53 1.64 0.81 
diuretic other 0.70 0.35 1.41 0.32 
Anticoagulant 0.99 0.13 7.70 0.99 
Sex (male) 0.83 0.20 3.46 0.79 
Age  1.03 1.01 1.06 0.01 
Total population: 8,730; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 908; Etodolac – 1,705; 
Rofecoxib – 358.  Endpoint events – 63; censored 8,667.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 






A summary of the previous analyses can be found in Table 3.28. 
 
Table 3.28  Summary – Adjusted association between NSAIDS & COX-2 inhibitors 
        and serious cardiovascular events (defined as acute myocardial 
        infarction, death from coronary heart disease, or cerebrovascular event)  
        – ibuprofen, comparison group. 
 
Exposure (reference group) 
 
Adjusted Risk Ratio 
(95% CI) 
  Lower        Upper 
 
Sig. (p) 
Any exposure      
Celecoxib (ibuprofen) 1.13 0.70 1.83 0.61
Etodolac   (ibuprofen) 0.82 0.48 1.40 0.47
Rofecoxib (ibuprofen) 1.59 0.87 2.90 0.13
Naproxen  (ibuprofen) 0.86 0.53 1.40 0.54
> 180 days exposure ξ  - excludes observations with  events during the first 180 days 
Celecoxib (ibuprofen) 3.64 1.36 9.70 0.01
Etodolac   (ibuprofen) 1.26 0.35 4.56 0.73
Rofecoxib (ibuprofen) 6.64 2.17 20.28 < 0.01
Naproxen  (ibuprofen) 1.15 0.35 3.77 0.81
≤ 180 days exposureσ – excludes long-term use observations 
Celecoxib (ibuprofen) 0.67 0.31 1.47 0.32
Etodolac   (ibuprofen) 0.63 0.30 1.34 0.23
Rofecoxib (ibuprofen) 1.40 0.59 3.33 0.44
Naproxen  (ibuprofen) 0.60 0.29 1.26 0.18
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 















SENSITIVITY ANALYSES   
 
Several sensitivity analyses were conducted.  These include: 
 
1) allowing events to occur during the first 180 days of exposure – long-term model; 
2) including long-term use observations into the short-term model (limited to the 
first 180 days);   
3) use of different comparator groups (i.e., naproxen and etodolac); 
4) evaluating only AMI and AMI-related deaths (excludes stroke cases); 
5) expanding the stroke definition (stroke sensitivity model);  
6) broadening the mortality definition to include deaths from ischemic heart disease; 
7) broadening the mortality definition to include deaths from major cardiovascular 
diseases; 
8) restricting the age groups to subjects 65 years of age and older; and  










1)  Including events that occur during the first 180 days of exposure - Long-term model 
  
This sensitivity analysis was primarily conducted to further evaluate the possible 
cardioprotective effects of naproxen.  The sample was expanded to evaluate long-term 
use observations (> 180 days exposure) with events occurring during the first 180 days.  
In doing so, 13 excluded ibuprofen observations; 11 excluded celecoxib observations; 10 
excluded etodolac observations; 2 excluded rofecoxib observations; and 15 excluded 
naproxen observations were added to the model (when compared to the long-term model 
that excluded endpoint events during the first 180 days).  However, even with this 
modification, long-term naproxen use was still not associated with a cardioprotective 
effect (aRR, 1.11; 95% CI, 0.56 – 2.18; p = 0.77).  See Table 3.29   
 
 
Table 3.29  Summary – Adjusted association between long-term exposure to 
       NSAIDs & COX-2 inhibitors and cardiovascular events (including events  
       occurring during the first 180 days) – including events during first 180 
       days.ξ 
 
Exposure (reference group) 
Adjusted 
Risk Ratio  
(95% CI) 
  Lower     Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 1.63 0.85 3.13 0.14 
Etodolac   (ibuprofen) 1.02 0.48 2.19 0.95 
Rofecoxib (ibuprofen) 2.00 0.86 4.68 0.11 
Naproxen  (ibuprofen) 1.11 0.56 2.18 0.77 
See Appendix T for full model  
ξ Long-term exposure defined as > 180 days (events may occur during the first 180 days). 
σ End point - defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular 









2)  Including long-term observations into the short-term model (limited to the first 180 
days). 
 
To further evaluate the short-term association between cardiovascular events and 
drug exposure, all observation periods were limited to the first 180 days.  In making this 
modification, the sample size was increased by 3,464 observations.  This modification 
did not find an association between serious cardiovascular events and short-term use of 
NSAIDs/COX-2 inhibitors.  All results were statistically nonsignificant.  See Table 3.30 
for further details.                
 
Table 3.30  Adjusted association between short-term exposure (limiting long-term 
        exposure periods to the first 180 days) to NSAIDS & COX-2 
        inhibitors and serious cardiovascular events – all observations. ξ 
 
Exposure (reference group) 
Adjusted 
Risk Ratio  
(95% CI) 
  Lower     Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.77 0.43 1.39 0.39 
Etodolac   (ibuprofen) 0.74 0.41 1.32 0.31 
Rofecoxib (ibuprofen) 0.87 0.40 1.88 0.72 
Naproxen  (ibuprofen) 0.85 0.49 1.46 0.55 
See Appendix U for full model 
ξ Short term exposure defined as ≤ 180 days; includes long-term use observations with exposure periods 


















3) Use of different comparator groups (i.e. naproxen and etodolac) 
 
The following sensitivity analysis evaluated the use of different comparator 
groups, i.e., naproxen and etodolac.  Compared to ibuprofen, naproxen yielded similar 
adjusted risk ratios in all categories.  Regarding long-term use, celecoxib users were 
found to be 3.16 (95% CI, 1.16 – 8.57; p = 0.02) times more likely to experience a 
serious cardiovascular event and rofecoxib users were 5.76 (95% CI, 1.82 – 18.21; p = < 
0.01) times more likely to experience an event than naproxen users.  Ibuprofen and 
etodolac yielded non-significant results.  Additionally, overall general use and short-term 
use of study medications were not associated with cardiovascular risk.  With regards to 
using etodolac as a comparator group, two of the results differed from the models using 
ibuprofen as a comparator.  Long-term users of celecoxib were not statistically different 
from long-term users of etodolac in terms of cardiovascular risk (aRR, 2.89, 95% CI, 
0.95 – 8.80; p = 0.06).  Additionally, overall use of rofecoxib (long-term and short-term 
use) was associated with a statistically significant increase in cardiovascular risk 
compared to etodolac (aRR, 1.93; 95% CI, 1.02 – 3.67; p = 0.04).  All other results were 
comparable to results with models using ibuprofen as the control group.  See Table 3.31 






            
Table 3.31  Summary – Adjusted association between NSAIDS & COX-2 inhibitors 
        and serious cardiovascular events (defined as acute myocardial 
        infarction, death from coronary heart disease, or cerebrovascular event)  
 naproxen, and etodolac comparison groups. 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower     Upper 
 
Sig. (p) 
Any exposure a      
Ibuprofen (naproxen) 1.17 0.72 1.90 0.54
Celecoxib (naproxen) 1.32 0.80 2.20 0.28
Etodolac   (naproxen) 0.96 0.55 1.67 0.88
Rofecoxib (naproxen) 1.85 0.99 3.45 0.05
> 180 days exposure b, ξ     
Ibuprofen (naproxen) 0.87 0.27 2.84 0.81
Celecoxib (naproxen) 3.16 1.16 8.57 0.02
Etodolac   (naproxen) 1.09 0.29 4.05 0.90
Rofecoxib (naproxen) 5.76 1.82 18.21 < 0.01
≤ 180 days exposure c, σ     
Ibuprofen (naproxen) 1.66 0.79 3.47 0.18
Celecoxib (naproxen) 1.12 0.46 2.67 0.81
Etodolac   (naproxen) 1.05 0.45 2.47 0.91
Rofecoxib (naproxen) 2.33 0.90 6.04 0.08
Any exposure d      
Ibuprofen (etodolac) 1.22 0.72 2.07 0.47
Celecoxib (etodolac) 1.38 0.81 2.35 0.24
Rofecoxib (etodolac) 1.93 1.02 3.67 0.04
Naproxen  (etodolac) 1.04 0.60 1.82 0.88
> 180 days exposure e, ξ      
Ibuprofen  (etodolac) 0.80 0.22 2.89 0.73
Celecoxib (etodolac) 2.89 0.95 8.80 0.06
Rofecoxib (etodolac) 5.28 1.51 18.44 0.01
Naproxen  (etodolac) 0.92 0.25 3.40 0.90
≤ 180 days exposure f, σ     
Ibuprofen (etodolac) 1.58 0.74 3.34 0.23
Celecoxib (etodolac) 1.06 0.45 2.49 0.90
Rofecoxib (etodolac) 2.21 0.86 5.71 0.10
Naproxen (etodolac) 0.95 0.40 2.23 0.91
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 
σ Excludes long-term use observations. 
a  See Appendix V for full model  
b See Appendix W for full model  
c  See Appendix X for full model 
d  See Appendix Y for full model  
e  See Appendix Z for full model  





4) Evaluating only AMI and AMI-related deaths (excludes stroke cases) 
 
 The next sensitivity analysis removes stroke from the endpoint classification and 
evaluates just acute myocardial infarctions and acute myocardial infarction-related 
deaths.  No statistically significant differences were found in the “any exposure” 
category.  Similar results to the primary model (the model containing stroke) were found 
in the evaluation of long-term users.  Long-term users of celecoxib and rofecoxib were 
3.59 times (95% CI, 1.03 – 12.56; p = 0.05) and 7.07 times (95% CI, 1.57 – 31.95; p = 
0.01) more likely to experience a serious coronary event as compared to long-term 
ibuprofen users, respectively.  No statically significant differences were found with short-

























Table 3.32  Summary – Adjusted association between NSAIDS & COX-2 inhibitors 
        and serious coronary events (defined as acute myocardial infarction or 
        death from coronary heart disease) 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower     Upper 
 
Sig. (p) 
Any exposure a       
Celecoxib (ibuprofen) 0.90 0.50 1.60 0.71 
Etodolac   (ibuprofen) 0.76 0.41 1.41 0.39 
Rofecoxib (ibuprofen) 1.02 0.46 2.26 0.96 
Naproxen  (ibuprofen) 1.01 0.60 1.71 0.98 
> 180 days exposure b, ξ      
Celecoxib (ibuprofen) 3.59 1.03 12.56 0.05 
Etodolac   (ibuprofen) 1.13 0.20 6.49 0.89 
Rofecoxib (ibuprofen) 7.07 1.57 31.95 0.01 
Naproxen  (ibuprofen) 1.86 0.48 7.27 0.37 
≤ 180 days exposure c, σ      
Celecoxib (ibuprofen) 0.58 0.23 1.48 0.26 
Etodolac   (ibuprofen) 0.51 0.21 1.27 0.15 
Rofecoxib (ibuprofen) 0.89 0.28 2.81 0.84 
Naproxen  (ibuprofen) 0.68 0.31 1.50 0.34 
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 
σ Excludes long-term use observations. 
a  See Appendix BB for full model  
b See Appendix CC for full model  





















5) Expanding the stroke definition (stroke sensitivity model) 
 
This sensitivity analysis modifies the endpoint definition by expanding the stroke 
definition (stroke sensitivity).  Using this model, all results were found to be statically 
non-significant.  However, a non-significant trend towards increased cardiovascular risk 
was found with long-term use of celecoxib and rofecoxib when compared to ibuprofen 
use.  Further details are available in Table 3.33         
 
Table 3.33   Summary – Adjusted association between NSAIDS & COX-2 inhibitors  
         and serious cardiovascular events (defined as acute myocardial 
        infarction, death from coronary heart disease, or cerebrovascular event)  
        - high sensitivity stroke model.* 
 
Exposure (reference group) 
Adjusted Risk Ratio  (95% CI) 
 Lower      Upper 
 
Sig. (p) 
Any exposure a     
Celecoxib (ibuprofen) 0.90 0.60 1.33 0.59 
Etodolac   (ibuprofen) 0.68 0.44 1.05 0.08 
Rofecoxib (ibuprofen) 1.03 0.60 1.76 0.92 
Naproxen  (ibuprofen) 0.85 0.58 1.26 0.42 
> 180 days exposure b, ξ     
Celecoxib (ibuprofen) 1.53 0.71 3.31 0.28 
Etodolac  (ibuprofen) 0.75 0.26 2.16 0.59 
Rofecoxib (ibuprofen) 2.16 0.81 5.77 0.12 
Naproxen (ibuprofen) 0.76 0.32 1.83 0.54 
≤ 180 days exposure c, σ     
Celecoxib (ibuprofen) 0.63 0.33 1.19 0.15 
Etodolac  (ibuprofen) 0.54 0.28 1.02 0.06 
Rofecoxib (ibuprofen) 0.81 0.34 1.91 0.63 
Naproxen (ibuprofen) 0.77 0.44 1.36 0.37 
* Note: uses stroke sensitivity model for prior stroke covariate 
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 
σ Excludes long-term use observations. 
a  See Appendix EE for full model  
b See Appendix FF for full model  




6)   Broadening the mortality definition to include deaths from ischemic heart disease 
 
The following two sensitivity analyses adjust the mortality definition of the 
primary model to evaluate deaths for ischemic heart diseases (not just AMI) and total 
cardiovascular disease.  As a reminder, death from ischemic heart disease encompasses 
angina pectoris, acute myocardial infarction, “other acute ischemic coronary heart 
disease,” and all other forms of chronic ischemic heart disease.  This modification did not 





























Table 3.34  Summary – Adjusted association between NSAIDS & COX-2 inhibitors  
         and serious cardiovascular events (defined as acute myocardial  
         infarction, death from ischemic heart disease, or cerebrovascular  
          event).* 
 
Exposure (reference group) 
 
Adjusted Risk Ratio 
(95% CI) 
  Lower      Upper 
 
Sig. (p) 
Any exposure a     
Celecoxib (ibuprofen) 1.14 0.71 1.82 0.59
Etodolac   (ibuprofen) 0.82 0.49 1.37 0.45
Rofecoxib (ibuprofen) 1.53 0.85 2.78 0.16
Naproxen  (ibuprofen) 0.96 0.61 1.53 0.87
> 180 days exposure b, ξ     
Celecoxib (ibuprofen) 3.03 1.20 7.63 0.02
Etodolac   (ibuprofen) 1.02 0.29 3.54 0.98
Rofecoxib (ibuprofen) 5.59 1.93 16.24   < 0.01
Naproxen  (ibuprofen) 1.49 0.53 4.15 0.45
≤ 180 days exposure c, σ    
Celecoxib (ibuprofen) 0.78 0.37 1.63 0.50
Etodolac   (ibuprofen) 0.66 0.32 1.36 0.26
Rofecoxib (ibuprofen) 1.41 0.60 3.31 0.43
Naproxen  (ibuprofen) 0.64 0.31 1.30 0.21
* Using the high specificity stroke model 
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 
σ Excludes long-term use observations. 
a  See Appendix HH for full model  
b See Appendix II for full model  




















7) Broadening the mortality definition to include deaths from major cardiovascular 
diseases 
 
 The second analysis expands the mortality definition a little further and evaluates 
all cardiovascular related deaths.  The precise definition for “total cardiovascular disease” 
can be found in Chapter One, page 16.  Using this broad definition, all study results were 
the same as the primary model except for long-term celecoxib use.  Long-term use 
celecoxib was associated with a non-significant increase in cardiovascular events as 
compared to ibuprofen (aRR, 2.17; 95% CI, 0.94 – 5.03; p = 0.07).  See Table 3.35 for 
















Table 3.35  Summary – Adjusted association between NSAIDS & COX-2 inhibitors  
         and serious cardiovascular events (defined as acute myocardial  
         infarction, death from major cardiovascular disease, or cerebrovascular  
         event).* 
 
Exposure (reference group) 
 
Adjusted Risk Ratio 
(95% CI) 
  Lower      Upper 
 
Sig. (p) 
Any exposure a     
Celecoxib (ibuprofen) 1.14 0.73 1.79 0.55 
Etodolac   (ibuprofen) 0.87 0.53 1.42 0.58 
Rofecoxib (ibuprofen) 1.58 0.90 2.77 0.11 
Naproxen  (ibuprofen) 1.01 0.65 1.56 0.98 
> 180 days exposure b, ξ     
Celecoxib (ibuprofen) 2.17 0.94 5.03 0.07 
Etodolac   (ibuprofen) 0.96 0.31 2.91 0.94 
Rofecoxib (ibuprofen) 3.90 1.43 10.62 0.01 
Naproxen  (ibuprofen) 1.14 0.45 2.91 0.78 
≤ 180 days exposure c, σ     
Celecoxib (ibuprofen) 0.86 0.43 1.74 0.67 
Etodolac   (ibuprofen) 0.64 0.31 1.32 0.23 
Rofecoxib (ibuprofen) 1.72 0.78 3.76 0.18 
Naproxen  (ibuprofen) 0.77 0.40 1.49 0.44 
* Using the high specificity stroke model 
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 
σ Excludes long-term use observations. 
a  See Appendix KK for full model  
b See Appendix LL for full model  




















8) Restricting the age groups to subjects 65 years of age and older 
 
Subjects were restricted to those aged 65 and older in order to assess an older 
population more at risk for cardiovascular disease.  When restricted to subjects 65 years 
of age and older, the risk associated with long-term celecoxib and rofecoxib use nearly 
doubles.  In this age group, celecoxib long-term users were 7.36 times (95% CI, 1.62 – 
33.48; p = 0.01) more likely to experience a serious cardiovascular event and rofecoxib 
long-term users were 13.24 times (95% CI, 2.59 – 67.68; p = < 0.01) more likely to 
experience a serious cardiovascular event when compared to ibuprofen users.  One 
additional difference from the primary model is the significant association between 
general use rofecoxib and serious cardiovascular events (aRR, 2.14; 95% CI, 1.09 – 4.19; 
p = 0.03).  All other results were not statistically significant.  See Table 3.36 for more 





















Table 3.36  Summary – Adjusted association between NSAIDS & COX-2 inhibitors  
        and serious cardiovascular eventsγ in VA subjects ≥ 65 years of age.* 
 
Exposure (reference group) 
 
Adjusted Risk Ratio 
(95% CI) 
  Lower      Upper 
 
Sig. (p) 
Any exposure a     
Celecoxib (ibuprofen) 1.52 0.87 2.67 0.14
Etodolac   (ibuprofen) 1.10 0.58 2.10 0.77
Rofecoxib (ibuprofen) 2.14 1.09 4.19 0.03
Naproxen  (ibuprofen) 1.08 0.59 1.97 0.81
> 180 days exposure b, ξ    
Celecoxib (ibuprofen) 7.36 1.62 33.48 0.01
Etodolac   (ibuprofen) 3.54 0.62 20.13 0.15
Rofecoxib (ibuprofen) 13.24 2.59 67.68 < 0.01
Naproxen  (ibuprofen) 1.72 0.28 10.50 0.55
≤ 180 days exposure c, σ    
Celecoxib (ibuprofen) 0.84 0.36 1.95 0.68
Etodolac   (ibuprofen) 0.78 0.32 1.89 0.59
Rofecoxib (ibuprofen) 1.60 0.62 4.16 0.33
Naproxen  (ibuprofen) 0.52 0.20 1.33 0.17
γ Defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular event 
* Using the high specificity stroke model 
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 
σ Excludes long-term use observations. 
a  See Appendix NN for full model  
b See Appendix OO for full model  



















9)  Including one additional year of data (2002) 
 
The final sensitivity analysis incorporates one more year of data to the overall 
analysis, the 2002 data.  The inclusion of the 2002 data increased the sample size to 
16,488, an increase of 4,300 observations.  Of note, the sample size refers to naproxen, 
ibuprofen, celecoxib, rofecoxib and etodolac users.  Drug specific increases are as 
follows: 
 
• Ibuprofen 4,481 → 5,699; 
• Naproxen 3,240 → 4,385; 
• Celecoxib 1,530 → 1,980; 
• Etodolac 2,371 → 3,615 and; 
• Rofecoxib 566 → 809. 
 
The number of endpoints increased from 146 to 238.  Study findings were similar 
to the model using data from 1999 – 2001; with non-significant findings for the “any 
exposure” and short-term use categories.  Long-term celecoxib and rofecoxib use was 
associated with an increase in cardiovascular risk when compared to long-term ibuprofen 
users.  However, the magnitude of association was less.  Celecoxib use were 2.05 times 
(95% CI, 1.03 – 4.07; p = 0.04) more likely to experience a serious cardiovascular event 
when compared to long-term ibuprofen use and rofecoxib users were 2.59 times (95% CI, 
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1.10 – 6.10; p = 0.03) more likely to experience a serious cardiovascular event when 
compared to long-term ibuprofen use.  See Table 3.37 for more details.     
 
 
Table 3.37  Summary – Adjusted association between NSAIDS & COX-2 inhibitors  
        and serious cardiovascular events – 1999 through 2002.γ, * 
 
Exposure (reference group) 
 
Adjusted Risk Ratio 
(95% CI) 
  Lower      Upper 
 
Sig. (p) 
Any exposure      
Celecoxib (ibuprofen) 1.14 0.77 1.70 0.51 
Etodolac   (ibuprofen) 0.99 0.67 1.47 0.97 
Rofecoxib (ibuprofen) 1.56 0.96 2.54 0.07 
Naproxen  (ibuprofen) 1.03 0.70 1.52 0.87 
> 180 days exposure      
Celecoxib (ibuprofen) 2.05 1.03 4.07 0.04 
Etodolac   (ibuprofen) 1.83 0.90 3.70 0.09 
Rofecoxib (ibuprofen) 2.59 1.10 6.10 0.03 
Naproxen  (ibuprofen) 1.39 0.68 2.88 0.37 
≤ 180 days exposure      
Celecoxib (ibuprofen) 0.69 0.35 1.37 0.29 
Etodolac   (ibuprofen) 0.65 0.34 1.23 0.19 
Rofecoxib (ibuprofen) 1.70 0.84 3.44 0.14 
Naproxen  (ibuprofen) 0.79 0.44 1.44 0.44 
γ Defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular event 
* Using the high specificity stroke model 
ξ Long-term exposure defined as > 180 days (with no events during the first 180 days). 
σ Excludes long-term use observations. 
a  See Appendix QQ for full model  
b See Appendix RR for full model  















ASSESSING THE STABILITY OF THE MODEL 
     
Proportional Hazard Assessment   
 
1) Graphical Assessment – The first step was to evaluate the overall model 
evaluating serious cardiovascular disease between NSAIDs/COX-2 inhibitors and 
ibuprofen (Figures 3.4 – 3.5).  The observational assessment looked as though the 
hazards are close to proportional; however, it is difficult to determine graphically.  
Of note, it is highly unlikely that the proportional hazard assumption is ever 
exactly satisfied. 3   
2) Time dependent covariate – To test the proportional hazard assumption, a time 
dependent variable was created evaluating the interaction between drug categories 
and time.  In the overall model assessing serious cardiovascular risk between 
NSAIDs/COX-2 inhibitors, no statistically significant interaction was found (p = 
0.68) between study drugs and time, suggesting proportional hazards.  However, 
when comparing only celecoxib and rofecoxib to ibuprofen, the interaction term 
approaches significance (p = 0.053), possibly indicating the violation of the 
proportional hazard assumption.         
 
One of the a priori hypotheses was that the risk of a cardiovascular event may not 
be proportional.  Specifically, long-term use of COX-2 inhibitors was 
hypothesized to have a different association between risk of a cardiovascular 
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event compared to short term use.  One method described by Therneau and 
Grambsch to allow for non-proportional hazards is to partition the follow-up time, 
creating multiple models.4  This was done a priori and exposure times were 
partitioned into two groups, long-term exposure and short-term exposure.  It is 
important to remember that the long-term model differs from the short-term and 
“any exposure” models by not allowing events to occur during the first 180 days.  
Furthermore, to control for nonproportional hazards, only observations still at risk 
after 180 days should be evaluated.4  Both the short-term model and the long-term 
models were assessed for proportional hazards via the graphical assessment 
method and incorporation of a time dependent covariate assessment method. 
    
    
1) Graphical Assessment, long/short term models – When visually evaluating the 
long-term and short-term models, the models do appear to violate the proportion 
hazard assumption.  See Figures 3.6 – 3.9. 
2) Time dependent covariate, long/short term models – Both models were evaluated 
with a time dependent interaction term between study drugs and time.  The long-
term model incorporating the time dependent variable resulted in a nonsignificant 
finding (p = 0.45), suggesting proportional hazards.  Additionally, the short-term 
model with the incorporated time dependent variable yielded nonsignificant 
results (p = 0.31).  The assessment of proportional hazards was also conducted for 
the short-term model and the long-term model using a study drug covariate 
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containing only ibuprofen, celecoxib, rofecoxib, and exposure time (the time 
dependent variable approaching significance in the “any exposure” model).  The 
long-term model with the limited study drug covariate revealed a non-significant 
interaction term (p = 0.98), indicating proportional hazards.  The short-term 
model yielded similar results with a non-significant interaction term between time 
and study medications (p= 0.81).         





















Figure 3.4  Kaplan-Meier curves – Serious 








































The log-minus-log plots are used to test the proportional hazard assumption, plotting the 
log-scale on the -axis; approximately parallel lines would indicate a proportional 
hazard between – . 
 
Figure 3.5  Transformed Kaplan-Meier curves – 

























Figure 3.6  Kaplan-Meier curves – Serious 
cardiovascular disease – > 180 days exposure  
←Rofecoxib 
180 days - 0 endpoints 






















Figure 3.7  Transformed Kaplan-Meier curves – 




←Ibuprofen, Naproxen, Etodolac 
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Figure 3.8  Kaplan-Meier curves – Serious 











































Figure 3.9  Transformed Kaplan-Meier curves – 











 To assess multicollinearity, correlation matrixes were created for all of the 
variables.  This was done for the “any exposure”, short-term, and long-term models (1999 
– 2001 data, serious cardiovascular events).  Intercorrelation among independent 
variables above 0.80 indicates a possible problem with multicollinearity.5  Several 
methods exist to handle multicollinearity.  However, upon assessment of the correlation 
matrixes, none of the covariates in any of the models were found to have problematic 
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COX-2 inhibitors were developed with the belief that their use would reduce 
adverse reactions caused by the inhibition of the COX-1 enzyme.  However, clinical, 
epidemiological, and other studies provide evidence that the use of COX-2 inhibitors is 
associated with an increased risk of cardiovascular events.  This study investigated the 
association between COX-2 inhibitor and NSAID use, and cardiovascular risk among 
Texas veterans.  In addition, this study evaluated naproxen’s cardioprotective capability.   
This chapter: summarizes and discusses the results of the study; provides possible 
biological explanations for the study findings; compares and contrasts study results with 
previous research findings; discusses the sensitivity analyses; addresses study limitations; 














HYPOTHESES – ACCEPT / REJECT  
 
The results of the hypotheses tests are presented in Table 4.1.   
 




Fail to Reject 
/Reject 
Null Hypotheses 
Objective I - To evaluate serious cardiovascular events (AMI, stroke, cardiovascular 
                     mortality) associated with COX-2 inhibitors.  
Ho1 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking rofecoxib versus patients taking a traditional NSAID (i.e., 
ibuprofen), while controlling for various covariates. Overall use (short-
term and long-term use) 
Fail to Reject 
Ho2 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking celecoxib versus patients taking a traditional NSAID (i.e., 
ibuprofen), while controlling for various covariates.  Overall use 
Fail to Reject 
Ho3 
There is no difference in the overall risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking etodolac versus patients taking a traditional NSAID (i.e., 
ibuprofen). “any exposure” model 
Fail to Reject 
Objective II - To determine if naproxen offers greater cardioprotective benefits  
                      compared to other NSAIDs.  
Ho4 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking naproxen versus patients taking another traditional NSAID (i.e., 
ibuprofen), while controlling for various covariates.  Overall use 
















Fail to Reject 
/Reject 
Null Hypotheses
Objective III - To determine if duration of naproxen/COX-2 inhibitor use has an 
                        effect on cardiovascular outcomes (protective for naproxen and  
                        cardio-negative for COX-2 inhibitors).     
Short-term exposure 
Ho5 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking celecoxib short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
Ho6 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking rofecoxib short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
Ho7 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking etodolac short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
Ho8 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking naproxen short term (≤ 180 days) and patients taking ibuprofen 
short-term, while controlling for various covariates. 
Fail to Reject 
Long-term exposure 
Ho9 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking celecoxib long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates.  
Reject 
Ho10 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking rofecoxib long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates. 
Reject 
Ho11 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking etodolac long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates. 
Fail to Reject 
Ho12 
There is no difference in the risk of experiencing a serious 
cardiovascular event (defined as acute myocardial infarction, death 
from coronary heart disease, or cerebrovascular event) between patients 
taking naproxen long-term (> 180 days) and patients taking ibuprofen 
long-term, while controlling for various covariates. 
Fail to Reject 
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SUMMARY OF PRIMARY STUDY RESULTS  
“Any exposure model” 
 
 The unadjusted model, allowing long-term and short-term exposure (“any 
exposure”), found a significant increase in cardiovascular risk associated with celecoxib 
and rofecoxib.  However, when the model was adjusted for various covariates the results 
were no longer significant.  No significant increase or decrease in risk was found with 




Compared to ibuprofen, a cardiovascular risk was not found with short-term 
exposure (< 180 days) to etodolac, naproxen, or celecoxib (unadjusted and adjusted 
models).  Rofecoxib, in the unadjusted short-term model showed a significant increase in 





  Long-term use of celecoxib and rofecoxib was associated with an increased risk 
of cardiovascular disease in the adjusted (aRR, 3.64 / aRR, 6.64, respectively) and 
unadjusted models (RR, 3.72 / RR, 7.46, respectively).   
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DISCUSSION OF SENSITIVITY ANALYSES 
 
Several sensitivity analyses were conducted.  The same outline used in Chapter 
Three will be adopted in this section.  Most of the sensitivity analyses found similar 
results to the primary models.             
 
Sensitivity analyses include: 
 
1) Allowing events to occur during the first 180 days of exposure – long-term model 
 
The long-term model excluded events occurring during the first 180 days to 
control for nonproportional hazards and to demonstrate the cardiovascular 
ramifications after long-term use.  According to Therneau and Grambsch, to control 
for nonproportional hazards, only observations still at risk after x days (180 days in 
this study) should be evaluated.1  This analysis allowed events to occur during the 
first 180 days of long-term exposure.  The primary purpose of this sensitivity analysis 
was to evaluate the long-term protective effects of naproxen.  However, this analysis 
did not reveal any cardioprotective properties with naproxen.  Additionally, rofecoxib 
and celecoxib were not associated with a statistically significant increase in 
cardiovascular risk as compared to ibuprofen, contrasting with the primary long-term 





2) Including long-term use observations into the short-term model (limited to the first 
180 days).   
  
The original study design divided the sample into two mutually exclusive 
portions, individuals receiving long-term therapy and individuals receiving short-term 
therapy.  This was done to help control for any unmeasured variables in the study; 
patients receiving long-term therapy may have different characteristics than 
individuals receiving short-term therapy.  To further evaluate the short-term effects, 
long-term use observations were included in the analysis; however, the duration of 
assessment was limited to the first 180 days of exposure.  This analysis did not yield 













3) Use of different comparator groups (i.e. naproxen and etodolac).   
 
This sensitivity analysis evaluated different comparator groups.  Each NSAID/COX-2 
inhibitor has unique properties that may detract from or contribute to cardiovascular 
risk.  A brief overview will be provided regarding a few differences among the 
comparator groups.  Ibuprofen was chosen because it has not been associated with an 
increase or decrease in cardiovascular risk.  One important factor to keep in mind is 
that ibuprofen has been found to interfere with aspirin’s antiplatelet effects which 
may result in an increased number of cardiovascular events in this group.  The exact 
ramifications associated with concomitant use of ibuprofen and aspirin is yet to be 
determined.2  Naproxen has not been associated with this effect and has the opposite 
problem, providing possible cardioprotective effects (discussed previously).  Etodolac 
is an NSAID possessing some level of COX-2 specificity; the exact level is currently 
under debate.  Similar results in all models were found with naproxen as compared to 
ibuprofen.  Etodolac yielded similar results; however, the increased risk associated 
with long-term celecoxib use was no longer statistically significant (aRR 2.89; 95% 
CI, 0.95 – 8.80; p = 0.06).  This could be attributed to etodolac’s COX-2 selectivity or 







4) Evaluating only AMI and AMI related deaths (excludes stroke cases)   
        
Due to the difficulty in evaluating stroke cases from ICD-9 codes, only AMI and 
AMI-related deaths were evaluated.  Additionally, many of the published 
observational studies evaluated just AMI cases (± AMI death).  This sensitivity 
analysis did not result in any significant changes in any of the results.       
 
5) Expanding the stroke definition (stroke sensitivity model) 
 
     As discussed previously, a study conducted within the VA healthcare system 
assessing code veracity of stroke related ICD-9 codes has been conducted.  When a 
high-sensitivity model was used, results yielded 89% sensitivity, 57% specificity, 
60% positive predictive value, and 88% negative predictive value.  When a high-
specificity algorithm was used, the results change to: 59% sensitivity, 84% 
specificity, 72% positive predictive value, and 74% negative predictive value.3  In 
order to evaluate the full range of possibilities, the endpoint was changed to capture 
additional stroke cases.  However, in doing so, many of the additional cases (nearly 
40 %) are false positive.  This alteration resulted in nonsignificant results in all 
analyses, even long-term therapy.  However, this can be explained by the high 
number of false positives.  Furthermore, the sensitivity analysis evaluating only AMI 
and AMI-related deaths found a significant trend with long-term use of rofecoxib and 




6) Broadening the mortality definition to include deaths from ischemic heart disease. 
7) Broadening the mortality definition to include deaths from major cardiovascular 
diseases. 
    
      The next two sensitivity analyses broaden the mortality definition by evaluating 
death from ischemic heart disease / total cardiovascular disease (definition found in 
Chapter One, page 16).  When expanding the definition to include death from 
ischemic heart disease, no significant changes in any of the models were found.  
Similar results were found when total cardiovascular disease-related deaths was 
assessed; however, the increased risk associated with long-term use of celecoxib was 
no longer statistically significant (aRR, 2.17; 95% CI, 0.94 – 5.03; p = 0.07).  The 
nonsignificant result may be explained by the broad scope of conditions found in the 











8) Restricting the age groups to subjects 65 years of age and older. 
                   
This sensitivity analysis served two purposes: the first was to evaluate the 
cardiovascular risk in elderly individuals at increased risk for cardiovascular disease; 
and secondly to utilize the most complete set of data available (Medicare data).  This 
sensitivity analysis resulted in a dramatic change in the results.  In this analysis, 
overall use of rofecoxib was associated with an increased risk of cardiovascular 
events (aRR, 2.14; 95% CI 1.09 – 4.19; p = 0.03).  Additionally, the magnitude of 
risk nearly doubles for long-term use of celecoxib (aRR, 7.36 vs. aRR, 3.64) and 
rofecoxib (aRR, 13.24 vs. aRR, 6.64).   
 
9) Including one additional year of data (2002). 
        
The last sensitivity analysis incorporated one additional year of data into the 
model.  This sensitivity analysis was conducted to allow for a larger sample.  The 
principal concern with using the 2002 data is a possible channeling effect.  Several 
reports linking cardiovascular risk to COX-2 inhibitors became prominent in 2002.  
This information could cause physicians to alter prescribing patterns and place high 
risk patients on alternative forms of medication (e.g., ibuprofen).  Results from this 
analysis yielded results similar to the original model.  However, the magnitude of risk 
associated with long-term celecoxib (3.64 vs. 2.05) and rofecoxib (6.64 vs. 2.59) use 





Several biological mechanisms of actions have been reported, ranging from 
changes in blood pressure, effects on LDL oxidation, and effects on the prostanoid 
synthetic pathways.  COX-1 inhibition blocks TXA2 production, a prostanoid that 
induces platelet activation, aggregation, and adhesion.4  In contrast, COX-2 inhibition 
blocks PGI2 production, a beneficial prostanoid possessing vasodilating and platelet anti-
aggregating properties.  By selectively inhibiting the COX-2 enzyme, the protective 
effects of PGI2 are removed and allow the production of TXA2 (a platelet aggregator); 
thereby, possibly causing elevations in blood pressure, hardening of arteries, and 
increasing the risk for heart attacks and strokes.5  Atherosclerosis is a slow, progressive 
disease, beginning with damage of the innermost layer of the vessel wall and progressing 
to possible occlusion or rupture.6  COX-2 and COX-1 have both been found to be 
elevated in atherosclerotic plaques, contributing to elevations in TXA2 and PGI2.7  
Inversely, COX-2 was not found in normal blood vessels.  This information suggests that 
COX-2 inhibition without COX-1 inhibition may be more problematic in individuals with 
atherosclerosis, possibly explaining why a cardiovascular signal was not found in short-
term studies or in longer-term studies that typically exclude high risk individuals.5,8  To 
obtain an overall estimate of cardiovascular risk in the study population, several 
cardiovascular comorbidities will be discussed/assessed.  Smoking, elevated cholesterol, 
diabetes, obesity, and high blood pressure are five factors associated with 





Smoking can disrupt the endothelium and precipitate coronary spasms; thereby, 
possibly contributing to a myocardial infarction in patients with minimal atherosclerosis.9  
The progression of atherosclerosis is directly related to the total pack-years of smoking, 
and may be cumulative and irreversable.10  The prevalence of smoking within the VA has 
been shown to be significantly higher than in the general population (33 percent vs. 23 
percent, respectively).11 Additionally, veterans receiving healthcare within the VA were 
52 percent more likely to be current smokers than other veterans.12  In addition to 
cardiovascular disease, smokers are at a higher risk of developing COPD and lung 
cancer.  Information regarding smoking was not available for this study; however, 
baseline diagnoses for COPD and lung cancer were available.  When comparing study 
groups, celecoxib and rofecoxib were found to have higher percentages of COPD 
compared to etodolac, ibuprofen, and naproxen.  Furthermore, celecoxib and rofecoxib 
were found to have higher percentages of lung cancer than ibuprofen and naproxen.  See 
Table 4.2 for more details.  The higher percentage of these conditions could indicate 
larger numbers of past or current smokers among users of COX-2 inhibitors.         
 
Table 4.2  Baseline percentages of COPD and lung cancer by study medication  
 CELECOXIB ETODOLAC IBUPROFEN NAPROXEN ROFECOXIB 
COPD 9.9% 7.1% 5.1% 5.4% 13.2% 
Lung Cancer 0.8% 0.8% 0.6% 0.6% 0.7% 
Total (N) 1530 2373 4483 3241 567 





                                  
Elevated Cholesterol 
 
In addition to smoking, high cholesterol has been identified as an independent risk 
factor for developing coronary heart disease.  Amongst the study groups, borderline to 
high total cholesterol readings were found in roughly 33 to 40 percent of the observations 
(using available readings – see Table 3.17, page 154).  A similar percentage of 
cholesterol medication use was found in the study population (30.8 %), ranging from 25.9 
percent to 37.9 percent between the study groups.  Higher percentages of cholesterol 
medication use were found in celecoxib (37.6%) and rofecoxib (37.9%) users as 
compared to ibuprofen (25.9%), etodolac (33.3%), and naproxen (31.6%) users.  
Inversely, a lower percentage of borderline to high total cholesterol readings were found 
in celecoxib (34.1%) and rofecoxib (33.0%) observations as compared to ibuprofen 
(40.1%), etodolac (39.9%), and naproxen (41.6%) observations.   
 
High Blood Pressure     
                  
 Hypertensive patients are shown to have accelerated development of 
macrovascular lesions, leading to an increased risk/incidence of coronary heart disease, 
peripheral arterial and cerebrovascular diseases.13  Additionally, hypertension has been 
implicated in 35 percent of all atherosclerotic events.14  Roughly 45 percent of the study 
population was classified with stage one or stage two hypertension (average SBP 
readings above 140 mmHg or average DBP reading above 90 mmHg).  When factoring in 
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prehypertension (SBP reading ≥ 120 mmHg or DBP ≥ 80), percentages rose to roughly 
85 percent.  Negligible differences were found between the study medication groups.  See 
Table 3.16 for further details.             
 
Diabetes  
 Diabetic patients have a two to four fold increase in the risk of developing 
coronary artery disease, and seventy-five percent of diabetics die from some form of 
heart or blood vessel disease.15  Roughly 21.5 percent of the study population was found 
to have diabetes (based on ICD-9 codes and diabetes medications).  Celecoxib (24.8%) 
and rofecoxib (27.9%) observations were found to have higher percentages of diabetes as 
compared to ibuprofen (19.4%), etodolac (21.5%), and naproxen (21.6%).   
 
Overweight and Obesity         
 Obese individuals have been associated with an increase risk of developing 
cardiovascular disease and diabetes.16,17  Obesity has been linked to increased levels of 
dyslipidemia, higher blood pressures, and glucose intolerance.18  Obesity (defined as a 
BMI of 30 kg/m2 or higher) is a condition affecting roughly 20 percent of the US 
population and 22.7 percent of the Texas population.16  Close to 40 percent of the study 
population was found to be obese, nearly double the US average.  When factoring in 
overweight individuals, this number rises to nearly 80 percent.  The mean BMI for all 




Overall Comorbidity             
 A brief assessment was conducted evaluating the coexistence of the previous 
conditions (with the exception of smoking) in the study population.  This was done to 
provide an overall assessment of cardiovascular risk in this population.   
The following criteria were used to classify subjects: 
a) Hypertension – stage 1 or stage 2 hypertension (SBP > 140 mmHg or DBP > 90 
mmHg) or use of a hypertensive medication 
b) Hyperlipidemia – average total cholesterol reading above 240 mg/dl or use of a 
cholesterol medication. 
c) Diabetes – use of a diabetic medication or diabetes related ICD-9 code 
d) Obesity – BMI > 30 kg/m2  
 
Using these criteria, 77.5 percent of the study population was found to have at least 
one cardiovascular risk factor.  Forty-nine percent of the observations possessed two or 
more risk factors and three or more factors were found in 21.4 percent of the population.  
This is only a crude estimate; many of the observations did not have laboratory and 
patient vitals.  However, this only means that the numbers provided are an underestimate 
of the true risk in this population.  Additionally, this assessment does not include all 
cardiovascular risk factors (e.g., prior stroke, MI, etc…).  Of note: a covariate 
representing this information was added to the model (post-hoc), and no significant 





BIOLOGICAL PLAUSABILITY – continued 
 
Based on the cardiovascular comorbidity assessment, nearly 80 percent of the 
population may be at risk for thrombosis.  Therefore, if the theory holds that only 
individuals at risk for thrombosis are at risk from COX-2 inhibitors, then an 
overwhelming majority of individuals using COX-2 inhibitors in this population are at 
risk.   
COX-2 inhibitors differ with regards to their potency as an inhibitor of the COX-2 
enzyme.  Etoricoxib, rofecoxib, and valdecoxib have been consistently shown to be more 
COX-2 selective than celecoxib (etoricoxib > rofecoxib ≈ valdecoxib > celecoxib).  
There is conflicting information with regard to etodolac’s COX-2 selectivity.  Several 
studies show celecoxib to be more COX-2 selective than etodolac; however, others do 
not.19-25  The selectivity and potency of COX-2 inhibitors may differ in different tissues 
or even different types of cells from the same tissue.26  Furthermore, even though 
rofecoxib is a more selective COX-2 inhibitor than celecoxib, it is used in 
correspondingly lower doses.26  Information regarding whether or not therapeutic 
equivalence equates to similar reductions in PGI2 is unavailable.  As discussed in Chapter 
One, COX-2 selectivity is lost at higher doses for celecoxib.  Celecoxib demonstrated a 
dose-dependent inhibition of COX-1 up to 800 mg.27,28  In contrast, rofecoxib did not 
demonstrate a dose-response relationship with platelet COX-1 activity up to 1000 mg.  
The high dose of celecoxib (800 mg) in the CLASS study may have provided sufficient 
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inhibition of COX-1 to prevent a significant number of cardiovascular events.  On the 
other hand, the high dose of rofecoxib use in the VIGOR study may have contributed to 
the increased number of cardiovascular events.  This factor is important to this study 
dissertation because a majority of celecoxib use was under 300 mg (74.2%).  High dose 
rofecoxib (> 25 mg) comprised 12.6 percent of rofecoxib use.  Due to the low percentage 
of high-dose celecoxib and rofecoxib use found in the VA population and the small 
sample size, the relationship between cardiovascular risk and dose was not evaluated.  
However, this study provides an excellent opportunity to evaluate the cardiovascular risk 
associated with routine celecoxib and rofecoxib prescribing.   
 
Another postulated mechanism for the increased cardiovascular risk associated 
with COX-2 inhibitors, is their effect on blood pressure.  Short-term studies of COX-2 
inhibitors and NSAIDs show little to no effects on blood pressure in normotensive 
individuals.29  However, for individuals treated for hypertension, these medications have 
been associated with elevated levels of blood pressure.  Therefore, nearly 40 percent of 
this population is at risk for NSAID/COX-2 inhibitor-associated blood pressure 
elevations.  In a study comparing celecoxib to rofecoxib in hypertensive patients over a 
6-week period, elevated SBP readings (> 20 mmHg plus SBP ≥ 140 mmHg) were found 
among 14.9 percent of elderly patients given rofecoxib 25 mg/day as compared to 6.9 
percent of patients receiving celecoxib 200 mg/day.30  However, there is no evidence that 




One of the latest theories explaining the association between rofecoxib and 
cardiovascular risk is the effect of rofecoxib on human low density lipoprotein (LDL) 
oxidation.  LDL oxidation is an important contributor to atherosclerosis.31  This effect is 
believed to be related to the chemical structure and not related to COX-2 inhibition.  
Etoricoxib and rofecoxib exhibited prooxidant activity; whereas, celecoxib, valdecoxib 




 Atherosclerosis can be a slow process, and multiple cardiovascular-related 
processes can be occurring as a result of COX-2 inhibition.  COX-2 inhibition could be 
causing minute amounts of damage to the cardiovascular system over time.  With regards 
to celecoxib, this drug has been shown to be less selective for the COX-2 enzyme, exhibit 
lower changes in blood pressure as compared to rofecoxib, and is not associated with 
lipid peroxidation rates.  Therefore, compared to rofecoxib, celecoxib may take longer to 
show signs of cardiovascular toxicity and present a lower risk to patients.  This biological 
hypothesis may explain why a cardiovascular risk was not found with short-term use (≤ 
180 days) and overall use.  Additionally, this may explain why the cardiovascular risk 
with long-term use (> 180 days) was nearly double in the rofecoxib group as compared to 
the celecoxib group (aRR – 6.64 vs. aRR – 3.64, respectively).  Etodolac was not found 
to be associated with a cardiovascular risk in any analyses.  This can explained by a 
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decreased selectivity for COX-2 or variations in tissue penetration, pharmacokinetics and 
other factors.26  The next section will discuss naproxen’s “cardioprotective” abilities.  
Naproxen was the NSAID being evaluated in this study for possible 
cardioprotective effects.  Traditional NSAIDs have not been found to inhibit platelet Tx 
(aspirin-like properties) throughout their dosing intervals, thereby not providing 
cardioprotection.  However, some studies indicate that naproxen may provide sustained 
platelet Tx inhibition throughout normal dosing intervals (~ 8 hours).32  One of the 
original hypotheses explaining the increased risk associated with rofecoxib in the VIGOR 
trial was that the comparator, naproxen, was cardioprotective.  This explanation has since 
been discounted as the sole reason for the elevated cardiovascular risk found with 
rofecoxib.  Nevertheless, naproxen was evaluated in this dissertation study to determine if 
it possessed cardioprotective properties.  Results from this study revealed that for these 
VA patients, naproxen was not associated with a cardioprotective effect when compared 
to ibuprofen users.  Of note, one reason a cardioprotective effect may be found in clinical 
trials and not in observational studies is that persistent use of naproxen is more likely to 
occur in clinical trials.  The next two sections will discuss observational and clinical trials 








OBSERVATIONAL STUDIES – review  
 
Study 1- Ray et al. 
 
 The study conducted by Ray et al. did not find an associated risk of serious 
coronary heart disease with ibuprofen, naproxen, celecoxib, or low dose rofecoxib (≤ 25 
mg) when compared to non-NSAID users.33  However, the study did show an associated 
risk with high dose rofecoxib (> 25 mg) when compared to celecoxib and non-NSAID 
users.      
 
Study 2 – Mamdani et al. 
  
 The second retrospective cohort study evaluated elderly patients 66 years of age 
and older.34  In this analysis, no significant association between cardiovascular risk and 
NSAID/COX-2 inhibitor exposure was found when compared to control or other drug 
groups (exposure < 1 year).  Additionally, patients taking naproxen did not show a 
significant reduction in AMI events as compared to the control group.             
 
Study 3 – Solomon et al.  
 
 Similarly, this study evaluated elderly patients exposed to COX-2 inhibitors and 
NSAIDs.35  This study evaluated duration of exposure and associated cardiovascular risk.  
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The study evaluated overall, short-term (< 30 days), intermediate (30 – 90 days), and 
long-term use (> 90 days).  In the overall model and for the time dependent models, 
celecoxib was not associated with an increased risk of acute myocardial infarctions.  
Overall use of rofecoxib was associated with an elevated cardiovascular risk when 
compared to celecoxib or the control group.  No increased risk was found between 
rofecoxib and naproxen/ibuprofen.  When duration of exposure was evaluated, short-term 
and intermediate exposure to rofecoxib was found to have the highest risk when 
compared to celecoxib.  No significant risk was associated with long-term use of 
rofecoxib (> 90 days).  Lastly, as seen with study 1, high dose rofecoxib was associated 
with a higher adjusted relative risk than low dose rofecoxib.  Naproxen’s cardioprotective 
effects were not evaluated in this study.      
 
Study 4 –  Graham et al.         
  
 Graham and colleagues conducted a nested case-control study among 6 million 
California Kaiser Permanente members to evaluate the cardiovascular risk associated 
with NSAIDs and COX-2 inhibitors.36  Study findings revealed an increased risk 
associated with high-dose rofecoxib when compared to remote users (no use of NSAIDs 
> 60 days prior to index date).  Evaluation of low-dose rofecoxib did not reveal an 
increased cardiovascular risk when compared to “remote users.”  However, an increased 
risk was found with low-dose rofecoxib as compared to celecoxib.  Paradoxically, 




Study 5 – Layton et al. 
  
 Two articles reported results from a study that used prescription event monitoring 
data in England to assess the cardiovascular safety of celecoxib and rofecoxib as 
compared to meloxicam.37,38  The studies showed an increase rate of cerebrovascular 
events in rofecoxib and celecoxib users as compared to meloxicam users.  No significant 
difference was found in the rate of cardiovascular events in rofecoxib and celecoxib users 
as compared to meloxicam users.  A decrease in peripheral venous thrombotic events was 
found in rofecoxib users as compared to meloxicam users.  Regarding celecoxib use, no 
significant difference was found.   
 
Study 6 – Kimmel et al.     
  
 Kimmel et al. conducted a case-control study evaluating the cardiovascular safety 
of celecoxib and rofecoxib.39  Patients who experienced a myocardial event and control 
subjects were evaluated for exposure to study medications via telephone interviews.  The 
study had a 50 percent response rate.  When compared to non-NSAID subjects, the study 
found a cardioprotective effect with celecoxib and traditional NSAIDs.  Rofecoxib was 
not associated with an increased risk when compared to non-NSAID subjects.  However, 
when compared to naproxen, rofecoxib was associated with an increased risk.  Celecoxib 
vs. ibuprofen and diclofenac did not reveal a cardioprotective or cardionegative effect.               
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Observational Studies – Assessment   
 
 A wide range of results regarding rofecoxib’s and celecoxib’s cardiovascular 
safety have been reported.  One consistent theme across the studies is that celecoxib has 
not been found to increase cardiovascular risk.  One study even found a cardioprotective 
effect among celecoxib users.  However, this study had several limitations and when 
compared to NSAIDs, the protective effect was not found.  Another anomaly is the study 
that found an increased cerebrovascular risk associated with celecoxib (this same study 
failed to detect a difference in cardiovascular risk).   
In reference to the observational studies discussed, similar results were found in 
this dissertation study with regards to short-term and overall use of celecoxib.  Short-term 
use of celecoxib and overall use of celecoxib was not found to be associated with an 
increased (or decreased) risk of cardiovascular events.  Unlike other studies, this study 
segmented the population into two time periods to evaluate the cardiovascular risk after 
long-term exposure (> 180 days).  The long-term use of celecoxib was found to be 
associated with an increased cardiovascular risk as compared to long-term ibuprofen use.  
Only one study (study 3) evaluated the duration of use and associated risk.  That study 
failed to show any increased risk in any time period for celecoxib.  However, that study 
defined long-term use as receiving celecoxib for greater than 90 days as opposed to the 
180 days in the dissertation study.  For study 3, the number of patients exposed for 
greater than 180 days is unclear.  Furthermore, patients using celecoxib spanning 90 – 
180 days may not have incurred enough cardiovascular damage to translate into a 
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significant increase in risk.  The study used rofecoxib as a comparator group for analyses 
involving duration of therapy; therefore, if celecoxib starts to increase the risk after 
several months of exposure and rofecoxib does as well, then a difference may not be 
found.       
The cardiovascular signal for rofecoxib seems to be much stronger than for 
celecoxib, especially at high doses.  Due to the low percentage of high dose celecoxib (≥ 
300 mg) and rofecoxib (> 25 mg) users, this dissertation study was unable to examine a 
dose-response relationship.  Across the observational studies, results varied as to the 
associated risk with rofecoxib.  Some studies revealed no risk with low doses of 
rofecoxib, whereas others did.(REF)  All of the studies evaluating high-dose rofecoxib 
found a significant link between cardiovascular risk and rofecoxib.  For our study, when 
evaluating overall use and short-term use, no association between rofecoxib use and 
cardiovascular risk was found.  This result was not unexpected, especially since several 
of the studies failed to find a significant increase in risk with low-dose rofecoxib or 
overall use (low-dose and high-dose combined).  As discussed above, one study (study 3) 
evaluated the temporal relationship between exposure and risk.  The study revealed 
significantly higher rates of cardiovascular events among low-dose and high-dose 
rofecoxib use when compared to celecoxib.  When evaluated over time, the risk 
dissipated after 90 days, either implying that the risk associated with rofecoxib is short-
term or that long-term exposure to celecoxib is associated with an increased risk.  
Another important factor to keep in mind is that overall use (high-dose and low-dose use 
 
203
over the entire study period) of rofecoxib was not associated with an increased 




 There are several limitations when evaluating the cardiovascular safety in clinical 
trials.  While they are considered the gold standard for determining safety and efficacy, 
they usually involve a small number of patients and may not be powered to detect 
unexpected side effects (such as cardiovascular disease).  Additionally, in attempts to 
obtain “clean” results, many of these studies exclude individuals with various risk factors 
(i.e., cardiovascular risk factors). Therefore, many of the studies conducted evaluating 
COX-2 inhibitors may not be representative of the population actually receiving the drug.  
Furthermore, risk factors may differ between clinical trials and may make comparisons 
difficult.  One prime example is the different populations in the CLASS (celecoxib) and 
VIGOR (rofecoxib) studies.40-42  The VIGOR study was comprised primarily of 
rheumatoid arthritis patients, whereas the CLASS trial was comprised primarily of 
osteoarthritis patients.  Rheumatoid arthritis patients have been shown to be at higher risk 
for cardiovascular events than osteoarthritis patients.  As discussed in the biological 
plausibility section, persons at risk for cardiovascular disease may be susceptible to the 
negative effects of COX-2 inhibitors.  Additionally, the CLASS trial allowed high-risk 
patients to take aspirin, thereby possibly nullifying any COX-2 associated risk.  Another 
flaw limiting the generalizability of these clinical trials results from the use of super-
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therapeutic doses.  Both of these clinical trials used nearly double the standard dose in 
their studies.  Therefore, patients receiving 800 mg of celecoxib (a dose found to inhibit 
COX-1) may be at less risk for cardiovascular events than normal doses and patients 
receiving 50 mg of rofecoxib may be at an elevated risk (does not lose COX-2 selectivity 
at this dose).   
 An interesting finding about valdecoxib (a COX-2 inhibitor not evaluated in this 
study) was recently released.  Two randomized, placebo-controlled studies in patients 
immediately after coronary-artery bypass grafting showed valdecoxib to increase 
cardiovascular risk by three-fold.43  This adds to the hypothesis that individuals at risk are 
more susceptible to the negative cardiovascular effects of COX-2 inhibitors.  As a 
reminder, valdecoxib is believed to have a similar COX-2 selectivity as rofecoxib.   
 Two clinical trials providing the most credence for the results found in this 
dissertation study are the APPROVe trial (Adenomatous Polyp Prevention On Vioxx) 
and the Adenoma Prevention with Celecoxib (APC) trial.44,45  In both of these trials, a 
significant cardiovascular risk was found with rofecoxib and celecoxib as compared to a 
placebo group.  In the APPROVe trial, it took nearly 18 months before a significant 
increase in cardiovascular risk was found.  This was a population on low-dose rofecoxib 
with few cardiovascular risk factors.  All the details are not known at this time regarding 
patient characteristics (↑ or ↓ cardiovascular risk) in the APC trial.  However, it is known 
that after a two-year period, a 2.5-fold increased risk was found in long-term users of 
celecoxib.              





 With any observational study several limitations exist.  One of the principal 
limitations to almost any observational study is the inability to control for various factors 
not found in the database.  In this study, several important variables were not available.  
These include: proximity to a VA hospital, smoking status, over-the-counter use of 
aspirin and NSAIDs, family history of cardiovascular events, persistent use of study 
medication, and others.   
 
Events occurring outside the VA medical system 
 
With regards to hospital proximity, VA patients not living near a VA hospital may 
have limited ability to receive health care services from a VA facility in the event of a 
major cardiovascular event.  To control for this factor, Medicare data were obtained to 
capture events occurring outside the VA health care system.  A study was conducted 
evaluating point of care for acute myocardial infarctions among elderly veterans (≥ 65 
years).  This study found that more than half (54%) of veterans with prior use of the VA 
medical system were initially hospitalized in a Medicare hospital when they suffered an 
AMI.46  While the Medicare data will help capture events occurring outside the VA 
medical system in patients enrolled in Medicare, data for individuals not enrolled who 
experience an event may not be captured.  The sensitivity analysis restricting the 




Baseline assessment  
 
At baseline, individuals receiving celecoxib and rofecoxib were found to have 
higher percentages of baseline risk factors when compared to ibuprofen, etodolac, and 
naproxen.  However, this could be explained by the larger percentage of individuals over 
the age of 65 receiving celecoxib (63.3%) and rofecoxib (59.3%) as compared to 
ibuprofen (33.2%), etodolac (38.4%), and naproxen (36.9%).  Additionally, the adjusted 
model helps to control for these factors.   
 
Laboratory values and patient vitals 
 
In the original study design, laboratory values and patient vitals were to be used 
as covariates in the study model.  However, due to the limited availability of readings and 
small sample size, they were excluded from the model.  In an attempt to account for this 
shortfall, an assessment was conducted to evaluate if systematic differences occurred 
between the study groups.  Blood pressure, cholesterol levels, and body mass index 







VA Formulary  
 
 One of the primary limitations surrounding the use of prescription claims data 
obtained from the VA is the restricted formulary.  In particular, COX-2 inhibitors are 
limited to individuals with a high risk of developing NSAID-induced GI injury.  Many 
patients were required to receive prior treatment with traditional NSAIDs or preferential 
COX-2 inhibitors.  (Preferential COX-2 inhibitors are NSAIDs with relative COX-2 
selectivity.  Drugs included in this category are etodolac, nabumetone, and salsalate.47)  
The requirement could result in a selection bias.   
 
OTC use and other confounding factors  
 
Regarding prescription coverage, even though automated pharmacy claims are 
one of the best sources of information on drug use, information concerning compliance 
and use of drugs from outside sources may be lacking.48  Concurrent use of aspirin was 
available in this study; however, very few patients were found to have overlapping use.  
Therefore, many patients were probably taking over-the-counter aspirin.  However, this 
would only be a problem if use differed across the study groups.  Comparable 
percentages of baseline aspirin use were found between all five study groups (~30%).  
Furthermore, other studies evaluating this issue have not shown a difference in aspirin 
use between NSAIDs/COX-2 inhibitors. 35,36   Furthermore, these same studies did not 
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find any clinically significant differences between NSAIDs/COX-2 inhibitors for 
smoking history or family history of coronary heart disease.     
 
Comorbidity and medical use  
 
Several analyses evaluating the association between cardiovascular risk and 
COX-2 inhibitor use had covariates measuring number of medical visits, number of 
comorbid conditions, and different types of medication.  These variables were not 
available in this study.  Only select medications and ICD-9 codes were available for 
analysis, thereby limiting the ability to determine overall disease burden or determine the 
frequency of medical care.  It is unknown if these variables would significantly contribute 




Research conducted within the VA healthcare system found a 96.9 percent 
positive predictive value of acute myocardial infarction coding in the primary position.49  
Patients discharged alive were required to have a length of stay no less than three days 
and no greater than 180 days.  Code position or length of stay was not available in this 
study.  Due to this, the positive predictive value for an AMI diagnosis may be reduced.  A 
recent study in Medicare recipients evaluated the validity of acute myocardial infarction 
ICD-9 codes.  That study found a 92.3 percent positive predictive value for an AMI 
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coded in the primary or secondary position without a length of stay restriction.50  That 
study provides some flexibility with regards to field position and length of stay 
requirement.  However, it is unknown if other fields were used in that study.   
Diagnostic code validity for cerebrovascular disease has been previously 
discussed.   This algorithm does not have a length of stay or code position requirement.  
Information regarding the code validity for mortality data was not available for this 




Utilizing databases can raise concerns regarding the generalizability of the results 
to other populations.  One of the primary differences between this population and other 
populations is the disproportionate number of men compared to women.  Women 
comprised roughly 6% of the study population.  The disproportionate number of men to 
women may be advantageous because most (if not all) of the observationsal studies 
evaluating COX-2 inhibitor related cardiovascular risk consisted primarily of women 
(COX-2 inhibitor study groups ~ 70 - 80% women).33,35,36,39  Additionally, a large 
proportion of this population was estimated to be at risk for cardiovascular disease and 






Sample Size  
 
 It should be noted that this study comprised only 12,194 observation periods 
between the five study drugs.  Sample size and number of endpoint events by drug is 
provided: 1,530 celecoxib observations with 39 events; 2,373 etodolac observations with 
23 events; 4,483 ibuprofen observations with 38 events; 3,241 naproxen observations 
with 29 events; and 567 rofecoxib observations with 17 events.  This number was 
reduced further when the sample was split into long-term and short-term use.  Due to the 
small numbers, this study may not have had sufficient power to detect a difference in 
short-term drug use (or in overall drug use).  Even with the addition of the 2002 data, this 
study may still be under-powered.  Additionally, due to the small number of observations 
and events, the significant findings from the long-term exposure model should be 
interpreted cautiously.        
 
Censoring    
 
Two forms of censoring occurred in this study, Type I and random censoring.  
Type I censoring occurs when censoring is under the control of the investigator (i.e., 
study termination); whereas, random censoring is not under the control of the 
investigator.51  There are two types of random censoring, informative and 
noninformative.  The later of the two could possibly lead to severe biases in the study.  
Informative censoring occurs when an individual is censored due to the effects of 
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treatment or other nonrandom event.  Therefore, bias can occur if censored cases tend to 
be at high risk for a future event or when censored cases would have had longer times to 
an event.  The censored case should be representative of all those subjects with the same 
values of the explanatory variables who survive to that point in time.  It is plausible that 
informative censoring may occur in this study.  For example, patients who are taking 
NSAIDs/COX-2 inhibitors experiencing elevated blood pressure or edema may 
discontinue therapy prior to an event.  However, it is more likely that patients were 
censored due to: discontinuation of medication due to dissatisfaction with pain relief; self 
modification of treatment therapy (e.g., taking one tablet daily in place of two tablets 
daily); experiencing noncardiovascular related side-effects (e.g., stomach discomfort); or 
other factors.  Nevertheless, knowledge regarding the exact reason an observation was 
















After long-term exposure to celecoxib and rofecoxib, an increased risk of serious 
cardiovascular disease (defined as acute myocardial infarction, death from an acute 
myocardial infarction, or cerebrovascular event) was found.  Compared to ibuprofen. 
long-term exposure to celecoxib increased the risk for a serious cardiovascular event by 
3.64 fold and long-term exposure to rofecoxib increased risk by 6.64 fold.  This study 
failed to find an increased risk associated with short-term use of celecoxib and rofecoxib.  
Although etodolac has been found to possess some affinity for the COX-2 enzyme over 
the COX-1 enzyme, an elevated cardiovascular risk was not found with this drug.  
Similar to other studies, no cardioprotective effects were found with naproxen use.  
Therefore, the explanation that naproxen’s “cardioprotective” ability was the cause for 
the 5-fold increase in cardiovascular events in the VIGOR study is highly unlikely. 
NSAIDs and COX-2 inhibitors are some of the most widely prescribed 
medications in the world.  Due to this factor, the findings of this study have wide 
reaching implications.  Two prospective clinical trials now support the findings of this 
study.  However, additional studies are needed to examine this issue in celecoxib and 
other COX-2 inhibitors currently on the market, especially in a population at risk for 
cardiovascular disease.  Due to the findings of this study and the two prospective clinical 
trials, caution is advised in the use of long-term celecoxib.  Rofecoxib has been 
voluntarily removed from the market.   
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Estimated Change in Risk Factors and Correlates for Heart Disease and Stroke – 
United States 
   







Adults aged 20-74 years with 
hypertension *¥ 1960-1962 37% 1988-1994 23% 14% 
Hypertensive patients taking action to 
control their blood pressure (e.g., 
medications, diet, reductions in sodium, 
and exercise. 
1985 79% 1990 90% 11% 
Controlled hypertensive patients  1976-1980 11% 1988-1991 29% 18% 
Adults aged 20-74 years with high 
cholesterol levels ¥ € 1960-1962 32% 1988-1994 29% 3% 
Mean serum cholesterol levels of adults 
(mg/dl) ¥ 1960-1962 220 1988-1994 203 17 
Adults aged ≥ 18 who are current 
smokers ¥ 1965 42% 1995 25% 17% 
Persons who are overweight ¥£ 1960-1962 24% 1988-1994 35% 11% 
Percentage of calories in the diet from 
fat ** 1976-1980 36% 1988-1994 12% 24% 
Percentage of calories in the diet from 
saturated fat ** 1976-1980 13% 1988-1994 12% 1% 
Number of physicians indicating 
cardiovascular disease as their primary 
area of practice 
1975 5,046 1996 14,304 9,258 
*  Systolic pressure ≥ 140 mm hg, diastolic pressure ≥ 90 mm hg, or taking hypertensive medications.  
¥  Estimate is age-adjusted to the 1940 U.S. population. 
€  Serum cholesterol level ≥ 240 mg/dl. 
£  Defined as body mass index ≥ 27.8 kg/m2  among men and 27.2 kg/m2  among women 
** Based on 1-day dietary recall.   
 
Source:  Cardiovascular Health Br, Div of Adult and Community Health, National Center for Chronic Disease Prevention and Health 
Promotion, CDC.  Achievements in Public Health, 1900-1999: Decline in Deaths from Heart Disease and Stroke – United States, 














Prevalence of Smoking in Adults 18 and Older, by Gender 
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Prevalence of High Blood Pressure in Americans 
































































    
Source:  Wolz M, et al.  Statement from the National High Blood Pressure Education Program: Prevalence 






Nonsteriodal Anti-inflammatory Drugs / COX-2 Inhibitors 
 
Non-Selective (Traditional) NSAID 
           Generic                                                                       Brand                                          
Ibuprofen  Motrin, Advil, Nuprin, Rufen 
Naproxen  Naprosyn, Aleve, Anaprox, EC-Naprosyn, Naprelan 
Diclofenac  Voltaren, Voltaren XR, Cataflam, Arthrotec* 
Etodolac  Lodine, Lodine XL 
Flurbiprofen  Ansaid 
Indomethacin  Indocin, Indocin SR, Indocid, Indotec 
Ketoprofen  Orudis, Actron, Oruvail, Orafen 
Ketorolac  Toradol 
Meclofenamate   
Meloxicam  Mobic 
Nabumetone  Relafen 
Oxaprozin  Daypro 
Piroxicam  Feldene, Fexicam 
Sulindac  Clinoril 
Tolmetin  Tolectin 
Salicylic Acid Derivatives 
                      Generic                                                                    Brand 
Aspirin  Ecotrin, Empirin, Bayer 
Choline magnesium trisalicylate  Trilisate 
Diflunisal  Dolobid 
Salsalate  Salflex, Disalcid 
COX-2 Inhibitors 
                     Generic                                                                    Brand                                   
Celecoxib  Celebrex 
Rofecoxib  Vioxx 
Valdecoxib  Bextra 
Etoricoxib Arcoxia 











Summary of the Analysis of Confirmed Adjudicated Serious Thrombotic Cardiovascular Adverse 
Events, Occurring in the VIGOR Study† 
 
Event Category Treatment 
Group 











All thrombotic events rofecoxib 4047 45 2697 1.67   
 naproxen 4029 19 2698 0.70 0.42 (0.25, 0.72) 
All cardiac events rofecoxib 4047 28 2698 1.04   
 naproxen 4029 10 2698 0.37 0.36 (0.17, 0.74) 
All cerebrovascular events rofecoxib 4047 11 2699 0.41   
 naproxen 4029 8 2699 0.30 0.73 (0.29, 1.80) 
All peripheral vascular events rofecoxib 4047 6 2699 0.22   
 naproxen 4029 1 2699 0.04 0.17 (0.00, 1.37) 
†  In keeping with the data analysis section of the Adjudication standard operating procedures (SOP), this table does not 
include events determined by adjudication to be hemorrhagic cerebrovascular accidents.   
 Data source: Adapted - FDA Advisory Committee.  Cardiovascular Safety Review of Rofecoxib. 
‡  Per 100 patient-years at risk (PYR). 
§  Relative risk of naproxen with respect to rofecoxib from unstratified Cox model where the number of cases is at least 11, 






Analysis of Cardiovascular Events in the VIGOR Study Using Endpoint Definitions Standard in 
Large Antiplatelet Trialsξ 
 
















deaths%, MI, CVA 
Rofecoxib 4047 35 2698 1.30   
 Naproxen 4029 18 2700 0.67 0.51 (0.29,0.91) 
Cardiovascular 
deaths% 
Rofecoxib 4047 7 2700 0.26   
 Naproxen 4029 7 2699 0.26 1.00 (0.35, 2.85) 
MI Rofecoxib 4047 20 2699 0.74   
 Naproxen 4029 4 2699 0.15 0.20 (0.07,0.58) 
Stroke* Rofecoxib 4047 11 2699 0.41   
 Naproxen 4029 9 2699 0.33 0.82 (0.34,1.97) 
Aspirin Indicated 
Cardiovascular 
deaths%, MI, CVA 
Rofecoxib 170 12 105 11.42   
 Naproxen 151 3 102 2.94 0.26 (0.07, 0.91) 
Cardiovascular 
deaths% 
Rofecoxib 170 1 106 0.95   
 Naproxen 151 2 102 1.96 2.07 (0.11, 122.10) 
MI Rofecoxib 170 8 105 7.60   
 Naproxen 151 0 102 0.00 0.00 (0.00, 0.60) 
Stroke* Rofecoxib 170 3 106 2.84   
 Naproxen 151 2 102 1.96 0.69 (0.06, 6.02) 
Aspirin Not Indicated 
Cardiovascular 
deaths%, MI, CVA 
Rofecoxib 3877 23 2593 0.89   
 Naproxen 3878 15 2596 0.58 0.65 (0.34, 1.25) 
Cardiovascular 
deaths% 
Rofecoxib 3877 6 2594 0.23   
 Naproxen 3878 5 2597 0.19 0.83 (0.25, 2.73) 
MI Rofecoxib 3877 12 2593 0.46   
 Naproxen 3878 4 2597 0.15 0.33 (0.11, 1.03) 
Stroke* Rofecoxib 3877 8 2593 0.31   
 Naproxen 3878 7 2597 0.27 0.87 (0.32, 2.40) 
ξ Data source: Adapted - FDA Advisory Committee.  Cardiovascular Safety Review of Rofecoxib. 
†  Patient-years at risk. 
‡  Per 100 PYR. 
§  Relative risk of naproxen with respect to rofecoxib from unstratified Cox model where the number of cases is at least 11, 
otherwise relative risk is ratio of rates. 
%  Includes sudden death, unknown cause of death, fatal myocardial infarction, fatal stroke (hemorrhagic or ischemic), fatal 
subarachnoid hemorrhage, fatal primary intracranial hemorrhage, fatal gastrointestinal bleeding episode. 
¶  Includes fatal and nonfatal ischemic strokes, and fatal or nonfatal hemorrhagic strokes. 
§  Relative risk of naproxen with respect to rofecoxib from unstratified Cox model where the number of cases is at least 11, 
otherwise relative risk is ratio of rates. 
*  Includes fatal or nonfatal ischemic strokes, and fatal or nonfatal hemorrhagic strokes. 
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#  “Aspirin Indicated” patients are patients with past medical histories of cerebrovascular accident, transient 
ischemic attack, myocardial infarction, unstable angina, angina pectoris, coronary artery bypass graft surgery, or 








Serious Cardiovascular Thromboembolic Events among CLASS Study Patients* 
 








Total Event (Crude Rate, %) 52(1.3) 49(1.2) 28(1.4) 21(1.1) 
Cardiac Events (fatal/nonfatal)  
   MI 
   Myocardial Ischemia 
   Unstable Angina 
   Fatal Acute MI 
   Other Cardiac Death 





























Cerebrovascular Events (Fatal/Nonfatal) ‡  









Peripheral Vascular Events (Fatal/Nonfatal)** 
   Arterial 





















Total Event (Crude Rate, %) 25(0.8) 23(0.7) 16(1.0) 7(0.4) 
Cardiac Events (fatal/nonfatal)  
   MI 
   Unstable Angina 
   Fatal Acute MI 
   Other Cardiac Death 

























Cerebrovascular Events (Fatal/Nonfatal) ‡ 









Peripheral Vascular Events (Fatal/Nonfatal)** 
   Arterial 













*     Data is provided as No. (%).  Unpublished data –adapted from information provided by Pharmacia/Pfizer. (Events during the 6  
       month treatment period). 
†     p < 0.05 vs. celecoxib  
‡     All strokes were ischemic except for 1 event on diclofenac.  No cerebrovascular events were fatal. 

























 (95% CI) 
 Rofecoxib  Placebo  
Rheumatoid 
arthritis 1622 3/337 (0.89) 989 1/201 (0.50) 1.78 (0.14, 9.37) 
Osteoarthritis 3165 12/655 (1.83) 1215 3/232 (1.30) 1.53 (0.43, 5.44) 
Alzheimer’s / 
low back pain 1503 18/1197 (1.50) 1278 28/1246(2.25) 0.68 (0.37, 1.23) 
Total 6290 33/2189 (1.51) 3482 32/1678 (1.91) 0.84 (0.51, 1.38) 
 Rofecoxib  Non-Naproxen NSAIDs  
Rheumatoid 
arthritis 0 … 0 … … 
Osteoarthritis 4549 21/1934 (1.09) 2755 14/984 (1.42) 0.79 (0.40, 1.55) 
Alzheimer’s / 
low back pain 0 … 0 … … 
Total 4549 21/1934 (1.09) 2755 14/984 (1.42) 0.79 (0.40, 1.55) 
 Rofecoxib  Naproxen  
Rheumatoid 
arthritis 6057 46/3947 (1.17) 4859 20/3078 (0.65) 1.74 (1.02, 2.96) 
Osteoarthritis 3026 11/675 (1.63) 3011 7/665 (1.05) 1.55 (0.60, 4.00) 
Alzheimer’s / 
low back pain 0 … 0 … … 
Total 9083 57/4622 (1.23) 7870 27/3742 (0.72) 1.69 (1.07, 2.69) 
* Antiplatelet Trialists’ Collaboration (APTC) defined events consisting of the culmination of (1) CV, hemorrhagic, 
   and unknown death; (2) nonfatal MI; and (3) nonfatal stroke. 
£  Rate = APTC events per 100 patient-years at risk   
§  Data source:  Konstam M, et al.  Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib. 






















Baseline Medication Categories 
 
Antiarrhythmic Aspirin Beta Blockers Calcium Channel Blocker 
ADENOSINE  ASPIRIN  ACEBUTOLOL  AMLODIPINE  
AMIODARONE  ATENOLOL BEPRIDIL  
DISOPYRAMIDE   BETAXOLOL  DILTIAZEM    
FLECAINIDE    BISOPROLOL  FELODIPINE  
IBUTILIDE FUMARATE   CARVEDILOL   ISRADIPINE  
LIDOCAINE   ESMOLOL  MIBEFRADIL  
MEXILETINE  LABETALOL    NICARDIPINE  
MORICIZINE   METOPROLOL    NIFEDIPINE 
PROCAINAMIDE  NADOLOL  NISOLDIPINE  
PROPAFENONE HCL   PENBUTOLOL  VERAPAMIL   
QUINIDINE   PINDOLOL   
SOTALOL    PROPRANOLOL    







Diuretic Other Diabetes Drugs Digoxin Estrogen 
HYDROCHLOROTHIAZIDE ACARBOSE  DIGOXIN CHLOROTRIANISENE  
SPIRONOLACTONE CHLORPROPAMIDE   ESTRADIOL  
AMILORIDE GLIMEPIRIDE   ESTROGEN 
CHLORTHALIDONE GLIPIZIDE   ESTROPIPATE  
TRIAMTERENE GLYBURIDE    RALOXIFENE  
INDAPAMIDE INSULIN    CONTRACEPTIVES 
METHYCLOTHIAZIDE METFORMIN    
METOLAZONE MIGLITOL    
 NATEGLINIDE    
 PIOGLITAZONE    
 REPAGLINIDE    
 ROSIGLITAZONE    
 TOLAZAMIDE   
 TOLBUTAMIDE    









Hypertension Other Loop Diuretic Methotrexate Nitrate 
CLONIDINE FUROSEMIDE METHOTREXATE 
ISOSORBIDE 
DINITRATE 
HYDRALAZINE BUMETANIDE  
ISOSORBIDE 
MONONITRATE 
TERAZOSIN ETHACRYNIC ACID  NITROGLYCERIN 
ALFUZOSIN TORSEMIDE   
BOSENTAN    
DOXAZOSIN    
EPLERENONE    
GUANABENZ    
GUANADREL    
GUANETHIDINE    
GUANFACINE    
METHYLDOPA    
MINOXIDIL    
PROZOSIN    








PVD drugs Other Anticoagulant Warfarin ACE/ARB 
CILOSTAZOL DALTEPARIN WARFARIN CAPTOPRIL 
CYCLANDELATE ENOXAPARIN  FOSINOPRIL 
PENTOXIFYLLINE HEPARIN  LISINOPRIL 
   BENAZEPRIL 
   CANDESARTAN 
   ENALAPRIL 
   VALSARTAN 
   LOSARTAN 
   IRBESARTAN 
   MOEXIPRIL 
   OLMESARTAN 
   QUINAPRIL 
   RAMIPRIL 
   TELMISARTAN 










Antiplatelet AntiRheumatic Steroid Cholesterol 
ANAGRELIDE ADALIMUMAB METHYLPREDNISOLONE ATORVASTATIN 
DIPYRIDAMOLE / 
ASPIRIN (25 MG) ANAKINRA PREDNISONE CHOLESTYRAMINE 
CLOPIDOGREL AURANOFIN BETAMETHASONE CLOFIBRATE 
DIPYRIDAMOLE  AUROTHIOGLUCOSE BUDESONIDE COLESEVELAM 
TICLOPIDINE AZATHIOPRINE CORTISONE COLESTIPOL 
 
CYCLOSPORINE 
(ONLY NEORAL) DEXAMETHASONE EZETIMIBE 
 ETANERCEPT HYDROCORTISONE FENOFIBRATE 
 INFLIXIMAB TRIAMCINOLONE FLUVASTATIN 
 LEFLUNOMIDE  GEMFIBROZIL 
 PENICILLAMINE  LOVASTATIN 
 GOLD THIOMALATE  NIACIN 
   PRAVASTATIN 
   ROSUVASTATIN 
   SIMVASTATIN 

























Appendix T:   
 
 
Adjusted association between long-term naproxen use (including events       
occurring during the first 180 days) and serious cardiovascular events σ, ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 1.63 0.85 3.13 0.14 
Etodolac   (ibuprofen) 1.02 0.48 2.19 0.95 
Rofecoxib (ibuprofen) 2.00 0.86 4.68 0.11 
Naproxen  (ibuprofen) 1.11 0.56 2.18 0.77 
Covariates     
Diabetes 1.83 1.13 2.96 0.01 
Angina 1.33 0.75 2.34 0.33 
PVD 1.31 0.61 2.80 0.49 
Atrial Fibrillation  1.39 0.53 3.63 0.50 
Cancer 0.66 0.35 1.23 0.19 
COPD 1.70 0.92 3.13 0.09 
Heart failure  1.46 0.73 2.92 0.29 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.64 0.99 2.71 0.05 
Renal failure  0.19 0.02 1.81 0.15 
Respiratory failure 0 . . . 
Rheumatoid arthritis 1.17 0.34 4.08 0.80 
Prior AMI 9.56 4.25 21.52 < 0.01 
Prior Stroke (specificity model) 3.74 0.80 17.44 0.09 
Antiarrhythmic 0.81 0.24 2.75 0.74 
Aspirin 0.74 0.44 1.24 0.26 
B-blocker 1.14 0.67 1.93 0.64 
Ca-blocker 1.14 0.70 1.83 0.60 
Digoxin 1.16 0.59 2.30 0.67 
Other HTN Meds 0.80 0.48 1.35 0.41 
Loop diuretic 3.02 1.78 5.14 < 0.01 
Methotrexate 3.84 0.47 31.28 0.21 
Warfarin 0.48 0.20 1.16 0.10 
ACE/ARBS 0.91 0.55 1.49 0.70 
Antiplatelet 1.88 0.95 3.75 0.07 
Antirheumatic 0 . . . 
Steroid 0.57 0.19 1.71 0.31 
Cholesterol drug 0.86 0.53 1.40 0.55 
Diuretic other 0.81 0.43 1.52 0.51 
Other Anticoagulant 0 . . . 
Sex (male) 0.67 0.16 2.80 0.59 
Age 1.04 1.01 1.06 < 0.01 
Total population: 3,894; Ibuprofen – 1,098; Celecoxib – 622; Etodolac – 666; Rofecoxib – 208; Naproxen 
– 864.  Endpoint events – 83; censored –  3,375.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days (events may occur during the first 180 days). 
σ Defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular event 
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Appendix U:   
 
Adjusted association between short-term exposure to NSAIDS & COX-2        
inhibitors and serious cardiovascular eventsσ – all observations.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.77 0.43 1.39 0.39 
Etodolac   (ibuprofen) 0.74 0.41 1.32 0.31 
Rofecoxib (ibuprofen) 0.87 0.40 1.88 0.72 
Naproxen  (ibuprofen) 0.85 0.49 1.46 0.55 
Covariates     
Diabetes 1.27 0.83 1.94 0.28 
Angina 1.52 0.92 2.50 0.10 
PVD 1.95 1.11 3.42 0.02 
Atrial Fibrillation  0.92 0.41 2.06 0.84 
Cancer 0.98 0.60 1.60 0.94 
COPD 2.18 1.30 3.68 < 0.01 
Heart failure  1.03 0.54 1.96 0.94 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 2.52 1.65 3.87 < 0.01 
Renal failure  0.68 0.16 2.94 0.61 
Respiratory failure 1.34 0.36 5.03 0.66 
Rheumatoid arthritis 0.55 0.13 2.36 0.42 
Prior AMI 3.31 1.59 6.89 < 0.01 
Prior Stroke (specificity model) 5.14 1.94 13.64 < 0.01 
Antiarrhythmic 1.64 0.72 3.75 0.24 
Aspirin 1.19 0.76 1.84 0.44 
B-blocker 1.92 1.22 3.02 < 0.01 
Ca-blocker 0.99 0.65 1.52 0.98 
Digoxin 1.14 0.60 2.14 0.69 
Other HTN Meds 0.74 0.45 1.22 0.24 
Loop diuretic 1.04 0.62 1.75 0.88 
Methotrexate 9.86 2.79 34.80 < 0.01 
Warfarin 1.42 0.71 2.81 0.32 
ACE/ARBS 1.35 0.88 2.08 0.17 
Antiplatelet 1.37 0.73 2.56 0.32 
Antirheumatic 0 . . . 
Steroid 0.44 0.17 1.15 0.09 
Cholesterol drug 0.84 0.55 1.30 0.45 
Diuretic other 0.63 0.36 1.11 0.11 
Other Anticoagulant 0.51 0.07 3.81 0.51 
Sex (male) 0.82 0.26 2.64 0.75 
Age 1.03 1.01 1.06 < 0.01 
Total population: 12,194; Ibuprofen – 4,483; Naproxen – 3,241; Celecoxib – 1,530; Etodolac – 2,373; 
Rofecoxib – 567.  Endpoint events – 104; censored 12,090.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Short term exposure defined as ≤ 180 days; includes long-term use observations with exposure periods 
  limited to the first 180 days. 
σ Defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular event. 
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Appendix V:   
 
Adjusted association between exposure to NSAIDS & COX-2 inhibitors and serious 
cardiovascular events (defined as acute myocardial infarction, death from coronary 
heart disease, or cerebrovascular event) – Naproxen Comparison 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Ibuprofen (naproxen) 1.17 0.72 1.90 0.54 
Celecoxib (naproxen) 1.32 0.80 2.20 0.28 
Etodolac   (naproxen) 0.96 0.55 1.67 0.88 
Rofecoxib (naproxen) 1.85 0.99 3.45 0.05 
Covariates     
Diabetes 1.32 0.92 1.90 0.13 
Angina 1.16 0.76 1.78 0.48 
PVD 1.48 0.87 2.49 0.15 
Atrial Fibrillation  1.29 0.66 2.52 0.45 
Cancer 0.89 0.58 1.37 0.60 
COPD 1.98 1.26 3.09 < 0.01 
Heart failure  1.27 0.74 2.16 0.38 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.85 1.27 2.68 < 0.01 
Renal failure  0.56 0.15 2.05 0.38 
Respiratory failure 0.74 0.20 2.78 0.65 
Rheumatoid arthritis 0.84 0.29 2.37 0.74 
Prior AMI 3.98 2.10 7.55 < 0.01 
Prior Stroke (specificity model) 4.07 1.42 11.67 0.01 
Antiarrhythmic 1.40 0.67 2.94 0.37 
Aspirin 1.07 0.74 1.56 0.72 
B-blocker 1.51 1.03 2.22 0.03 
Ca-blocker 0.95 0.67 1.37 0.80 
Digoxin 1.03 0.60 1.75 0.92 
Other HTN Meds 0.69 0.45 1.04 0.08 
Loop diuretic 1.58 1.03 2.41 0.03 
Methotrexate 5.90 1.72 20.22 < 0.01 
Warfarin 0.98 0.54 1.79 0.96 
ACE/ARBS 1.21 0.84 1.73 0.31 
Antiplatelet 1.79 1.07 2.99 0.03 
Antirheumatic 0 . . . 
Steroid 0.47 0.21 1.06 0.07 
Cholesterol drug 0.91 0.63 1.31 0.62 
Diuretic other 0.74 0.47 1.18 0.20 
Other Anticoagulant 0.33 0.04 2.49 0.29 
Sex (male) 0.69 0.25 1.89 0.47 
Age 1.04 1.02 1.05 < 0.01 
Total population: 12,188; Ibuprofen – 4,481; Naproxen – 3,240; Celecoxib – 1,530; Etodolac – 2,371; 
Rofecoxib – 566.  Endpoint events – 146; censored 12,042.   




Appendix W:   
 
Adjusted association between long-term exposure to NSAIDS & COX-2                    
inhibitors and serious cardiovascular events (defined as acute myocardial infarction, 
death from coronary heart disease, or cerebrovascular event) – Naproxen 
Comparison ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Ibuprofen (naproxen) 0.87 0.27 2.84 0.81 
Celecoxib (naproxen) 3.16 1.16 8.57 0.02 
Etodolac   (naproxen) 1.09 0.29 4.05 0.90 
Rofecoxib (naproxen) 5.76 1.82 18.21 < 0.01 
Covariates     
Diabetes 1.38 0.67 2.83 0.39 
Angina 0.58 0.23 1.45 0.25 
PVD 0.24 0.03 1.97 0.18 
Atrial Fibrillation  3.27 0.93 11.45 0.06 
Cancer 0.50 0.19 1.28 0.15 
COPD 1.85 0.73 4.72 0.20 
Heart failure  3.11 1.12 8.65 0.03 
HIV 0 . . . 
Lupus* 0.00 . . . 
Osteoarthritis 0.93 0.41 2.12 0.86 
Renal failure  0.34 0.03 3.50 0.36 
Respiratory failure 0 . . . 
Rheumatoid arthritis 1.98 0.43 9.13 0.38 
Prior AMI 9.65 2.39 38.95 < 0.01 
Prior Stroke (specificity model) 0.00 . . . 
Antiarrhythmic 0.43 0.06 3.24 0.41 
Aspirin 0.71 0.32 1.54 0.38 
B-blocker 0.79 0.34 1.87 0.60 
Ca-blocker 0.73 0.36 1.50 0.39 
Digoxin 0.91 0.31 2.68 0.87 
Other HTN Meds 0.47 0.20 1.10 0.08 
Loop diuretic 4.13 1.95 8.76 < 0.01 
Methotrexate 0 . . . 
Warfarin 0.21 0.05 0.87 0.03 
ACE/ARBS 0.96 0.47 1.98 0.91 
Antiplatelet 2.78 1.08 7.15 0.03 
Antirheumatic 0 . . . 
Steroid 0.76 0.17 3.43 0.72 
Cholesterol drug 1.12 0.57 2.21 0.74 
Diuretic other 1.22 0.54 2.77 0.63 
Other Anticoagulant 0.00 . . . 
Sex (male) 0.54 0.07 4.06 0.55 
Age 1.03 1.00 1.06 0.09 
Total population: 3,317; Ibuprofen – 1,085; Naproxen – 849; Celecoxib – 611; Etodolac – 656; Rofecoxib – 206.  Endpoint events – 
42; censored 3,275.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
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Appendix X:   
 
Adjusted association between short-term exposure to NSAIDS & COX-2                    
inhibitors and serious cardiovascular events (defined as acute myocardial infarction, 
death from coronary heart disease, or cerebrovascular event) – Naproxen 
Comparison.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Ibuprofen (naproxen) 1.66 0.79 3.47 0.18 
Celecoxib (naproxen) 1.12 0.46 2.67 0.81 
Etodolac   (naproxen) 1.05 0.45 2.47 0.91 
Rofecoxib (naproxen) 2.33 0.90 6.04 0.08 
Covariates     
Diabetes 1.38 0.67 2.83 0.39 
Angina 0.58 0.23 1.45 0.25 
PVD 0.24 0.03 1.97 0.18 
Atrial Fibrillation  3.27 0.93 11.45 0.06 
Cancer 0.50 0.19 1.28 0.15 
COPD 1.85 0.73 4.72 0.20 
Heart failure  3.11 1.12 8.65 0.03 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 0.93 0.41 2.12 0.86 
Renal failure  0.34 0.03 3.50 0.36 
Respiratory failure 0 0.00 . 0.99 
Rheumatoid arthritis 1.98 0.43 9.13 0.38 
Prior AMI 9.65 2.39 38.95 < 0.01 
Prior Stroke (specificity model) 0 . . . 
Antiarrhythmic 0.43 0.06 3.24 0.41 
Aspirin 0.71 0.32 1.54 0.38 
B-blocker 0.79 0.34 1.87 0.60 
Ca-blocker 0.73 0.36 1.50 0.39 
Digoxin 0.91 0.31 2.68 0.87 
Other HTN Meds 0.47 0.20 1.10 0.08 
Loop diuretic 4.13 1.95 8.76 < 0.01 
Methotrexate 0 . . . 
Warfarin 0.21 0.05 0.87 0.03 
ACE/ARBS 0.96 0.47 1.98 0.91 
Antiplatelet 2.78 1.08 7.15 0.03 
Antirheumatic 0.00 . . . 
Steroid 0.76 0.17 3.43 0.72 
Cholesterol drug 1.12 0.57 2.21 0.74 
Diuretic other 1.22 0.54 2.77 0.63 
Other Anticoagulant 0 . . . 
Sex (male) 0.54 0.07 4.06 0.55 
Age 1.03 1.00 1.06 0.09 
Total population: 8,730; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 908; Etodolac – 1,705; Rofecoxib – 358.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 




Appendix Y:   
 
Adjusted association between exposure to NSAIDS & COX-2 inhibitors and serious 
cardiovascular events (defined as acute myocardial infarction, death from coronary 
heart disease, or cerebrovascular event) – Etodolac Comparison. 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Ibuprofen (etodolac) 1.22 0.72 2.07 0.47 
Celecoxib (etodolac) 1.38 0.81 2.35 0.24 
Etodolac   (etodolac) 1.93 1.02 3.67 0.04 
Rofecoxib (etodolac) 1.04 0.60 1.82 0.88 
Covariates     
Diabetes 1.32 0.92 1.90 0.13 
Angina 1.16 0.76 1.78 0.48 
PVD 1.48 0.87 2.49 0.15 
Atrial Fibrillation  1.29 0.66 2.52 0.45 
Cancer 0.89 0.58 1.37 0.60 
COPD 1.98 1.26 3.09 < 0.01 
Heart failure  1.27 0.74 2.16 0.38 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.85 1.27 2.68 < 0.01 
Renal failure  0.56 0.15 2.05 0.38 
Respiratory failure 0.74 0.20 2.78 0.65 
Rheumatoid arthritis 0.84 0.29 2.37 0.74 
Prior AMI 3.98 2.10 7.55 < 0.01 
Prior Stroke (specificity model) 4.07 1.42 11.67 0.01 
Antiarrhythmic 1.40 0.67 2.94 0.37 
Aspirin 1.07 0.74 1.56 0.72 
B-blocker 1.51 1.03 2.22 0.03 
Ca-blocker 0.95 0.67 1.37 0.80 
Digoxin 1.03 0.60 1.75 0.92 
Other HTN Meds 0.69 0.45 1.04 0.08 
Loop diuretic 1.58 1.03 2.41 0.03 
Methotrexate 5.90 1.72 20.22 < 0.01 
Warfarin 0.98 0.54 1.79 0.96 
ACE/ARBS 1.21 0.84 1.73 0.31 
Antiplatelet 1.79 1.07 2.99 0.03 
Antirheumatic 0 . . . 
Steroid 0.47 0.21 1.06 0.07 
Cholesterol drug 0.91 0.63 1.31 0.62 
Diuretic other 0.74 0.47 1.18 0.20 
Other Anticoagulant 0.33 0.04 2.49 0.29 
Sex (male) 0.69 0.25 1.89 0.47 
Age 1.04 1.02 1.05 < 0.01 
Total population: 12,188; Ibuprofen – 4,481; Naproxen – 3,240; Celecoxib – 1,530; Etodolac – 2,371; 
Rofecoxib – 566.  Endpoint events – 146; censored 12,042. 




Appendix Z:   
 
Adjusted association between long-term exposure to NSAIDS & COX-2                    
inhibitors and serious cardiovascular events (defined as acute myocardial infarction, 
death from coronary heart disease, or cerebrovascular event) – Etodolac 
Comparison.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Ibuprofen (etodolac) 0.80 0.22 2.89 0.73 
Celecoxib (etodolac) 2.89 0.95 8.80 0.06 
Etodolac   (etodolac) 5.28 1.51 18.44 0.01 
Rofecoxib (etodolac) 0.92 0.25 3.40 0.90 
Covariates     
Diabetes 1.38 0.67 2.83 0.39 
Angina 0.58 0.23 1.45 0.25 
PVD 0.24 0.03 1.97 0.18 
Atrial Fibrillation  3.27 0.93 11.45 0.06 
Cancer 0.50 0.19 1.28 0.15 
COPD 1.85 0.73 4.72 0.20 
Heart failure  3.11 1.12 8.65 0.03 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 0.93 0.41 2.12 0.86 
Renal failure  0.34 0.03 3.50 0.36 
Respiratory failure 0.00 0.00 . 0.99 
Rheumatoid arthritis 9.65 2.39 38.95 < 0.01 
Prior AMI 1.98 0.43 9.13 0.38 
Prior Stroke (specificity model) 0 . . . 
Antiarrhythmic 0.43 0.06 3.24 0.41 
Aspirin 0.71 0.32 1.54 0.38 
B-blocker 0.79 0.34 1.87 0.60 
Ca-blocker 0.73 0.36 1.50 0.39 
Digoxin 0.91 0.31 2.68 0.87 
Other HTN Meds 0.47 0.20 1.10 0.08 
Loop diuretic 4.13 1.95 8.76 < 0.01 
Methotrexate 0 . . . 
Warfarin 0.21 0.05 0.87 0.03 
ACE/ARBS 0.96 0.47 1.98 0.91 
Antiplatelet 2.78 1.08 7.15 0.03 
Antirheumatic 0 . . . 
Steroid 0.76 0.17 3.43 0.72 
Cholesterol drug 1.12 0.57 2.21 0.74 
Diuretic other 1.22 0.54 2.77 0.63 
Other Anticoagulant 0 . . . 
Sex (male) 0.54 0.07 4.06 0.55 
Age 1.03 1.00 1.06 0.09 
Total population: 3,317; Ibuprofen – 1,085; Naproxen – 849; Celecoxib – 611; Etodolac – 656; Rofecoxib – 206.  .  Endpoint events – 
42; censored 3,275.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
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Appendix AA:   
 
Adjusted association between short-term exposure to NSAIDS & COX-2                    
inhibitors and serious cardiovascular events (defined as acute myocardial infarction, 
death from coronary heart disease, or cerebrovascular event) – Etodolac 
Comparison.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Ibuprofen (etodolac) 1.58 0.74 3.34 0.23 
Celecoxib (etodolac) 1.06 0.45 2.49 0.90 
Etodolac   (etodolac) 2.21 0.86 5.71 0.10 
Rofecoxib (etodolac) 0.95 0.40 2.23 0.91 
Covariates     
Diabetes 0.89 0.50 1.58 0.68 
Angina 1.08 0.56 2.09 0.82 
PVD 1.82 0.86 3.85 0.12 
Atrial Fibrillation  1.40 0.54 3.63 0.49 
Cancer 1.22 0.67 2.25 0.51 
COPD 2.43 1.24 4.75 0.01 
Heart failure  1.44 0.64 3.22 0.37 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 2.35 1.33 4.14 < 0.01 
Renal failure  1.33 0.24 7.20 0.74 
Respiratory failure 1.67 0.37 7.66 0.51 
Rheumatoid arthritis 1.99 0.65 6.06 0.23 
Prior AMI 0.37 0.04 3.11 0.36 
Prior Stroke (specificity model) 4.35 0.93 20.45 0.06 
Antiarrhythmic 1.93 0.70 5.33 0.20 
Aspirin 1.59 0.90 2.83 0.11 
B-blocker 1.92 1.06 3.45 0.03 
Ca-blocker 0.76 0.43 1.35 0.35 
Digoxin 0.80 0.33 1.96 0.63 
Other HTN Meds 0.51 0.24 1.05 0.07 
Loop diuretic 0.66 0.32 1.34 0.25 
Methotrexate 10.38 2.10 51.26 < 0.01 
Warfarin 1.74 0.73 4.14 0.21 
ACE/ARBS 1.89 1.08 3.32 0.03 
Antiplatelet 1.46 0.63 3.39 0.37 
Antirheumatic 0 . . . 
Steroid 0.38 0.11 1.34 0.13 
Cholesterol drug 0.93 0.53 1.64 0.81 
Diuretic other 0.70 0.35 1.41 0.32 
Other Anticoagulant 0.99 0.13 7.70 0.99 
Sex (male) 0.83 0.20 3.46 0.79 
Age 1.03 1.01 1.06 0.01 
Total population: 8,730; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 908; Etodolac – 1,705; Rofecoxib – 358.  Endpoint events 
– 63; censored 8,667.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Short term exposure defined as ≤ 180 days. 
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Appendix BB:   
 
Adjusted association between exposure to NSAIDS & COX-2 inhibitors and serious 
coronary events (defined as acute myocardial infarction or death from coronary 
heart disease) – Ibuprofen Comparison. 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.90 0.50 1.60 0.71 
Etodolac   (ibuprofen) 0.76 0.41 1.41 0.39 
Rofecoxib (ibuprofen) 1.02 0.46 2.26 0.96 
Naproxen  (ibuprofen) 1.01 0.60 1.71 0.98 
Covariates     
Diabetes 1.42 0.92 2.17 0.11 
Angina 2.01 1.22 3.31 0.01 
PVD 1.42 0.76 2.67 0.27 
Atrial Fibrillation  0.81 0.33 1.98 0.65 
Cancer 0.83 0.49 1.39 0.48 
COPD 1.80 1.05 3.11 0.03 
Heart failure  1.03 0.53 1.99 0.94 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.69 1.07 2.66 0.02 
Renal failure  0.95 0.23 3.88 0.94 
Respiratory failure 1.21 0.29 5.10 0.80 
Rheumatoid arthritis 0.94 0.28 3.15 0.92 
Prior AMI 5.93 3.03 11.62 < 0.01 
Prior Stroke (specificity model) 1.16 0.16 8.58 0.88 
Antiarrhythmic 1.32 0.53 3.28 0.55 
Aspirin 0.95 0.61 1.47 0.80 
B-blocker 1.43 0.91 2.26 0.12 
Ca-blocker 1.00 0.66 1.52 1.00 
Digoxin 1.37 0.74 2.51 0.31 
Other HTN Meds 0.56 0.33 0.95 0.03 
Loop diuretic 1.21 0.72 2.03 0.46 
Methotrexate 5.49 1.23 24.63 0.03 
Warfarin 0.82 0.38 1.78 0.61 
ACE/ARBS 1.15 0.75 1.77 0.52 
Antiplatelet 1.93 1.07 3.51 0.03 
Antirheumatic 0 . . . 
Steroid 0.55 0.23 1.34 0.19 
Cholesterol drug 0.78 0.51 1.21 0.27 
Diuretic other 0.70 0.40 1.23 0.22 
Other Anticoagulant 0.62 0.08 4.68 0.64 
Sex (male) 0.46 0.11 1.88 0.28 
Age 1.04 1.02 1.06 < 0.01 
Total population: 12,189; Ibuprofen – 4,482; Naproxen – 3,240; Celecoxib – 1,530; Etodolac – 2,371; 
Rofecoxib – 566.  Endpoint events – 106; censored 12,083. 




Appendix CC:   
 
Adjusted association between long-term exposure to NSAIDS & COX-2         
inhibitors and serious coronary events (defined as acute myocardial infarction or 
death from coronary heart disease) – Ibuprofen comparison.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 3.59 1.03 12.56 0.05 
Etodolac   (ibuprofen) 1.13 0.20 6.49 0.89 
Rofecoxib (ibuprofen) 7.07 1.57 31.95 0.01 
Naproxen  (ibuprofen) 1.86 0.48 7.27 0.37 
Covariates     
Diabetes 0.87 0.32 2.37 0.79 
Angina 1.10 0.37 3.25 0.86 
PVD 0 0 . 0.99 
Atrial Fibrillation  2.27 0.39 13.09 0.36 
Cancer 0.48 0.13 1.79 0.28 
COPD 2.73 0.81 9.22 0.11 
Heart failure  2.35 0.59 9.39 0.23 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 0.48 0.13 1.83 0.28 
Renal failure  1.26 0.08 18.80 0.87 
Respiratory failure 0.00 0.00 . 1.00 
Rheumatoid arthritis 1.73 0.20 15.04 0.62 
Prior AMI 18.05 3.50 93.05 < 0.01 
Prior Stroke (specificity model) 0 . . . 
Antiarrhythmic 0.29 0.02 3.98 0.36 
Aspirin 0.62 0.22 1.72 0.36 
B-blocker 0.55 0.18 1.73 0.31 
Ca-blocker 1.01 0.42 2.46 0.98 
Digoxin 1.43 0.36 5.72 0.61 
Other HTN Meds 0.43 0.14 1.38 0.16 
Loop diuretic 3.54 1.33 9.45 0.01 
Methotrexate 0 . . . 
Warfarin 0.28 0.05 1.49 0.14 
ACE/ARBS 0.78 0.30 2.02 0.61 
Antiplatelet 3.73 1.13 12.33 0.03 
Antirheumatic 0 . . . 
Steroid 0.38 0.04 3.39 0.38 
Cholesterol drug 1.15 0.48 2.73 0.76 
Diuretic other 1.34 0.47 3.81 0.58 
Other Anticoagulant 0 . . . 
Sex (male) 0 . . . 
Age 1.01 0.97 1.05 0.74 
Total population: 3,241; Ibuprofen – 1,088; Naproxen – 850; Celecoxib – 615; Etodolac – 657; Rofecoxib 
– 206.  Endpoint events – 27; censored 3,214.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
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Appendix DD:   
 
Adjusted association between short-term exposure to NSAIDS & COX-2        
inhibitors and serious coronary events (defined as acute myocardial infarction or 
death from coronary heart disease) – Ibuprofen comparison.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.58 0.23 1.48 0.26 
Etodolac   (ibuprofen) 0.51 0.21 1.27 0.15 
Rofecoxib (ibuprofen) 0.89 0.28 2.81 0.84 
Naproxen  (ibuprofen) 0.68 0.31 1.50 0.34 
Covariates     
Diabetes 1.05 0.55 2.03 0.87 
Angina 1.57 0.73 3.40 0.25 
PVD 2.09 0.89 4.91 0.09 
Atrial Fibrillation  0.70 0.19 2.60 0.59 
Cancer 0.98 0.46 2.09 0.96 
COPD 1.63 0.70 3.81 0.26 
Heart failure  1.24 0.46 3.37 0.67 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 2.85 1.47 5.54 < 0.01 
Renal failure  1.96 0.32 11.89 0.47 
Respiratory failure 3.48 0.66 18.24 0.14 
Rheumatoid arthritis 0.74 0.09 6.48 0.79 
Prior AMI 2.79 0.89 8.77 0.08 
Prior Stroke (specificity model) 3.49 0.43 28.66 0.24 
Antiarrhythmic 1.83 0.51 6.56 0.35 
Aspirin 1.35 0.68 2.68 0.39 
B-blocker 2.29 1.15 4.55 0.02 
Ca-blocker 0.95 0.49 1.82 0.87 
Digoxin 1.20 0.43 3.30 0.73 
Other HTN Meds 0.30 0.10 0.84 0.02 
Loop diuretic 0.50 0.21 1.19 0.12 
Methotrexate 4.77 0.51 45.10 0.17 
Warfarin 1.28 0.44 3.76 0.65 
ACE/ARBS 2.18 1.13 4.21 0.02 
Antiplatelet 1.48 0.58 3.78 0.42 
Antirheumatic 0 . . . 
Steroid 0.65 0.18 2.31 0.51 
Cholesterol drug 0.77 0.39 1.50 0.44 
Diuretic other 0.56 0.23 1.34 0.19 
Other Anticoagulant 1.78 0.23 13.73 0.58 
Sex (male) 0.57 0.08 4.26 0.59 
Age 1.03 1.00 1.06 0.04 
Total population: 8,730; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 908; Etodolac – 1,705; 
Rofecoxib – 358.  Endpoint events – 46; censored 8,684.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Short term exposure defined as ≤ 180 days. 
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Appendix EE:   
 
Adjusted association between exposure to NSAIDS & COX-2 inhibitors and serious 
cardiovascular events (defined as acute myocardial infarction, death from coronary 
heart disease, or cerebrovascular event) - high sensitivity stroke model.§ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.90 0.60 1.33 0.59 
Etodolac   (ibuprofen) 0.68 0.44 1.05 0.08 
Rofecoxib (ibuprofen) 1.03 0.60 1.76 0.92 
Naproxen  (ibuprofen) 0.85 0.58 1.26 0.42 
Covariates     
Diabetes 1.18 0.87 1.61 0.28 
Angina 1.24 0.88 1.74 0.22 
PVD 1.30 0.83 2.03 0.25 
Atrial Fibrillation  1.48 0.88 2.51 0.14 
Cancer 0.98 0.70 1.39 0.93 
COPD 1.65 1.12 2.43 0.01 
Heart failure  1.13 0.72 1.78 0.59 
HIV 0 . . . 
Lupus* 1.05 0.14 7.67 0.96 
Osteoarthritis 1.52 1.10 2.08 0.01 
Renal failure  0.52 0.19 1.41 0.20 
Respiratory failure 1.41 0.60 3.32 0.43 
Rheumatoid arthritis 1.42 0.68 2.95 0.35 
Prior AMI 3.38 1.90 6.00 < 0.01 
Prior Stroke (sensitivity model) 6.33 4.13 9.71 < 0.01 
Antiarrhythmic 1.01 0.50 2.03 0.98 
Aspirin 1.25 0.92 1.69 0.16 
B-blocker 1.15 0.83 1.60 0.40 
Ca-blocker 0.96 0.71 1.30 0.79 
Digoxin 1.21 0.78 1.86 0.40 
Other HTN Meds 0.71 0.50 1.00 0.05 
Loop diuretic 1.24 0.86 1.80 0.25 
Methotrexate 1.98 0.52 7.52 0.32 
Warfarin 1.10 0.68 1.79 0.69 
ACE/ARBS 1.20 0.89 1.62 0.23 
Antiplatelet 2.21 1.48 3.28 < 0.01 
Antirheumatic 3.79 0.75 19.14 0.11 
Steroid 0.57 0.30 1.09 0.09 
Cholesterol drug 0.75 0.55 1.02 0.07 
Diuretic other 0.77 0.52 1.13 0.18 
Other Anticoagulant 0.26 0.04 1.87 0.18 
Sex (male) 0.70 0.29 1.73 0.44 
Age 1.05 1.03 1.06 < 0.01 
Total population: 12,182; Ibuprofen – 4,481; Naproxen – 3,239; Celecoxib – 1,528; Etodolac – 2,369; 
Rofecoxib – 565.  Endpoint events – 212; censored 11,970. 
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
§ Note: uses stroke sensitivity model for prior stroke covariate 
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Appendix FF:       
 
Adjusted association between long-term exposure to NSAIDS & COX-2 inhibitors and 
serious cardiovascular events (defined as acute myocardial infarction, death from 
coronary heart disease, or cerebrovascular event) - high sensitivity stroke model.ξ, § 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 1.53 0.71 3.31 0.28 
Etodolac   (ibuprofen) 0.75 0.26 2.16 0.59 
Rofecoxib (ibuprofen) 2.16 0.81 5.77 0.12 
Naproxen  (ibuprofen) 0.76 0.32 1.83 0.54 
Covariates     
Diabetes 0.95 0.48 1.87 0.88 
Angina 0.84 0.40 1.76 0.64 
PVD 1.21 0.42 3.50 0.73 
Atrial Fibrillation  2.85 0.98 8.24 0.05 
Cancer 1.07 0.53 2.18 0.85 
COPD 1.52 0.63 3.65 0.35 
Heart failure  1.11 0.42 2.92 0.83 
HIV 0 . . . 
Lupus* 1.96 0.21 18.23 0.56 
Osteoarthritis 0.79 0.37 1.68 0.54 
Renal failure  0.54 0.05 5.39 0.60 
Respiratory failure 0 . . . 
Rheumatoid arthritis 1.47 0.40 5.45 0.56 
Prior AMI 5.04 1.36 18.69 0.02 
Prior Stroke (sensitivity model) 3.42 1.01 11.62 0.05 
Antiarrhythmic 1.06 0.24 4.66 0.94 
Aspirin 1.08 0.57 2.04 0.82 
B-blocker 0.62 0.29 1.34 0.23 
Ca-blocker 0.78 0.42 1.45 0.43 
Digoxin 1.83 0.80 4.19 0.15 
Other HTN Meds 0.50 0.24 1.04 0.06 
Loop diuretic 2.33 1.15 4.72 0.02 
Methotrexate 0 . . . 
Warfarin 0.31 0.09 1.00 0.05 
ACE/ARBS 1.11 0.58 2.13 0.74 
Antiplatelet 3.10 1.41 6.82 < 0.01 
Antirheumatic 0.00 . . . 
Steroid 1.45 0.52 4.03 0.47 
Cholesterol drug 0.80 0.43 1.48 0.47 
Diuretic other 1.05 0.50 2.18 0.91 
Other Anticoagulant 0 . . . 
Sex (male) 0.48 0.07 3.61 0.48 
Age 1.05 1.02 1.08 < 0.01 
Total population: 3,295; Ibuprofen – 1,080; Naproxen – 846; Celecoxib – 604; Etodolac – 652; Rofecoxib 
– 202.  Endpoint events – 55; censored 3,240.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
§ Note: uses stroke sensitivity model for prior stroke covariate 
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Appendix GG:   
 
Adjusted association between short-term exposure to NSAIDS & COX-2        inhibitors 
and serious cardiovascular events (defined as acute myocardial infarction, death from 
coronary heart disease, or cerebrovascular event) - high sensitivity stroke model.ξ, § 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.63 0.33 1.19 0.15 
Etodolac   (ibuprofen) 0.54 0.28 1.02 0.06 
Rofecoxib (ibuprofen) 0.81 0.34 1.91 0.63 
Naproxen  (ibuprofen) 0.77 0.44 1.36 0.37 
Covariates     
Diabetes 1.27 0.80 2.02 0.30 
Angina 1.20 0.69 2.08 0.51 
PVD 1.43 0.74 2.76 0.29 
Atrial Fibrillation  1.95 0.91 4.17 0.09 
Cancer 1.14 0.68 1.92 0.61 
COPD 1.63 0.89 3.00 0.11 
Heart failure  1.39 0.69 2.79 0.36 
HIV 0 .  . 
Lupus* 0 . . . 
Osteoarthritis 1.87 1.15 3.05 0.01 
Renal failure  0.88 0.22 3.52 0.86 
Respiratory failure 1.95 0.61 6.19 0.26 
Rheumatoid arthritis 0.24 0.03 1.96 0.18 
Prior AMI 1.76 0.60 5.16 0.30 
Prior Stroke (sensitivity model) 4.86 2.32 10.18 < 0.01 
Antiarrhythmic 1.18 0.43 3.23 0.75 
Aspirin 1.41 0.88 2.26 0.15 
B-blocker 1.27 0.76 2.12 0.36 
Ca-blocker 0.95 0.60 1.51 0.83 
digoxin 0.86 0.41 1.82 0.69 
other HTN Meds 0.71 0.40 1.24 0.22 
loop diuretic 0.61 0.33 1.13 0.12 
methotrexate 7.53 1.59 35.77 0.01 
warfarin 1.63 0.79 3.37 0.19 
ACE/ARBS 1.90 1.20 3.00 0.01 
Antiplatelet 1.61 0.83 3.13 0.16 
Antirheumatic 7.01 0.70 70.01 0.10 
Steroid 0.41 0.14 1.22 0.11 
cholesterol drug 0.88 0.55 1.41 0.59 
diuretic other 0.67 0.37 1.21 0.18 
Other Anticoagulant 0.47 0.05 4.48 0.51 
Sex (male) 0.96 0.30 3.11 0.95 
Age 1.04 1.02 1.06 < 0.01 
Total population: 8,725; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 906; Etodolac – 1,703; 
Rofecoxib – 357.  Endpoint events – 92; censored 8,633.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Short term exposure defined as ≤ 180 days. 
§ Note: uses stroke sensitivity model for prior stroke covariate 
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Appendix HH:   
 
Adjusted association between exposure to NSAIDS & COX-2 inhibitors and serious 
cardiovascular events (defined as acute myocardial infarction, death from ischemic 
heart disease, or cerebrovascular event).ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 1.14 0.71 1.82 0.59 
Etodolac   (ibuprofen) 0.82 0.49 1.37 0.45 
Rofecoxib (ibuprofen) 1.53 0.85 2.78 0.16 
Naproxen  (ibuprofen) 0.96 0.61 1.53 0.87 
Covariates     
Diabetes 1.28 0.90 1.82 0.17 
Angina 1.18 0.79 1.77 0.42 
PVD 1.36 0.81 2.28 0.25 
Atrial Fibrillation  1.28 0.67 2.43 0.46 
Cancer 0.90 0.60 1.36 0.62 
COPD 1.84 1.19 2.85 0.01 
Heart failure  1.32 0.79 2.19 0.28 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.88 1.31 2.70 < 0.01 
Renal failure  0.77 0.25 2.40 0.65 
Respiratory failure 0.69 0.19 2.55 0.58 
Rheumatoid arthritis 0.82 0.29 2.32 0.71 
Prior AMI 3.73 1.97 7.04 < 0.01 
Prior Stroke (specificity model) 4.21 1.48 12.00 0.01 
Antiarrhythmic 1.27 0.61 2.64 0.52 
Aspirin 1.11 0.77 1.59 0.57 
B-blocker 1.57 1.09 2.28 0.02 
Ca-blocker 0.91 0.64 1.29 0.60 
Digoxin 1.27 0.78 2.08 0.33 
Other HTN Meds 0.72 0.48 1.07 0.11 
Loop diuretic 1.68 1.12 2.52 0.01 
Methotrexate 5.41 1.59 18.44 0.01 
Warfarin 0.93 0.52 1.66 0.80 
ACE/ARBS 1.24 0.87 1.76 0.23 
Antiplatelet 1.67 1.00 2.76 0.05 
Antirheumatic 0 . . . 
Steroid 0.54 0.25 1.14 0.11 
Cholesterol drug 0.99 0.70 1.40 0.95 
Diuretic other 0.70 0.45 1.10 0.13 
Other Anticoagulant 0.29 0.04 2.19 0.23 
Sex (male) 0.65 0.24 1.77 0.40 
Age 1.03 1.02 1.05 < 0.01 
Total population: 12,188; Ibuprofen – 4,481; Naproxen – 3,240; Celecoxib – 1,530; Etodolac – 2,371; 
Rofecoxib – 566.  Endpoint events – 156; censored 12,032. 




Appendix II:   
 
Adjusted association between long-term exposure to NSAIDS & COX-2 inhibitors and 
serious cardiovascular events (defined as acute myocardial infarction, death from 
ischemic heart disease, or cerebrovascular event).ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 3.03 1.20 7.63 0.02 
Etodolac   (ibuprofen) 1.02 0.29 3.54 0.98 
Rofecoxib (ibuprofen) 5.59 1.93 16.24 < 0.01 
Naproxen  (ibuprofen) 1.49 0.53 4.15 0.45 
Covariates     
Diabetes 1.37 0.69 2.73 0.36 
Angina 0.61 0.27 1.40 0.24 
PVD 0.23 0.03 1.80 0.16 
Atrial Fibrillation  2.75 0.82 9.26 0.10 
Cancer 0.55 0.23 1.31 0.18 
COPD 1.45 0.58 3.65 0.43 
Heart failure  3.00 1.17 7.67 0.02 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.20 0.57 2.53 0.63 
Renal failure  0.39 0.04 4.02 0.43 
Respiratory failure 0.00 . . . 
Rheumatoid arthritis 1.93 0.43 8.66 0.39 
Prior AMI 8.72 2.24 33.99 < 0.01 
Prior Stroke (specificity model) 0.00 0.00 . 0.99 
Antiarrhythmic 0.40 0.06 2.82 0.35 
Aspirin 0.86 0.42 1.75 0.67 
B-blocker 1.03 0.48 2.19 0.94 
Ca-blocker 0.71 0.36 1.39 0.32 
Digoxin 1.25 0.49 3.19 0.63 
Other HTN Meds 0.53 0.24 1.16 0.11 
Loop diuretic 3.89 1.88 8.05 < 0.01 
Methotrexate 0 . . . 
Warfarin 0.23 0.06 0.88 0.03 
ACE/ARBS 0.90 0.45 1.79 0.77 
Antiplatelet 2.55 1.02 6.37 0.05 
Antirheumatic 0 . . . 
Steroid 0.70 0.16 3.10 0.63 
Cholesterol drug 1.25 0.66 2.36 0.50 
Diuretic other 1.23 0.57 2.66 0.60 
Other Anticoagulant 0 . . . 
Sex (male) 0.49 0.07 3.70 0.49 
Age 1.03 0.99 1.06 0.11 
Total population: 3,317; Ibuprofen – 1,085; Naproxen – 849; Celecoxib – 611; Etodolac – 656; Rofecoxib 
– 206.  Endpoint events – 46; censored 3,271.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
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Appendix JJ:   
 
Adjusted association between short-term exposure to NSAIDS & COX-2        
inhibitors and serious cardiovascular events (defined as acute myocardial infarction, 
death from ischemic heart disease, or cerebrovascular event).ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.78 0.37 1.63 0.50 
Etodolac   (ibuprofen) 0.66 0.32 1.36 0.26 
Rofecoxib (ibuprofen) 1.41 0.60 3.31 0.43 
Naproxen  (ibuprofen) 0.64 0.31 1.30 0.21 
Covariates     
Diabetes 0.82 0.47 1.43 0.49 
Angina 1.11 0.59 2.08 0.74 
PVD 1.70 0.82 3.55 0.16 
Atrial Fibrillation  1.43 0.58 3.49 0.44 
Cancer 1.18 0.65 2.13 0.58 
COPD 2.32 1.21 4.44 0.01 
Heart failure  1.61 0.76 3.42 0.21 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 2.26 1.31 3.91 < 0.01 
Renal failure  1.27 0.24 6.69 0.78 
Respiratory failure 1.42 0.32 6.26 0.65 
Rheumatoid arthritis 0.36 0.04 2.90 0.34 
Prior AMI 1.90 0.63 5.69 0.25 
Prior Stroke (specificity model) 4.39 0.94 20.48 0.06 
Antiarrhythmic 1.63 0.60 4.42 0.33 
Aspirin 1.45 0.83 2.53 0.19 
B-blocker 1.97 1.11 3.47 0.02 
Ca-blocker 0.74 0.43 1.30 0.30 
Digoxin 1.01 0.46 2.24 0.98 
Other HTN Meds 0.53 0.27 1.07 0.08 
Loop diuretic 0.82 0.43 1.58 0.56 
Methotrexate 8.40 1.74 40.40 0.01 
Warfarin 1.59 0.70 3.63 0.27 
ACE/ARBS 1.99 1.16 3.43 0.01 
Antiplatelet 1.33 0.58 3.03 0.50 
Antirheumatic 0 . . . 
Steroid 0.52 0.17 1.55 0.24 
Cholesterol drug 1.06 0.62 1.82 0.84 
Diuretic other 0.62 0.31 1.24 0.18 
Other Anticoagulant 0.89 0.12 6.81 0.91 
Sex (male) 0.73 0.17 3.04 0.66 
Age 1.03 1.00 1.05 0.02 
Total population: 8,730; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 908; Etodolac – 1,705; 
Rofecoxib – 358.  Endpoint events – 68; censored 8,662.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Short term exposure defined as ≤ 180 days. 
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Appendix KK:   
 
Adjusted association between exposure to NSAIDS & COX-2 inhibitors and serious 
cardiovascular events (defined as acute myocardial infarction, death from major 
cardiovascular disease, or cerebrovascular event).ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 1.14 0.73 1.79 0.55 
Etodolac   (ibuprofen) 0.87 0.53 1.42 0.58 
Rofecoxib (ibuprofen) 1.58 0.90 2.77 0.11 
Naproxen  (ibuprofen) 1.01 0.65 1.56 0.98 
Covariates     
Diabetes 1.16 0.83 1.63 0.39 
Angina 1.14 0.78 1.68 0.49 
PVD 1.24 0.74 2.07 0.41 
Atrial Fibrillation  1.52 0.83 2.76 0.17 
Cancer 0.99 0.67 1.45 0.94 
COPD 1.64 1.06 2.52 0.02 
Heart failure  1.16 0.71 1.90 0.56 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.70 1.20 2.41 < 0.01 
Renal failure  0.75 0.25 2.31 0.62 
Respiratory failure 1.02 0.32 3.18 0.98 
Rheumatoid arthritis 1.01 0.40 2.56 0.99 
Prior AMI 3.21 1.71 6.02 < 0.01 
Prior Stroke (specificity model) 3.77 1.32 10.73 0.01 
Antiarrhythmic 1.10 0.53 2.28 0.79 
Aspirin 1.14 0.81 1.60 0.46 
B-blocker 1.73 1.22 2.46 < 0.01 
Ca-blocker 0.90 0.64 1.25 0.53 
Digoxin 1.31 0.83 2.08 0.24 
Other HTN Meds 0.73 0.50 1.06 0.10 
Loop diuretic 1.74 1.18 2.56 0.01 
Methotrexate 4.15 1.22 14.10 0.02 
Warfarin 0.89 0.51 1.55 0.68 
ACE/ARBS 1.20 0.86 1.68 0.28 
Antiplatelet 1.78 1.10 2.87 0.02 
Antirheumatic 0 . . . 
Steroid 0.64 0.32 1.26 0.19 
Cholesterol drug 1.00 0.71 1.39 0.99 
Diuretic other 0.70 0.46 1.08 0.11 
Other Anticoagulant 0.58 0.14 2.42 0.45 
Sex (male) 0.59 0.22 1.62 0.31 
Age 1.04 1.02 1.05 < 0.01 
Total population: 12,188; Ibuprofen – 4,481; Naproxen – 3,240; Celecoxib – 1,530; Etodolac – 2,371; 
Rofecoxib – 566.  Endpoint events – 172; censored 12,016. 







Adjusted association between long-term exposure to NSAIDS & COX-2 inhibitors and 
serious cardiovascular events (defined as acute myocardial infarction, death from 
major cardiovascular disease, or cerebrovascular event).ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 2.17 0.94 5.03 0.07 
Etodolac   (ibuprofen) 0.96 0.31 2.91 0.94 
Rofecoxib (ibuprofen) 3.90 1.43 10.62 0.01 
Naproxen  (ibuprofen) 1.14 0.45 2.91 0.78 
Covariates     
Diabetes 1.23 0.64 2.38 0.53 
Angina 0.65 0.30 1.38 0.26 
PVD 0.21 0.03 1.62 0.13 
Atrial Fibrillation  3.76 1.22 11.58 0.02 
Cancer 0.70 0.32 1.54 0.38 
COPD 1.19 0.48 2.95 0.71 
Heart failure  2.45 0.99 6.08 0.05 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.03 0.49 2.15 0.94 
Renal failure  0.60 0.06 5.76 0.66 
Respiratory failure 0 . . 0.99 
Rheumatoid arthritis 2.94 0.86 10.08 0.09 
Prior AMI 6.75 1.78 25.60 < 0.01 
Prior Stroke (specificity model) 0 . . . 
Antiarrhythmic 0.36 0.05 2.61 0.31 
Aspirin 1.08 0.56 2.09 0.82 
B-blocker 1.27 0.63 2.55 0.50 
Ca-blocker 0.84 0.45 1.57 0.58 
Digoxin 1.21 0.50 2.92 0.67 
Other HTN Meds 0.53 0.25 1.12 0.10 
Loop diuretic 2.95 1.46 5.98 < 0.01 
Methotrexate 0 . . . 
Warfarin 0.22 0.06 0.82 0.02 
ACE/ARBS 0.96 0.50 1.84 0.90 
Antiplatelet 2.17 0.90 5.21 0.08 
Antirheumatic 0 . . . 
Steroid 1.03 0.30 3.53 0.96 
Cholesterol drug 1.21 0.66 2.21 0.54 
Diuretic other 0.98 0.46 2.07 0.95 
Other Anticoagulant 0 . . . 
Sex (male) 0.46 0.06 3.40 0.44 
Age 1.04 1.01 1.07 0.02 
Total population: 3,317; Ibuprofen – 1,085; Naproxen – 849; Celecoxib – 611; Etodolac – 656; Rofecoxib – 206.  Endpoint events – 
51; censored 3,317.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
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Appendix MM:   
 
Adjusted association between short-term exposure to NSAIDS & COX-2        
inhibitors and serious cardiovascular events (defined as acute myocardial infarction, 
death from major cardiovascular disease, or cerebrovascular event).ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.86 0.43 1.74 0.67 
Etodolac   (ibuprofen) 0.64 0.31 1.32 0.23 
Rofecoxib (ibuprofen) 1.72 0.78 3.76 0.18 
Naproxen  (ibuprofen) 0.77 0.40 1.49 0.44 
Covariates     
Diabetes 0.81 0.47 1.37 0.42 
Angina 1.06 0.59 1.92 0.84 
PVD 1.52 0.74 3.11 0.25 
Atrial Fibrillation  1.34 0.58 3.14 0.49 
Cancer 1.26 0.73 2.18 0.41 
COPD 2.07 1.10 3.87 0.02 
Heart failure  1.33 0.64 2.77 0.44 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 2.11 1.26 3.55 < 0.01 
Renal failure  0.99 0.20 5.00 0.99 
Respiratory failure 2.24 0.62 8.15 0.22 
Rheumatoid arthritis 0.37 0.05 2.96 0.35 
Prior AMI 1.82 0.61 5.39 0.28 
Prior Stroke (specificity model) 3.70 0.80 17.02 0.09 
Antiarrhythmic 1.42 0.53 3.77 0.49 
Aspirin 1.39 0.83 2.35 0.21 
B-blocker 1.95 1.14 3.34 0.01 
Ca-blocker 0.71 0.42 1.21 0.20 
Digoxin 1.19 0.58 2.44 0.64 
Other HTN Meds 0.57 0.30 1.08 0.09 
Loop diuretic 1.08 0.59 1.99 0.80 
Methotrexate 6.96 1.48 32.58 0.01 
Warfarin 1.39 0.64 3.02 0.40 
ACE/ARBS 1.72 1.04 2.87 0.04 
Antiplatelet 1.72 0.82 3.61 0.15 
Antirheumatic 0 . . . 
Steroid 0.45 0.15 1.31 0.14 
Cholesterol drug 1.12 0.67 1.86 0.67 
Diuretic other 0.69 0.36 1.30 0.25 
Other Anticoagulant 1.59 0.37 6.96 0.54 
Sex (male) 0.64 0.16 2.68 0.55 
Age 1.03 1.01 1.05 0.01 
Total population: 8,730; Ibuprofen – 3,383; Naproxen – 2,376; Celecoxib – 908; Etodolac – 1,705; Rofecoxib – 358.  Endpoint events 
– 76; censored 8,654.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 




Appendix NN:   
 
Adjusted association between NSAIDS & COX-2 inhibitors and serious        
cardiovascular eventsσ in VA subjects ≥ 65 years of age.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 1.52 0.87 2.67 0.14 
Etodolac   (ibuprofen) 1.10 0.58 2.10 0.77 
Rofecoxib (ibuprofen) 2.14 1.09 4.19 0.03 
Naproxen  (ibuprofen) 1.08 0.59 1.97 0.81 
Covariates     
Diabetes 1.20 0.79 1.81 0.39 
Angina 0.94 0.59 1.52 0.81 
PVD 1.68 0.97 2.91 0.06 
Atrial Fibrillation  1.37 0.68 2.78 0.38 
Cancer 0.87 0.56 1.37 0.55 
COPD 2.13 1.33 3.40 < 0.01 
Heart failure  1.41 0.80 2.50 0.23 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.69 1.13 2.55 0.01 
Renal failure  0.61 0.17 2.25 0.46 
Respiratory failure 0.74 0.19 2.84 0.66 
Rheumatoid arthritis 0.87 0.30 2.54 0.80 
Prior AMI 3.12 1.46 6.67 < 0.01 
Prior Stroke (specificity model) 4.58 1.55 13.54 0.01 
Antiarrhythmic 1.54 0.69 3.42 0.29 
Aspirin 0.96 0.63 1.45 0.84 
B-blocker 1.59 1.04 2.44 0.03 
Ca-blocker 1.04 0.70 1.55 0.85 
Digoxin 1.00 0.55 1.80 0.99 
Other HTN Meds 0.54 0.33 0.87 0.01 
Loop diuretic 1.54 0.96 2.49 0.08 
Methotrexate 5.90 1.69 20.55 0.01 
Warfarin 0.86 0.44 1.67 0.65 
ACE/ARBS 0.96 0.63 1.44 0.83 
Antiplatelet 1.90 1.09 3.32 0.02 
Antirheumatic 0 . . . 
Steroid 0.49 0.20 1.18 0.11 
Cholesterol drug 0.80 0.53 1.21 0.30 
Diuretic other 1.01 0.62 1.64 0.97 
Other Anticoagulant 0.43 0.06 3.29 0.42 
Sex (male) 1.00 0.31 3.20 1.00 
Age 0.99 0.96 1.03 0.62 
Total population: 4,971; Ibuprofen – 1,486; Naproxen – 1,196; Celecoxib – 968; Etodolac – 986; 
Rofecoxib – 335.  Endpoint events – 114; censored 4,857. 
* Systemic lupus erythematosus and connective tissue disorders diagnosis 




Appendix OO:   
 
Adjusted association between NSAIDS & COX-2 inhibitors and serious        
cardiovascular eventsσ in VA subjects ≥ 65 years of age – long-term exposure.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 7.36 1.62 33.48 0.01 
Etodolac   (ibuprofen) 3.54 0.62 20.13 0.15 
Rofecoxib (ibuprofen) 13.24 2.59 67.68 < 0.01 
Naproxen  (ibuprofen) 1.72 0.28 10.50 0.55 
Covariates     
Diabetes 1.12 0.49 2.55 0.78 
Angina 0.34 0.11 1.03 0.06 
PVD 0.34 0.04 2.74 0.31 
Atrial Fibrillation  3.21 0.81 12.72 0.10 
Cancer 0.47 0.18 1.25 0.13 
COPD 2.14 0.80 5.68 0.13 
Heart failure  4.23 1.40 12.83 0.01 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.08 0.45 2.58 0.86 
Renal failure  0.38 0.04 3.87 0.41 
Respiratory failure 0.00 0.00 . 0.99 
Rheumatoid arthritis 2.33 0.48 11.43 0.30 
Prior AMI 6.41 1.16 35.33 0.03 
Prior Stroke (specificity model) 0 . . . 
Antiarrhythmic 0.85 0.10 7.52 0.88 
Aspirin 0.64 0.27 1.54 0.32 
B-blocker 1.13 0.46 2.83 0.79 
Ca-blocker 0.83 0.37 1.82 0.64 
Digoxin 0.95 0.29 3.06 0.93 
Other HTN Meds 0.27 0.10 0.77 0.01 
Loop diuretic 4.31 1.89 9.82 < 0.01 
Methotrexate 0 . . . 
Warfarin 0.21 0.05 0.93 0.04 
ACE/ARBS 0.70 0.30 1.65 0.41 
Antiplatelet 3.02 1.06 8.64 0.04 
Antirheumatic 0.00 0.00 . 0.99 
Steroid 0.87 0.18 4.11 0.86 
Cholesterol drug 1.10 0.50 2.39 0.82 
Diuretic other 1.56 0.63 3.84 0.33 
Other Anticoagulant 0 . . . 
Sex (male) 0.95 0.12 7.35 0.96 
Age 0.97 0.91 1.03 0.31 
Total population: 1,610; Ibuprofen – 413; Naproxen – 381; Celecoxib – 411; Etodolac – 315; Rofecoxib – 
127.  Endpoint events – 34; censored 1,576.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
σ Defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular event 
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Appendix PP:   
 
Adjusted association between NSAIDS & COX-2 inhibitors and serious        
cardiovascular eventsσ in VA subjects ≥ 65 years of age – short-term exposure.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.84 0.36 1.95 0.68 
Etodolac   (ibuprofen) 0.78 0.32 1.89 0.59 
Rofecoxib (ibuprofen) 1.60 0.62 4.16 0.33 
Naproxen  (ibuprofen) 0.52 0.20 1.33 0.17 
Covariates     
Diabetes 1.00 0.53 1.92 0.99 
Angina 0.75 0.36 1.59 0.46 
PVD 1.98 0.91 4.32 0.09 
Atrial Fibrillation  1.69 0.64 4.45 0.29 
Cancer 1.01 0.52 1.95 0.99 
COPD 2.82 1.39 5.74 < 0.01 
Heart failure  1.58 0.66 3.76 0.30 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 2.33 1.26 4.33 0.01 
Renal failure  1.61 0.32 8.21 0.57 
Respiratory failure 1.37 0.30 6.32 0.69 
Rheumatoid arthritis 0.20 0.02 2.38 0.20 
Prior AMI 2.16 0.60 7.78 0.24 
Prior Stroke (specificity model) 4.13 0.82 20.80 0.09 
Antiarrhythmic 1.55 0.49 4.95 0.45 
Aspirin 1.31 0.69 2.47 0.40 
B-blocker 1.66 0.85 3.26 0.14 
Ca-blocker 0.83 0.44 1.57 0.56 
Digoxin 0.55 0.20 1.54 0.26 
Other HTN Meds 0.40 0.17 0.92 0.03 
Loop diuretic 0.73 0.33 1.62 0.44 
Methotrexate 11.80 2.10 66.29 0.01 
Warfarin 1.83 0.72 4.67 0.21 
ACE/ARBS 1.52 0.80 2.89 0.20 
Antiplatelet 2.08 0.85 5.13 0.11 
Antirheumatic 0 . . . 
Steroid 0.45 0.12 1.67 0.23 
Cholesterol drug 0.74 0.38 1.42 0.36 
Diuretic other 0.89 0.42 1.87 0.76 
Other Anticoagulant 2.16 0.27 17.58 0.47 
Sex (male) 0.71 0.09 5.37 0.74 
Age 0.97 0.92 1.02 0.26 
Total population: 3,283; Ibuprofen – 1,065; Naproxen – 801; Celecoxib – 547; Etodolac – 664; Rofecoxib 
– 206.  Endpoint events – 49; censored 3,234.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Short term exposure defined as ≤ 180 days. 
σ Defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular event 
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Appendix QQ:  Data - Years 1999 – 2002 – all observations 
 
Adjusted association between exposure to NSAIDS & COX-2 inhibitors and serious 
cardiovascular events (defined as acute myocardial infarction, death from coronary 
heart disease, or cerebrovascular event) – Ibuprofen Comparison, 1999 - 2002. 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 1.14 0.77 1.70 0.51 
Etodolac   (ibuprofen) 0.99 0.67 1.47 0.97 
Rofecoxib (ibuprofen) 1.56 0.96 2.54 0.07 
Naproxen  (ibuprofen) 1.03 0.70 1.52 0.87 
Covariates     
Diabetes 1.60 1.21 2.12 < 0.01 
Angina 1.27 0.91 1.76 0.16 
PVD 1.44 0.95 2.19 0.08 
Atrial Fibrillation  1.06 0.63 1.81 0.82 
Cancer 0.97 0.70 1.34 0.83 
COPD 1.75 1.23 2.47 < 0.01 
Heart failure  1.45 0.97 2.18 0.07 
HIV 0.99 0.12 8.48 1.00 
Lupus* 0 . . . 
Osteoarthritis 1.63 1.21 2.20 < 0.01 
Renal failure  0.80 0.31 2.11 0.66 
Respiratory failure 0.82 0.32 2.10 0.68 
Rheumatoid arthritis 0.74 0.29 1.91 0.54 
Prior AMI 2.90 1.73 4.86 < 0.01 
Prior Stroke (specificity model) 2.67 1.02 6.98 0.05 
Antiarrhythmic 1.63 0.91 2.90 0.10 
Aspirin 1.04 0.78 1.40 0.78 
B-blocker 1.46 1.08 1.97 0.01 
Ca-blocker 0.95 0.71 1.26 0.70 
Digoxin 1.23 0.82 1.85 0.32 
Other HTN Meds 0.86 0.63 1.17 0.33 
Loop diuretic 1.47 1.05 2.05 0.02 
Methotrexate 2.33 0.64 8.44 0.20 
Warfarin 0.72 0.43 1.19 0.20 
ACE/ARBS 0.98 0.74 1.30 0.89 
Antiplatelet 1.78 1.19 2.66 < 0.01 
Antirheumatic 1.18 0.14 10.08 0.88 
Steroid 0.79 0.44 1.39 0.41 
Cholesterol drug 0.85 0.64 1.13 0.26 
Diuretic other 0.87 0.62 1.22 0.41 
Other Anticoagulant 0.59 0.18 1.88 0.37 
Sex (male) 0.84 0.39 1.79 0.64 
Age 1.04 1.02 1.05 < 0.01 
Total population: 16,488; Ibuprofen – 5,699; Naproxen – 4,385; Celecoxib – 1,980; Etodolac – 3,615; 
Rofecoxib – 809.  Endpoint events – 238; censored 16,250.   




Appendix RR:   
 
Adjusted association between long-term NSAIDS & COX-2 inhibitor use and 
serious cardiovascular events σ – 1999 through 2002.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 2.05 1.03 4.07 0.04 
Etodolac   (ibuprofen) 1.83 0.90 3.70 0.09 
Rofecoxib (ibuprofen) 2.59 1.10 6.10 0.03 
Naproxen  (ibuprofen) 1.39 0.68 2.88 0.37 
Covariates     
Diabetes 1.74 1.09 2.76 0.02 
Angina 1.19 0.69 2.06 0.54 
PVD 0.90 0.39 2.11 0.81 
Atrial Fibrillation  1.52 0.59 3.94 0.38 
Cancer 0.78 0.44 1.38 0.39 
COPD 1.81 1.01 3.28 0.05 
Heart failure  2.28 1.17 4.46 0.02 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 1.14 0.67 1.94 0.62 
Renal failure  0.65 0.12 3.56 0.62 
Respiratory failure 1.34 0.24 7.55 0.74 
Rheumatoid arthritis 1.67 0.51 5.47 0.40 
Prior AMI 2.75 0.91 8.28 0.07 
Prior Stroke (specificity model) 0 . . 0.98 
Antiarrhythmic 0.78 0.21 2.81 0.70 
Aspirin 0.72 0.44 1.20 0.21 
B-blocker 1.29 0.77 2.14 0.33 
Ca-blocker 0.79 0.49 1.27 0.33 
Digoxin 1.33 0.66 2.66 0.43 
Other HTN Meds 0.77 0.46 1.30 0.33 
Loop diuretic 2.00 1.16 3.44 0.01 
Methotrexate 0 . . . 
Warfarin 0.38 0.15 0.98 0.04 
ACE/ARBS 0.75 0.46 1.21 0.24 
Antiplatelet 2.42 1.26 4.64 0.01 
Antirheumatic 9.28 1.12 76.72 0.04 
Steroid 0.74 0.28 1.97 0.54 
Cholesterol drug 1.01 0.63 1.60 0.98 
Diuretic other 1.25 0.74 2.11 0.41 
Other Anticoagulant 0 . . . 
Sex (male) 0.84 0.25 2.74 0.77 
Age 1.03 1.01 1.05 0.02 
Total population: 5,112; Ibuprofen – 1,535; Naproxen – 1,316; Celecoxib – 814; Etodolac – 1,238; 
Rofecoxib – 310.  Endpoint events – 88; censored 5,024.   
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Long-term exposure defined as > 180 days. 
σ Defined as acute myocardial infarction, death from coronary heart disease, or cerebrovascular event 
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Appendix SS:   
 
Adjusted association between short-term NSAIDS & COX-2 inhibitor use and 
serious cardiovascular events σ – 1999 through 2002.ξ 
 
Exposure (reference group) 
 
Adjusted Risk Ratio  
(95% CI) 
  Lower         Upper 
 
Sig. (p) 
Celecoxib (ibuprofen) 0.69 0.35 1.37 0.29 
Etodolac   (ibuprofen) 0.65 0.34 1.23 0.19 
Rofecoxib (ibuprofen) 1.70 0.84 3.44 0.14 
Naproxen  (ibuprofen) 0.79 0.44 1.44 0.44 
Covariates     
Diabetes 1.03 0.64 1.66 0.90 
Angina 1.17 0.68 2.01 0.57 
PVD 1.74 0.93 3.28 0.08 
Atrial Fibrillation  1.06 0.46 2.42 0.90 
Cancer 1.16 0.70 1.94 0.56 
COPD 2.56 1.49 4.42 < 0.01 
Heart failure  1.32 0.68 2.54 0.41 
HIV 0 . . . 
Lupus* 0 . . . 
Osteoarthritis 2.10 1.30 3.41 < 0.01 
Renal failure  1.29 0.37 4.44 0.69 
Respiratory failure 0.75 0.16 3.47 0.71 
Rheumatoid arthritis 0 . . . 
Prior AMI 3.09 1.32 7.25 0.01 
Prior Stroke (specificity model) 4.78 1.38 16.55 0.01 
Antiarrhythmic 1.92 0.82 4.46 0.13 
Aspirin 1.48 0.91 2.40 0.11 
B-blocker 1.52 0.92 2.50 0.10 
Ca-blocker 0.88 0.55 1.42 0.61 
Digoxin 0.89 0.43 1.82 0.74 
Other HTN Meds 0.67 0.38 1.16 0.15 
Loop diuretic 1.04 0.59 1.84 0.90 
Methotrexate 4.96 0.63 38.87 0.13 
Warfarin 1.38 0.66 2.91 0.39 
ACE/ARBS 1.56 0.97 2.51 0.07 
Antiplatelet 1.47 0.74 2.92 0.27 
Antirheumatic 0 . . . 
Steroid 0.58 0.23 1.51 0.27 
Cholesterol drug 0.79 0.49 1.26 0.32 
Diuretic other 0.71 0.40 1.27 0.25 
Other Anticoagulant 1.27 0.38 4.19 0.70 
Sex (male) 0.84 0.26 2.73 0.78 
Age 1.03 1.01 1.06 < 0.01 
Total population: 11,198; Ibuprofen – 4,149; Naproxen – 3,051; Celecoxib – 1,149; Etodolac – 2,354; 
Rofecoxib – 495.  Endpoint events – 89; censored 11,109.     
* Systemic lupus erythematosus and connective tissue disorders diagnosis 
ξ Short term exposure defined as ≤ 180 days. 
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